¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/1/12 ¤U¤È 08:20:32
²Ä 6536 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/1/11 ¤W¤È 03:13:56
²Ä 6535 ½g¦^À³
|
¯u¤û¹G ©³³¡¤û¥« ¤S¤jº¦20% ¿ð¿ð¤£´±¥[½X¤@ª½¦b¬ÝÀ¸ n¦^¥»¤]¦nÃø |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/9 ¤U¤È 06:43:30
²Ä 6534 ½g¦^À³
|
Eblasakimab ¦bºC©Êªý¶ë©ÊªÍ¯fCOPD ªº¼ç¤O (¥þ²yCOPD¥«³õ 2022¦~181»õ¬ü¤¸ ¹w´Á¨ì 2032¦~¹F298.8»õ¬ü¤¸)
Eblasakimab¬O¤@ºØ·s«¬¥þ¤H·½³æ®è IgG4 §ÜÅé¡A¥i¯S²§©Êµ²¦X¥Õ¦å²y¤¶¯À (IL)-13 ¨üÅé (IL-13R)¡Aªý¤î³z¹L 2 «¬¨üÅé¶Ç»¼ IL-4 ©M IL-13 °T¸¹¡C 2«¬¨üÅé¬O¥]§tIL-4¨üÅé(IL-4R)©MIL-13¨üÅé(IL-13R)ªº²§¤G»EÅé¡C²ÓM¿E¯À IL-4 ©M IL-13 ³z¹L 2 «¬¨üÅéµo¥X°T¸¹¡A¬Oµoª¢ªºÃöÁäÅX°Ê¦]¯À¡A¬O¤Þµo AD¡B®ð³Ý©M COPD µ¥ 2 «¬¯e¯fªº¹L±Ó¯gª¬ªºÃöÁä¡C
Dupilumab ¬O¤@ºØ¥þ¤H·½³æ®è§ÜÅé¡A¥iªýÂ_¥Õ²ÓM¤¶¯À 4 ©M¥Õ²ÓM¤¶¯À 13 ªº¦@¨É¨üÅ馨¤À¡A¥Õ²ÓM¤¶¯À 4 ©M¥Õ²ÓM¤¶¯À 13 ¬O 2 «¬µoª¢ªºÃöÁäÅX°Ê¦]¯À¡C
Dupilumab¥h¦~°ò©ó BOREAS ªº¥¿±µ²ªG¡AFDA ±Â¤© Dupixent ¬ð¯}©ÊÀøªk»{©w¡A§@¬°¥¼¨ü±±¨îªº COPD ¦¨¦~±wªÌªºªþ¥[ºû«ùªvÀø¡A³o¨Ç±wªÌ¦³¥[«¥v©M¶Ý»Ä©Ê²É²ÓMªí«¬¡CFDA ®Ú¾Ú¸Ó¸ÕÅ窺¼Æ¾Ú±Â¤© Dupixent ªvÀøºC©Êªý¶ë©ÊªÍ¯fªº¬ð¯}©ÊÀøªkºÙ¸¹¡C ¼Ú¬wÃÄ«~ºÞ²z§½¤w¸g¦b¼f¬d Dupixent §@¬°ªvÀø¥¼¨ü±±¨îªº±w¦³ 2 «¬µoª¢ªº COPD ±wªÌªºÃĪ«¡C
Dupixent 3 ´Á¸ÕÅçÁ{§É¼Æ¾Ú Dupixent ¦b²Ä¤G¶µ¿n·¥ªº 3 ´Á¸ÕÅ礤ÅãµÛ´î¤Ö¤F COPD ´c¤Æ¡A¥[³t¤F FDA ªº´£¥æ¨Ã½T»{¤F¦¨¬°²Ä¤@Ó§åã¥Î©óªvÀø³oºØÄY«¯e¯fªº¥Íª«»s¾¯ªº¼ç¤O NOTUS ¸ÕÅç¥HÀ£Ë©ÊªºÀø®Ä¹F¨ì¤F¥Dn²×ÂI¡AÅã¥Ü¦b¦³2 «¬µoª¢ÃÒ¾Ú¡]§Y¦å²G¶Ý»Ä©Ê²É²ÓM≥300 Ó²ÓM/£gL¡^ªº¤¤««×COPD ±wªÌ¤¤¡A»P¦w¼¢¾¯¬Û¤ñ¡ADupixent ÅãµÛ°§C¤F34% ªº¯f±¡¥[«¡AÃÒ¹ê¤Fµ²ªG¨Ó¦Û¨ã¦³¨½µ{¸O·N¸qªº BOREAS ÃöÁä¸ÕÅç¦b²Ä 12 ¶g®É¡A»P¦w¼¢¾¯¡]FEV 1¬° 57 mL¡^¬Û¤ñ¡ADupixent ¨³³tÅãµÛ§ïµ½¤FªÍ¥\¯à¡] FEV 1¬° 139 mL¡^ p¹º©ó 2023 ¦~©³´£¥æ¸É¥R BLA ¥ú¬O¦b¬ü°ê´N¦³¬ù 30 ¸U¤H±w¦³¤£¨ü±±¨îªººC©Êªý¶ë©ÊªÍ¯f¡A¨Ã¦³ 2 «¬µoª¢ªºÃÒ¾Ú¡F¤Q¦h¦~¨Ó¨S¦³·sªºªvÀø¤èªkÀò±o§åã
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/1/9 ¤W¤È 01:07:44
²Ä 6533 ½g¦^À³
|
³Ìªñ0.4¥ª¥k «Ü®e©ö´N©Ô1¸ò10´X% ´N½u½×½uªº¸Ü 0.58 ÀV½u¹L¥h¤j®a·|¨ÓÉu¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/1/8 ¤U¤È 04:03:08
²Ä 6532 ½g¦^À³
|
¥¼¨Ó®i±æ¦pªG¯uªºÀu¨q¡A³Ì¤jªÑªF¦ó¥H¤j½æ¤â¤¤«ùªÑ?Ãø¤£¦¨TANG CAPITAL¤ñ¦U¦ìÁÙ¤£²M·¡ASLAN?TANG CAPITAL¤]¬O«ù¦³¤F ¤@¬q®É¶¡¡A¬°¦ó¿ï¦b¥¼¨Ó¤j¨Æ¥óµo¥Í«e½æªÑ?¤ñ°_2.3¤ë¥Ó³ø2023/12«ùªÑ¤~µo²{¤jªÑªF¶]¤F¡A²{¦bSEC¤å¥ó¤w¸g´¦ÅS¤F¡A¤£¥Î µ¥¨ìTANG CAPITAL¥Ó³ø«ùªÑ´Nª¾¹D¤w¸g½æ¥ú쥻«ù¦³ADS¡A¥h½½Â¤å´N¥i¥Hª¾¹D¬Y¨Ç¯S©w¤H¤h¦h·R´£TANG CAPITAL¦h¤j©@ ¡A«ùÄò¥[½X«ùªÑ¡A¤S¬O¤jªÑªF¤S¬OSurveyor¡Aµ²ªGTANG CAPITAL¤w¸g¥X²MADS¡A«o¤£·í¤@¦^¤l¨Æ¡AÁ`¤§¤jªÑªF¥X²æ«ùªÑ¬OÓ Äµ°T¡AYÁÙ«ù¦³ªº·à¤Í¤]¤£«Øij½æ¤F¡A¥Ø«e»ù®æ»P¨ä³B¤À¡AÁÙ¤£¦p©ñµÛµ¥«Ý©_ÂÝ¡A¦ýY¬O·Qn¥[½XÅu¥½Ð¤T«ä¡A²¦³º¯uªº©_ Âݵo¥Í¡A즳«ùªÑ¥»´N²zÀ³¦³Àò§Q¡A¦ý¦pªG¤£¦p¹w´Áªº¸Ü¡A¬ü³W¾À¯È¤£µL¥i¯à....... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/3 ¤U¤È 10:23:41
²Ä 6531 ½g¦^À³
|
¤µ¦~·|µo§GCOPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅç¶i¤@¨B¼Æ¾Ú ºë±K¤Á³ÎªÍ¤Á¤ù (PCLS) ¤¤ÀY¹ïÀY¤ñ¸ûªº·sªº¡B¦³§Æ±æªº¼Æ¾Úªí©úeblasakimab ¤ñ dupilumab ¨ã¦³´£°ªÀø®Äªº¼ç¤O
¤°»ò¬OÀY¹ïÀY¬ã¨s( Head to Head study)
¬O¨Ï¥Î¤w¸g¦b¨Ï¥ÎªºªvÀøÃĪ«§@爲ª½±µ¹ï·Ó²Õ¡A¥iµø爲¨âºØÃĪ«ªºª½²y¹ï¨M, ª½±µPK( ¬ã¨sÃĪ«»P¨Ï¥Î¤¤ªºªvÀøÃÄ) ¡C°w¹ïÃĪ«ªºÀø®Ä»P¦w¥þ©Ê¶i¦æ§óª½±µªºPK ¡A¥HÁקKÂùª¼¸ÕÅç®É¯f±w©â¨ì¦w¼¢¾¯²Õ¦Ó¼vÅT¯f±¡ ¬OÄÝ©ó¤ñ¸û²Å¦X¤H¹DªºÁ{§É¸ÕÅç³]p, Head to Head study ³]p¥¼¨Ó·|¶V¨Ó¶V¨ü¨ì«µø»P±Ä¥Î
Âà¤Æ¤u§@ÃÒ©ú¤F eblasakimab ¦b COPD ¤¤ªº¼ç¤O¡AÀY¹ïÀY¼Æ¾Úªí©ú¨ä¥i¯àÀu©ó dupilumab¡A¤ä«ù eblasakimab ¸Ñ¨M¼sªxªº AD ¦@¨Ö¯gªº¼ç¤O¡C¥O¤H¿³¾Äªº¬O¡A¦b¨Ï¥Î¤HÃþ COPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅ礤¡A§ÚÌÆ[¹î¨ì eblasakimab ¤ñ dupilumab ¨ã¦³§ó±jªº®ÄªG¡A§ÚÌ´Á«Ý©ú¦~µo¥¬³o¨Ç¬ã¨sªº¶i¤@¨B¼Æ¾Ú¡C
New, promising data of head-to-head comparison in PCLS suggests eblasakimab has potential for improved efficacy over dupilumab ( 2024 ¦~1¤ë ²³øP18)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/1/3 ¤W¤È 10:36:42
²Ä 6530 ½g¦^À³
|
¦³½ìªº¨Æ±¡¨Ó¤F.....
1.2023/7/11ªºSEC¤å¥óÅã¥Ü¡ATANG CAPITAL«ù¦³180.6¸UªÑADS + 5ªÑì©lªÑ(0.2ªÑADS)¡C
2.ºI¦Ü2023/9/30¡ATANG CAPITAL¥Ó³ø«ù¦³aslan190.16¸UªÑads¡A«ùªÑ¬ù11.41%¡C
3.2024/1/2ªºSEC¤å¥óÅã¥Ü¡ATANG CAPITAL¥X²M©Ò¦³ADS¡A¶È³Ñ«ù¦³5ªÑì©lªÑ + °õ¦æ»{ÁÊÅvªº6,134,970ªÑì©lªÑ¡A ¦Xp¬ù245,399ªÑADS¡A«ùªÑ¬ù1.5%¡C(¾ÚSEC¤å¥ó´¦ÅS¡A°õ¦æ»{ªÑÅv«á«ùªÑ¶W¹L9.99%¡A«h»{ªÑÅvµLªk°õ¦æ¡A¤£ª¾¹DTANG CAPITAL¬O§_¬°¤F°õ¦æ»{ªÑÅv½æ¥X«ùªÑ¡A¦ý¥þ³¡¥X²M¤S»{ªÑ¡A§Ú¬Oı±o¦³ÂI¥Ù¬Þ...)¡C
2023/9/30ªÑ»ùÁÙ¦³1.8ªþªñ¡A±q10¤ë¶}©l¤@¸ô±Y¶^¡A¬Ý¨ÓÀ³¸Ó¤j·§²v¬OTANG CAPITAL¥X²M190.16¸UªÑADSªº½t¬G¡AÁ`¤§´N¬O¨Æ¹ê³¯z¤F¡A«ç»ò¸ÑŪ´N¬Ý¦U¦ì·à¤Í¤F.......
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/1/2 ¤U¤È 08:38:54
²Ä 6529 ½g¦^À³
|
覬¨ì·à¤lªºmail n¶}§ë¸êªÌ·|ij ¸Ó¤£·|¦³¤°»ò®ø®§ ¦³ÂI·Q¶R¦^«ùªÑ½ä¤@¤U¡]Äo¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/29 ¤U¤È 04:41:15
²Ä 6528 ½g¦^À³
|
¤£¥Îµe¥¼¨Ó¤j»æ
©ú¦~TREK-DX ¸ÕÅç¡A¦p¥¼¹F²ÎpÅãµÛ®ÄªG
°¨¤W´N¤@¤M²¦©R |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/12/29 ¤U¤È 03:04:38
²Ä 6527 ½g¦^À³
|
P±M®a¡B¾ÇªÌ¡B§ë¸êªÌ¡B½ä®{¡B«Ó°¶¡G ¨È·à±d¶}©l¦³360¤Ñ(ªÑ»ù§C©ó1¬ü¤¸)(§t180¤Ñ«á¤½¥q´£¥Xªº²§Ä³)§K©ó¤U¥«¡C ªÑ»ù¤£¬O«ÂI¡A«ÂI¬O¨È·à±d²{ª÷¥u°÷¥Î¨ì113¦~©³(ÄY®æ¨ÓÁ¿¥u°÷¥Î¨ì113¦~9¤ë)¡C ¥B¶i¤JÁ{§É¤T´Á¸ÕÅç¤]¶·¥Î¿ú¡C ¤½¥q¤]»¡©ú¥Ø«e¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡C ¤½¥q113¦~©³«e¤@©wn§ä¨ì¿ú¡A¤£µM´NˤF(¤£¬O¤U¥«¡A¬O˳¬)¡C
112¦~12¤ë23¤é¤½¥q¤½§i¼W¥[ªk©wªÑ¥» «Ü©úÅã¦X§@¹Ù¦ñ©Ò¶}ªº±ø¥ó¤w¸g¥X¨Ó¤F¡A©Ò¥H¤½¥q«ö³W©wn´£ªÑªF·|¦P·N (¤½¥qµLªk¾B»\ÂX¼Wªk©wªÑ¥»¡A¦]³onªÑªF·|¦P·N)(¦pªG¨S´£½ÐªÑªF·|¦P·Nªº¨Æ¶µ¡A§Ṳ́£·|ª¾¹D¶i«×) (¦X§@¹Ù¦ñ©M«´¬ù±ø¥óÅSÀ`¤F) ¦X§@¹Ù¦ñ¨¤À¤w¸g½T»{¤F¡C ¬O¨p¶Ò¡B°Ï°ì±ÂÅv¡B³Q¨ÖÁÊ¡A¤]¤w¸g½T»{¤F¡C ºî¤W ®¥³ß¦U¦ì¡A³Ñ¤£¨ì¥b¦~®É¶¡´N·|ª¾¹D¨È·à±d¬OÅܦ¨²r·àÁÙ¬O¡K¡K ½Ð¤U¦nÂ÷¤â
112¦~1¤ë1¤é~112¦~6¤ë21¤é¡G¨È·à±d»P¤é¥»Zenyaku Kogyo °Ó°Q¤é¥»±ÂÅv¤º®e¡C 112¦~6¤ë22¤é¡G¨È·à±d¤½§iEblasakimab¦b¤é¥»°Ïªº±ÂÅv¥ÑZenyaku Kogyo¿WÅó¡C 112¦~12¤ë12¤é¡G¨È·à±d»¡©ú¥Ø«e¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡C 112¦~12¤ë23¤é¡G¨È·à±d¼W¥[ªk©wªÑ¥»©ó113¦~1¤ë24¤é´£ªÑªF·|¦P·N¡C (¥ý§âªk©wªÑ¥»ÂX¨ì¬Û·í¤j(50»õ´¶³qªÑ)¡A¥H½T©w¯à²Å¦X¨C(¦h)®a¦X§@¹Ù¦ñ©Ò¶}ªº±ø¥ó) (ªk©wªÑ¥»ÂX¨ì¬Û·í¤j¬Oµ¦²¤¡A¤]¬O¥²¶·§@ªº¡AÅý¦X§@¹Ù¦ñµLªkª¾¹D¨È·à±d¥´¤°»òºâ½L) (¦X§@¹Ù¦ñ¤£²M·¡¨È·à±d¸ò´X®a¡§¹Ù¦ñ¡¨±µ¬¢¡A¤è«KÅý¨È·à±d¯à¿ï¾Ü±ø¥ó¦nªº¹Ù¦ñ) (½Í§P»ÝnÂI®É¶¡¡A±Ä¥Î©ì©µ¾Ô³N¡A³q±`¯àÅý·NÄ@°ªªº¹Ù¦ñ¥[»ù) (¨È·à±d¸³®y¬O¨ÖÁÊ°ª¤â¡A§ÚÌn¬Û«H¥L¡C) 113¦~1¤ë8~10¤é¡G¨È·à±d¦bª÷¤s°Ñ¥[¥Ö½§¯f¾Ç·|¡A·|¨q¥X¥Íª«¼Ð»x¬ÛÃö¼Æ¾Ú¡C (¼Æ¾ÚºCºCºÝ¥X¨Ó¡A¦A¥[¤W©ì©µ¾Ô³N¡A³q±`¯àÅý·NÄ@°ªªº¹Ù¦ñÄ~Äò¥[»ù) (¼Æ¾Ú¨ì§Ṳ́â¤W³£¬Oªº¡A¦]«e´XÓ§«ô¡A¬Æ¦Ü«e´XӤ뤽¥q´Nª¾¹D¤F¡AÃø©Çªñ´ÁªÑ»ù¥X¶q) 112¦~10¤ë1¤é~113¦~2¤ë29¤é¡G¨È·à±d¤w±q¦h®a¦X§@¹Ù¦ñ¤¤¿ï¥X³Ì¾A¦Xªº¦³¼ç¤O¦X§@¹Ù¦ñ¡A¬ÛÃö«´¬ù±ø¥ó¤jP©³©w¡C 113¦~2¤ë1¤é¡G¦¬ADRºÞ²z¶O(2¤ë8¤é²Ä¤@¦¸¶Êú¡B2¤ë15¤é²Ä¤G¦¸¶Êú)¡C 113¦~3¤ë1¤é¡G¨È·à±d¤½§i¥Ñù¤ó¥H¬üª÷¦Ü¤Ö25»õ¤¸¦¬ÁÊ¡C 113¦~5¤ë1¤é¡G¨È·à±dADR°±¤î¥æ©ö¡C
¨ÖÁʪ÷ÃBºâªk¦p¤U¡G °Ñ¦Ò·|û¡G¤Ñ©R¤j10141925 µoªí®É¶¡:2023/6/22 ¤U¤È 08:20:52 ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô ¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸. ¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸ 27.7-7.8(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»¤§§Q¯q) ASLN004 ¤§»ùÈ:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í ¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q) ¥H¤W¥¼§t003°Ó¥Î«á¤§¨ÖÁÊ»ù¡C ¥[003°Ó¥Î«á¤§¨ÖÁÊ»ù¦ô¬ù¬üª÷25»õ¤¸³Q¨ÖÁÊ(©¹«áªº20¦~¡C¨C¤@¦~ªº10% ¾P°â¤À¼í¥¼ºâ¶i¥h)¡C
¥tÃö©ó¾P°â¤À¼í¨C¦~10%¡G ¥H§ùÁת¢2022¦~Á`¾P°âÃB86.8»õpºâ¡A ·sÃĤò§Q¥H8¦¨pºâ¡G86.8*0.8=69.44»õ¬ü¤¸¬OÁÉ¿Õµá³æ³æ2022¦~½æ§ùÁת¢²bÁÈÈ 86.8*10%=8.68»õ¬ü¤¸´N¬O·í¦~¾P°â¤À¼í10%ªºÈ
§ùÁת¢¦~«×¾P¦¬ª÷ÃB¦p¤U¡G(·PÁ¤ѩR¤j´£¨Ñ) 2017¦~/2.279»õ¬ü¤¸ 2018¦~/9.22»õ¬ü¤¸ 2019¦~/23.156»õ¬ü¤¸ 2020¦~/40.448»õ¬ü¤¸ 2021¦~/61.988»õ¬ü¤¸ 2022¦~/86.811»õ¬ü¤¸ §ùÁת¢2022¦~¤î¦@¾P°â223.902»õ¬ü¤¸ ¾P°â¤À¼í10%=22.902»õ¬ü¤¸(¾P°â¤À¼í15¦~§Y¶W¹L¦Ê»õ)( Eblasakimab¬O¶W¯Å¤jÃÄ)
ASLN ¦¨¾À¯È¾÷²v¬Û·í§C¡D ¦ý¶W°ªÀø®Ä¤£¥i¯à¡D ¥unÀø®Ä¡B¥ÎÃÄÀW²vĹ¹L§ùÁת¢§Y¥i
Eblasakimab¦b©¹«á20¦~ªº¾P°â¹w¦ôȤ@©w°Ñ¦Ò§ùÁת¢q©w ³o20¦~ªº¾P°â¤À¼í¥[Á`(¾P°â¤À¼í¨C¦~10%)¤]·|¨Ö¤J¨È·à±d³Q¨Öª÷ÃB¸Ì±¡C
(¥H¤W³¡¤À¯ÂÄÝÁr´ú¡BÁr´ú¦p¦³¹p¦P¡B¹êÄÝ¥©¦X) ¥H¤W½Ð«ü¥¿ (§ë¸ê¦³·ÀI¡B½Ð¦Ût¬ÕÁ«)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/12/28 ¤U¤È 11:37:24
²Ä 6526 ½g¦^À³
|
ÁöµM§Ú¤w¨S¦³¨È·à±d ¦ý§Úı±o¥Ø«e0.4ªºªÑ»ù¨ä¹ê®t¤£¦h¬O©³ ¦]¬°§ë¸êªÌ²{¦b½æ¤]½æ¤£¤F¦h¤Ö¿ú,©Ò¥H°ò¥»¤W³£·|©ñµÛµ¥©_ÂÝ °£«D³Ì²×Ãz±¼¥¢±ÑÂk¹s ¤£µM²{¦b¨ä¹ê¤]¤£¥Î©È·|¶^¨ìþ¸Ì¥h |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/28 ¤U¤È 09:35:42
²Ä 6525 ½g¦^À³
|
ªÑ¤Í§ë¸êASLAN Pharmaceuticals ¤w¸g·l¥¢ºG«¤F¡A·Q¤£³q¬°¦ó¦³¤H¤@ª½©¹¤U¹w´úªÑ»ù ¡A¤£Â_©¹¶Ë¤fÅxÆQ¡A¤SµLªk½×z¤½¥q¬ãµoÃĪ«¨º¸Ì¨S¦³¼ç¤O¡A¯u¤£ª¾¦ó¥H¥Î¤ß¦p¦¹¨}W¡H ·íµM¤p¥Í§Þ¤½¥q¦bªì´Á¬ãµo¹Lµ{¤¤¥²µM·|¾D¹J®À§é¡A¥þ²yªº¥Í§Þ¤½¥qµo®i³£¬O¦b¦p¦¹ªº¹D¸ô¤¤¤£Â_¦¨ªø_§§¡A¨«¥X£¸¤ù¤Ñ ª©¤W¦UºØ½×z¦³¥¿±¤]¦³t±¡A³£À³µ¹¤©´L«¡A¥¿±n»¡¥X¥¿±²z¥Ñ¡At±n»¡¥Xt±²z¥Ñ¡A¤~¯àÅý¤H«HªA¡A ¥Ø«e¶^¨ì³oÓ»ù¦ì¦A½æ¤]¨S¦³¤°»ò·N¸q¡A¦pªG¦Û¤vµû¦ô¥Ø«e¤½¥q¬ãµoÃĪ«¦³¼ç¤O¡A¨S¦³ª©¤W©Ò¨¥¨º»ò®t ±©¤@ªº°Ê§@´N¬O¦Ò¼{¦^¸É¡A¤½¥q¸Ó°µªº°Ê§@¤w¸g°µ¥X¨Ó¤F¡A¸Ó¶}ªºÁ{®ÉªÑªF·|¤]¥l¶}¤F¡A³o·|Åý¸êª÷¡A¨ÖÁʽͧP¡A§l¤Þ§ë¸ê¡AÂX¥Rª©¹Ï ¦³§ó¥[ÆF¬¡©P©µ»P°j±ÛªÅ¶¡
¥H¤W¸É¥R¤À¨É»P«Øij¡A¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/12/28 ¤U¤È 04:16:20
²Ä 6524 ½g¦^À³
|
ÞË......§Ú¦b¤§«eªº½×z¤]¬O¦³»¡n¨Ì¹ê»Úµo¦æªÑ¼Æ¬°¥D¡A§Ú¬Æ¦Ü³s(¥Hasln¤½¥¬ªº2023Q3°]³øÅ㠥ܡAÁöµMªk©wµn°OªÑ¼Æ¦³10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ¡A25ªÑ=1ads¨Óºâ¡A¤j¬ù¬°1720¸UªÑ ads¡Aµ¥©óÁÙ¦³2280¸UadsªºªÅ¶¡¥i¥H¼W¸ê)¤½¥qÁÙ¦³2280¸UªÑ¥i¥Hµo¦æ¼W¸ê³£ºâ¥X¨Óµ¹¦U¦ì·à¤Í¬Ý ¤F¡A¨ì©³¬O½Ö¨S¦b¬ÝXD¡AµM«á¤@ª½¶K¤@¨Ç½Ķ¹L¨Ó·F¹Àªü¡A§Ú¦Û¤vª¦Â¤å´N¦æ¤Fªü......¡A¦³¤H ¬O«æ¤FÁÙ¬O«ç¼ËXD¡A¥H¤U¬O´XÂIÓ¤H¬ÝªkÅý¦U¦ì·à¤Íµû¦ô§a!
1.³W©w¸ò¹ê°È¤W¾Þ§@°ò¥»¤W¬O¤G¦^¤l¨Æ¡AªÑ²¼¤U¥«°ò¥»¤W¤£·|®ø¥¢¡AOTC¥i¥H¥æ©ö¨S¿ù¡A¸Õ°Ý¦U¦ì ªº¨é°ÓþӤ䴩OTC¥æ©öªº!?¬Æ¦Ü¤U¥«¤§«á¬ÛÃöªÑ°È¥N²z®ü¥~¨é°Ó©Î°ê¤º½Æ©e°UÁÙ¥i¥H¤ä´©? °ê¤º¤U¥«ªÑ²¼¥æ©ö¸òªÑ°ÈÃø«×´N°÷¤j¤F¡AÁÙ·d¨ì®ü¥~ªºADS?
2.¯uªº¹ê»Úµo¦æªÑ²¼¡A³W©w¤WnªÑªF¦P·N¡A¦ý¹ê°È¤W1/24¸¹ªºªÑªF·|¤@©w·|ªþ±a¨Mij¡A¨Ò¦pµn°O ¸ê¥»ÃB´£°ª«á¡A«áÄòµo¦æ·sªÑ(¥]¬A¦ý¤£©ó¨p¶Òµ¥)¥þ©e¥Ñ¸³¨Æ·|¿ì²z¡Aµ¥¦PªÑªF¦P·N«áÄò³£ ¥Ñ¸³¨Æ·|¿ì²z¡A¤£µM³Ìªñ´X¦¸¨p¶Ò¤½¥q¦³¼x¨D¹LªÑªFªº·N¨£!?
3.¸Û¦p¤§«epºâ¤½¥q¤j·§ÁÙ¦³2280¸UªÑADS¥i¥H¼W¸ê¡A²{¦bµn°O¸ê¥»ÃB´£°ª¨ì¥i¥Hµo¦æ2»õªÑADS ¡A¬O¬°¤F¤°»ò?¡A¤£´N¬O즳2280¸UªÑ¤£°÷¤F¡A¥ýµn°O¨ì2»õªÑ¬°¤F¤§«á¶Ò¸ê¤§¥Î¡A¤§«á·|¤£·|µo º¡2»õªÑ¤£½T©w¡A¦ýµ´¹ï¬°¼Æ¤£¤Ö°_½X¤£·|®t¤G»õªÑ¤Ó¦h¡A¤£µM¨S¨Æµn°O¨ì³o»ò¦h·F¹À¡A¦pªG¨S ¦³¸ÕÅçµ²ªG¨Ó´£°ªªÑ»ù¡A¥H¹ê°È¤W¨Ó¬Ý³q±`¨p¶Ò»ù®æ¤£·|¶W¹L²{ªÑ»ù®æ¡A¥H²{¦bªÑ»ùºâ0.45¦n¤F ¡A´Nºâµoº¡2»õªÑ¦n¤F¡A¤]¤~Äw¸ê0.8»õ¡A³s°µ¤T´Á³£¤£°÷¡A©Ò¥H§Ú¹w¦ô¤j·§²v¬O¥H¤U2ºØ±¡ªp
(1)¤Þ¶i¦X§@¹Ù¦ñ¡AµM«á¨«¦X§@¹Ù¦ñ±ÂÅvªº¼Ò¦¡¡Aµ¥¨ì3´Áµ²ªG½T»{«á¥Ñ¦X§@¹Ù¦ñ¦¬ÁÊ¡A¦ý«e´Á ¨p¶Ò¦X§@¹Ù¦ñ¼W¸ê¤JªÑ¼Æ¶qÀ³¸Ó«Ü¥iÆ[¡A²¦³º¤½¥q³£¨S¿ú¥i¥H¿N¤F¡A¨S¦X§@¹Ù¦ñ´£¨Ñ¸êª÷¤] ª±¤£¤U¥h¡A½Í§P±ø¥ó¤£·|¤Ó¦n¡C
(2)¥i¯à¶Ò¸ê®Éµ{¨S³o»ò§Ö¡Aµ¥¸ÕÅçµ²ªG¥X¨Ó¡A¥B¾Ô¥B¨«¡AªÑ»ù¼Q¥Xªº¸Ü¡A«áÄò¶Ò¸êªÑ¥»¤]¤£¦Ü ©ó¿±µÈªº¤Ó§Ö¡A¦ýn¬O¸ÕÅçµ²ªG¥X¨Ó¤£²z·Q¡AÀ³¸Ó´Nª½±µ¦º¤`¤F¡A¨«³o¤è¦¡¥i¥H´Á«Ý¤@¤U¡A ¥Nªí¤½¥q¥i¯à«Ü¦³«H¤ß¡A¦ý¾÷²v¤£°ª¡A²¦³º·ÀI¤Ó¤j¤FXD¡C ¤£ºÞ¬O¨«(1)©Î(2)¡A³£¥i¥H¬Ý¥X·íªÑ»ù§C°g¡AÄw¸ê¯à¤O´N¬OºG¡A³o¤]¬O§Ú³Ì²×©ñ±óASLANªºì¦]¡A ¤½¥q°ª¼hµLªkºû«ùªÑ»ù¡An¿ú´N¬On®³¤j¶qªÑ²¼¨Ó´«¡A¤@³s¦ê¤U¨Ó´N¬O³ø¹S²v¥i¯à¨S·Q¹³¤¤¦n¡A §Ú¤]ª½±µ¦Y·l¥X³õ¡AÃÄ¥i¯à«Ü¦n¡A¦ý¹ï¤½¥q°ª¼hµLªke¦P¡A¦Y·l§Ú»{¤F¡A¤Ï¥¿§ë¸ê¦Y·l¥¿±`¡A¥u ¬O§Ú11/8µo¤å´¿¸g¤ÀªR¹L¡A¦pªG¥«È1»õ¤¸¬ù²öµ¥©ó¤@ªÑads6¤¸(«e´£¬OªÑ¥»¤£¿±µÈ)¡A±µµÛ¤@Ó ¤ë«áª½±µ·Ç³Æ´£°ªµn°O¸ê¥»ÃB¡AÁöµMÁÙ¨Sµo¦æ¡A¦ý§ó¥[¦LÃÒ°ª¼h¨S¯à¤O´£°ªªÑ»ù¡A¥u¯à¤j¦LªÑ²¼ Äw¸ê¡A¥H²{¦³®Éµ{¨Ó¬ÝEblasakimab¸òFarudodstat³Ì§Ö³£n¦~¤¤¤~¦³µ²ªG¡A§Ú¬O¤£Ä±±o¤½¥q°ª¼h ¦³¿ìªk¥i¥H¦b³o¬q®É¶¡´£°ªªÑ»ù³â¡A´Nµ¥µÛ¬Ýµ²ªG¦p¦ó§a¡A¥uı±o¤½¥q¤§«eÄw¸ê¤£¤Ö¡Aµ²ªG¤@¤â µP¥´¦¨³o¼Ë¡A¿ú³£¿N¥ú¤FÁÙ¨SÔ£¦¨ªG¡A§Ú¤]¬O¥u¯àW¯º¡C 4.¤p¤Ï»é¤@¤U©Î³\¥Îµoº¡2»õªÑ¨Ó°²³]¥i¯à¬O¦³ÂI¯B¸Ø¤F¡A¦ý§Ú¦¬ÁÊ»ù®æ¥i¤£¬O¥Î3~10»õ¨Óºâ³á¡A §Ú¥i¬O´£°ª¨ì20»õ¤FXD¡A¦pªG³Ì«á¥uµo1»õªÑ¡A¦ý¦¬ÁÊ»ù5»õ¤¸¡A¥i¬O¤@ªÑ¥u¦³5¤¸³á¡A¦ýµo¦æªÑ ¼Æ¦h¡AÄw±o¸êª÷¸û¦h¡A²bÈÂॿ¼Æ¤F¡A¤½¥q¥«È¤~¦³¤£§C©ó²{ª÷¤ô¦ìªºÄ³ÃD¡A²¦³º²{ª÷³¡¦ì°£¤F ɨӪºÁÙ¦h¤F¼W¸êªº¸ê¥»¡A¹ï¦¬ÁÊ¥«È¤]¬O¯à´£°ª³â¡A¥u¬O®Ä¯q·¥«×¤£¹ü´N¬O¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/28 ¤W¤È 09:31:23
²Ä 6523 ½g¦^À³
|
¤µ¤Ñ¦¬½L«á¦³¤@µ§±µªñ63¸UªÑ¦¨¥æ¡AªÑ»ù¥¼¥¨¤jªi°Ê¡A
§Ú»{¬°¬O¯S©w¤H¤¬ºV¥æ©ö¡A
½Ð°Ý¤j¤j̬ݪk¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/27 ¤U¤È 10:26:53
²Ä 6522 ½g¦^À³
|
½Ð¤Å§â¼W¥[ªk©wªÑ¥»»Pµo¦æ·sªÑ²V¬°¤@½Í , ªk©wªÑ¥»¬O«ü¤½¥q¨Ìªk¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº³Ì¤j¼Æ¶q¡C ¥i¤À¦¸¼W¥[ªk©wªÑ¥», ¤]¥i´î¤Öªk©wªÑ¥», ¥u¬Oµ¹¤@ÓÃB«× , ¤½¥q·|¨Ì¾Ú¹ê»Ú±¡ªp¼u©Ê¨Ï¥Î´£¨Ñ¤FÆF¬¡©Ê ©M¥¼¨ÓÄw¶°§ó¦h¸ê¥»ªº¯à¤O¡C¨Ï¤½¥q ¯à°÷§ì¦í¦¨ªø¾÷·|¡A§l¤Þ§ë¸ê,«P¶i¨ÖÁʹê¬I, ¼W¥[ªk©wªÑ¥»¤£·|ª½±µ ¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ùÈ¡Cµo¦æ·sªÑ¤~·|µ}ÄÀªÑÅv , ¥H«eªk©wªÑ¥»10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ ,¥»¦¸Á{®ÉªÑªF·| ªk©wªÑ¥»10»õªÑ´¶³qªÑ»P50»õªÑ´¶³qªÑ¶i¦æªí¨M( 50»õ´¶³qªÑ³o¬O¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº ³Ì¤j¼Æ¶q,³Ì«nªº¬O¹ê»Úµo¦æªÑ¼Æ, ³Ì«nªº¬O¹ê»Úµo¦æªÑ¼Æ, ³Ì«nªº¬O¹ê»Úµo¦æªÑ¼Æ, ¹ê»Úµo¦æªÑ¼Æ·|¤ñ ªk©wªÑ¥»¤Ö )
ªoºj¤j»¡: ¥H³Ì«á¼W¸ê¨ì50»õªÑ=2»õªÑADS¨Óºâ¡A´Nºâ³Ì«á³Q20»õ¤¸¦¬ÁÊ¡A´«ºâ¦^¨Ó¤]¤~¤@ªÑADS10¤¸ ½Ð°Ý¤½¥qÁÙ¨S¤½§in¹ê»Úµo¦æªÑ¼Æ¤£¯à¥Î°²³]¼W¸ê¨ì50»õªÑ´¶³qªÑ¨Ó¶i¦æ½×z
¼g³o»ò²M·¡¦n¦n¬Ý
1 ªk©wªÑ¥»¬O«ü¤½¥q¨Ìªk¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº³Ì¤j¼Æ¶q¡C¥¦¥Nªí¤½¥q¥i¥Hµo¦æªºªÑ²¼Á`»ùÈ¡C
2 ¤½¥q¿ï¾Ü¼W¥[ªk©wªÑ¥»ªºì¦]¦³«Ü¦h¡C¥¦¥i¯à¬O¬°¤F¾AÀ³¥¼¨Óªº¦¨ªø©MÂX±ip¹º¡A§l¤Þ§ë¸êªÌ©M¸êª÷¡A «P¶i¨ÖÁÊ¡A©Î¹ê¬Iû¤u«ùªÑp¹º¡]ESOP¡^
3 ¼W¥[ªk©wªÑ¥»¬°¤½¥q´£¨Ñ¤FÆF¬¡©Ê©M¥¼¨ÓÄw¶°§ó¦h¸ê¥»ªº¯à¤O¡C¥¦¨Ï¤½¥q¯à°÷§ì¦í¦¨ªø¾÷·|¡A§l¤Þ§ë¸êªÌ¡A «P¶i¤½¥q¦æ°Ê¡A¨Ã³z¹Lû¤u«ùªÑpµe¨ó½Õû¤u§Q¯q¡C
4 ¼W¥[ªk©wªÑ¥»ªº¬yµ{¨Ì¥qªkºÞÁÒ°Ï©M¤½¥q³¹µ{ªº¤£¦P¦Ó¦³©Ò¤£¦P¡C¤@¯ë¥]¬AÀò±o¸³¨Æ·|§åã¡B³z¹LªÑªF·| ´M¨DªÑªF§åã¡B¿í¦uºÊºÞn¨D¡Bק綠¥q³¹µ{
5 ªk©wªÑ¥»¼W¥[«á¥i¥H³z¹LÀò±o¸³¨Æ·|©MªÑªF§å㪺Ãþ¦ü¬yµ{¨Ó´î¤Öªk©wªÑ¥»¡CµM¦Ó»Ý¿í¦uªk«ßn¨D¨Ã¿í´` ´î¤Öªk©wªÑ¥»ªº¥²nµ{§Ç
6 ¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ùÈ¡CµM¦Ó¡A¦pªGµo¦æ·sªÑ¡A´N·|µ}ÄÀªÑÅv¡C ²{¦³ªÑªF¦³Åv¥H¨ä²{¦³«ùªÑ¤ñ¨ÒÁʶR·sªÑ¡A¥Hºû«ù¨ä«ùªÑ¤ñ¨Ò¡C
7 ¼W¥[ªk©wªÑ¥»»Pµo¦æ·sªÑ¬O¤£¬Û¦P , ¥[ªk©wªÑ¥»¬O«ü´£°ª¤½¥q¥i¥Hµo¦æªºªÑ²¼¼Æ¶qªº¨î¡C¥t¤@¤è± µo¦æ·sªÑ¯A¤Î¹ê»Ú³Ð«ØªÑ¥÷¨Ã±N¨ä¤À°tµ¹ªÑªF
8 ¥[ªk©wªÑ¥»®É»Ýn¤½¥q¦b¼W¿í¦u¨äºÞÁÒ½d³ò¤º¯S©wªºªk«ß©MºÊºÞn¨D¡C³o¨Çn¨D¥i¯à¥]¬A´£¥æ¥²nªº¤å¥ó ¡B¤ä¥I¶O¥Î¥H¤ÎÀò±oºÊºÞ¾÷ºc©MªÑªFªº§åã
9 ¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT¤½¥qªº°]°È³øªí¡CµM¦Ó¡A·í¦]¼Wµo¦Óµo¦æ·sªÑ®É¡A¥i¯à·|¼vÅT¸ê²£t¶Åªíªº Åv¯q³¡¤À©M¨CªÑ¬Õ¾l¡]EPS¡^ªºpºâ¡C
10 ªk©wªÑ¥»¨Ó¥i¥H®Ú¾Ú¤½¥qn¨D¦h¦¸¼W¥[¡CµM¦Ó¨C¦¸¼W¸ê³£»Ýn¿í¦uªk«ßµ{§Ç¨ÃÀò±oªÑªF©MºÊºÞ¾÷ºcªº¥²n§åã¡C
¸ê°T¨Ó·½ : Understanding the Increase in Authorized Share Capital: A Comprehensive Guide
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/27 ¤U¤È 06:06:06
²Ä 6521 ½g¦^À³
|
¨Ì³o®a¤½¥q¸Û«H¡A
¥¼¨Ó¦¨¥\ªº§Æ±æ¡AÀ³¸Ó¬O¤£¤j¡A
¤Ñ©R¤j¡A¤]¥i¯à¦¤w±ó¨®¤F¡A
ªüÀ±ªû¦ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/12/27 ¤U¤È 12:55:35
²Ä 6520 ½g¦^À³
|
n¹w´úªÑ»ù¦V¤Uªº²z¥Ñ¤Ó¦h¤Fªü¡A¦Ó¥B§Ú°ò¥»¤W³£¬O®Ú¾Ú¤½¥q´¦ÅSªº°]³ø¸ò ¸ê°T±Ôz¡A¤£¹³ª©¤W¤j¤j±q¼Æ¾Ú¥¼¤½¥¬´N¶}©l¹w´ú¸ÕÅçµ²ªG¡A³Ì«á¸ÕÅçµ²ªG ¥X¨Ó¤£¦p¹w´Á¤]¥i¥HÄ~Äò§j±·¡AµM«á¦UºØ¹w¦ô¨ÖÁʮɵ{¦ý³Ì«á³£¦UºØdelay¡A ³o¼Ë³£¸Ë¨S¨ÆÄ~Äò½Ð¤j®aÅÞ¿è«ä¦Ò¤F¡A§ÚˬOı±o§ÚÆZ¤¤¥ß«ÈÆ[ªº¡A¨ä¥L¬Ý Ãaªº¤H¤]³£¬O´¿¸gªº·à¤Íªü¡A¬O¯uªºÄê¨ì³s´¿¸g¤j¶q«ù¦³ªº³£¸õ²î¡A¬ÝµÛªÑ »ùÄ~Äò§C°g¨Ó¦R¼Ñ¡A¥H¤U¬O²³æ´XÂI¤£¬Ý¦nªºì¦]¡A¦]¦¹§Ú¤]¥X²Maslan¡A ²{¦bÄ~ÄòÃöª`¥u¬O·Q¬Ý¬Ý³Ì«á·|¤£·|¯uªº¤U¥«¡Aµ¥¯uªº¤U¥«´Nª¾¹DOTC¥æ©ö ¥u¬O»¡»¡¡A°ò¥»¤WµL¥æ©ö¥i¯à...
1.¥Ø«e´X®a§ë¸ê¾÷ºc§¡µ¹¥XUSD16¤¸¤W¤Uªº¥Ø¼Ð»ù¡A¦ý¥h¬Ý¤@¤U¤ÀªR®v(CHEN YI)ªº¸ê®Æ¡A±Æ¦W¶È¤¤¬q¡A¹w´ú¦¨¥\²v¤£¨ì30%¡A¥§¡³ø¹S²v-10%¥H¤W¡A¥t ¤@®a¤]®t¤£¦h¡A³o¨Ç¤ÀªR®vµ¹¥Xªº¥Ø¼Ð»ù§Ú¬Oı±o°Ñ¦Ò¥i¥H¡A¦ýn©^¦p¦c ¯å¤j¥i¤£¥²¡A³oÂI½Ð·à¤Í°Ñ¦Ò§Y¥i¡C
2.ºI¦Ü2023¦~Q3¤½¥q²{ª÷ÁÙ¦³4000¸U¤W¤U¡A¥Ø«e¥«È¤£¨ì700¸U§C©ó¤â¤¤²{ ª÷¬O¥¿±`ªº¡A¦]¬°¤½¥q²bȦ´N¬Ot¼Æ¤F¡A¸ê¤£©è¶Å¡AªÑªFªº¿ú¦´N³£¿N ¥ú¤F¡A¤â¤Wªº²{ª÷³£¬OɨӪº¡A©Ò¥Hn¬O¨S¦³¶Ò¸ê¦¨¥\©Î¦¬¨ìÅv§Qª÷¡A°ò ¥»¤W´N¬Oµ¥µÛ¯}²£²Mºâ¡C
3.§Ú´£¤F«Ü¦h¦¸ªÑ¥»¿±µÈªº«ÜÄY«¡A¯uªº¤§«á¼W¸ê§¹¦¨±¡§Î¤§¤U¡AìªÑªFªº «ùªÑ¤ñ¨Ò¯uªº³Qµ}ÄÀ¤Ó¦h¤F¡A¥H³Ì«á¼W¸ê¨ì50»õªÑ=2»õªÑADS¨Óºâ¡A´Nºâ ³Ì«á³Q20»õ¤¸¦¬ÁÊ¡A´«ºâ¦^¨Ó¤]¤~¤@ªÑADS10¤¸¡A¬Ý¬Ý´î¸ê«e(1ADS=5ªÑ)¤@ °ï¦Ñ·à¤Í¦b1~3¶ô¤§¶¡¡A¦]¬°¬Y¨Ç¤HºÆ¨g¹ª§j¦Ó¥[½X¤£¤Ö¡A´«ºâ´î¸ê«á(1AD S=25ªÑ)¡Aµ¥©ó¥[½X»ù®æ¦bUSD5~15¤¸¤§¶¡¡A¯uªº20»õ¤¸³Q¨ÖÁÊ¡A¥i¯à³£ÁÙ ¬O½ß¿úªº¡A§ó¦óªpÁÙ¦³§ó¦´Á¦¨¥»§ó°ªªº·à¤Í¡A´N³o¨¤«×¨Ó¬Ý¡A½Öªºµo¨¥ ¤ñ¸ûµ½·N¡A§Ú·Q¦Û¦³¤½µû³â¡A¤Ï¥¿¥[ӶȨѰѦҤ§Ãþªº¦ý®Ñ´N¥i¥H¤F¹ï§a!? 4.¤½¥qªº¬ãµo¬O§_¦¨¥\³oÓ§Ú¨S³o»ò±M·~¥i¥H§PÂ_¡A¦ý¥H³Ì¼ÖÆ[ªº±¡§Î¨Ó¬Ý ´Nºâ¤½¥q¥i¥H¬ãµo¦¨¥\¡A¥H¤½¥q²³ø¨Ó¬Ýµû¦ôAD¤j·§¥i®³¤UDupixent¬ù30% ~40%ªº¾P°â¡A¦ýDupixent¬O¥]§t¤F¤@°ï¾AÀ³¯g(COPD¡Bý³Ýµ¥)¡A°²³] Eblasakimab¬ÛÃö¾AÀ³¯g¤]³£®³¤U¡A¤]³£®³¤UDupixent¬ù30%~40%ªº¾P°â¡A ¥HDupixent°ª®p¹w¦ô¾P°â150»õ¨Ó¬Ý¡A¦ôÓ50»õ¦n¤F¡A¦ý¤½¥qÁÙn¥Iµ¹CSL ¨½µ{ª÷¸òÅv§Qª÷¡A¦©°£µ¹CSLªº´Ú¶µ¡A¹w¦ô¤j·§´N¬O®³Ó¾P°âÃB10%~15%¬O ·¥¤F¡A¤j·§¦~À禬¥i¥H¹F¨ì5»õ~7.5»õ¡A§é²{¦^¨Ó¤½¥q»ùȦh¤Ö´Nµ¹·à¤Í ¦Û¤v§PÂ_¤F(³o¬O°ò©óEblasakimab¦¨¥\¥B®³¤U¦h¼Ë¾AÀ³¯gªº±¡ªp°µ¥Xªº°² ³])¡A¦Ü©óFarudodstat³£ÁÙ¬O¥¼ª¾¼Æ´N¥ý¤£¦Ò¼{¤F.....
¥H¤W¬O§Ú¦Û¤v¤£¬Ý¦nªºì¦]³â¡A³æ¯Âı±o¦º©ê¤U¥h¡A¦¨¥\¤F¤]µLªk¤jÁÈ¡A¥¢±Ñ ¤F´N·Ç³Æ¤U¥«¡A¨º´N¤£Ä~Äò°Ñ»P¤F¡A¦ý¥H¥Ø«eªº»ù®æ¨Ó¬Ý¡A·à¤ÍÌ¥X²M¤]®³¤£ ¦^¦h¤Ö¤F¡A°ò¥»¤W´N¬O©ñµÛµ¥©_ÂÝ¥X²{¤F.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¼z²´µøª÷10152715 |
µoªí®É¶¡:2023/12/27 ¤W¤È 10:55:59
²Ä 6519 ½g¦^À³
|
www.google.com/finance/quote/ASLN:NASDAQ?sa=X&ved=2ahUKEwia4Y7bzq6DAxXgrlYBHYUVCwcQ3ecFegQIIhAf |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/26 ¤U¤È 10:23:42
²Ä 6518 ½g¦^À³
|
¦³¤H¤ß¦sµ½©À©¹¤U¹w´úªÑ»ù¡A¤S»¡¤£¥X¥ô¦ó¨ãÅé²z¥Ñ ¬Ý°_¨Ó¬O¦b¦æ¾P®£Äß¡A·Ç³Æ¦^¸É¡A§_«h¬Ý¤£¥X¥ô¦ó²z¥Ñ³o¼Ë°µ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2023/12/26 ¤U¤È 06:01:56
²Ä 6517 ½g¦^À³
|
¤w¸g´X¦~¤F¡A³o¨Ç¾÷ºc³Û¥Xªº»ù®æ¦ó®É¹F¼Ð¤F©O¡A¬Û«H³o¨Ç¾÷ºc´N¨¬°÷Åý§A½ß¥»½ß¨ì¦º |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/24 ¤W¤È 12:12:52
²Ä 6516 ½g¦^À³
|
¤£½×¬Ý¦n¬ÝÃa³£¬OÓ¤Hªº¿W¥ß«ä¦Ò»P§PÂ_¡A³£À³µ¹¤©´L«¡A§Ú¤]¥i¯à¬Ý¿ù ¼W¥[ªk©wªÑ¥»³o¬Oªk³Wªº°ÝÃD¡A¤£¬O£¸¯ë¤H¥i¥H§Ë²M·¡¡A©Ò¥H §Ú¥Î¤F½Ķª©¡A¦Ü©ó¤½¥qªº·s»D¸ê°T»P²³ø¡A§Ú»P¤j³¡¥÷ª©¤Í£¸¼Ë³£¬O¥ý¬Ý^¤åª©ªº¡A §Ú±`§ó¥¿Google½Ķªº¿ù»~¡A¦³¨Ç¤H¨S¦b¬Ý¥i¯à¤£ª¾¹D§Ú¤w§ï¹L¡A®É¶¡·|ÃÒ©ú£¸¤Á ¦pªG¦p§ë¸ê¾÷ºc¹w¦ô£¸¦~¤ºªÑ»ù16¬ü¤¸¡A¥ý«e½æªº«Ü°ª¿³ªºª©¤Í¥¼¨Ó¯uªº·|«á®¬¡C ³oÓ¥¼¨Ó¤£·|«Ü¤[¡A¥Ø«e§Ú¤ñ¸û¤£¾á¤ßªÑ»ù°ª§C¡A§Ú¤ñ¸ûÃö¤ß¨ÖÁÊ»ùªº°ª§C¡A§Ú·Q «Ü¦h¤H·|¸ò§Ú¦³¬Û¦P·Qªk¡A¥Î¦Û¦³¸êª÷§ë¸ê¡A¦b¤£¼vÅT¥Í¬¡±¡ªp¤U¤~¯à¦w¤ß§ë¸ê¡A·íµMÀò§Q»P§_¹B®ð§êºt ¬Û·í¤jªº¤ñ²v¡A¤£¬OÀ´ªº¦h´N·|Àò§Q
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/12/23 ¤U¤È 11:28:55
²Ä 6515 ½g¦^À³
|
1.¼W¥[ªk©wµn°O¸ê¥»ÃB¥»¨Ó´N¬O¤½¥q¬°¤FÂX±iÀç¹B³W¼Ò©ÎÄw¸êªº¹Lµ{¡A¨S¹ê»Úµo¦æ·sªÑ¤£·|¦³¹ê½è¼vÅT¡A¦ý³o¦¸µn°O¸ê¥»ÃB¿±µÈ¨ì5¿Ãø¹D¤£¬O¦]¬°ªÑ»ù§C·G¦Ó¾ÉPªº¡I¡H¦Ó¥B½T¹ê´N¬O¦³»Ý¨D¤~·|¥Ó½Ð¼W¥[³o»ò¦h¡A¤£µMµn°O¸ê¥»ÃB¨S¨Æ¿±µÈ¨ì5¿¬O¡I¡H 2.½T©w¼W¸ê·|¥ÑìªÑªF»{ªÑ¤£·|µ}ÄÀ«ùªÑ¤ñ¨Ò¡I¡Hµn°O¸ê¥»ÃB¼W¥[¥u¬O´£°ª¤½¥q¥iµo¦æªÑ¼Æ¤W¡A¦ý¦pªG¨«¨p¶Òªº¸Ü¥i¬O¤£·|¦³ìªÑªF»{ªÑ³á¡Aaslan003¤@´Á¸Ñª¼«áªº¨p¶Ò¡ABVF¸òK2ªº«ùªÑ¤]¬O¨p¶Ò+»{ªÑÅv¡A½Ð°ÝìªÑªF¦³«ö«ùªÑ¤ñ¨Ò»{ªÑ¡H²{¦b¤â¤W¦³aslnªº«ùªÑ¤ñ¨Ò¦³Qµ}ÄÀ¨ìÄê±¼°Õ¡C 3.±q¨º»ò¤[¥H«e¶}©lµe¤j»æ¡A¨S·Q¨ì¤j¥[½X¦b0.7¡A¯u¬O¨I±o¦í®ð¡A¨ØªA¡I 4.½Ð·à¤ÍÌ¥H«áºÉ¶q¥h¬Ý¤½¥qªº^¤å¤½§iì¤å¡A¦³®ÉÔ¤Ó¥õ¿à½Ķ³nÅé©Î¬Oª©¤Íªº·N¨£Ãø§K¦³¿ù¡AªÈµ²¦b³æ¦rªº±¹Ãã·Q¹³¤F¤@°ï¡Aµ²ªG¤½¥q¤½§i³£¨S¥J²Ó¬Ý¡A³o¦¸¼W¥[µn°O¸ê¥»³£¥Õ¯È¶Â¦r¼g¤FªÑªF·|¨Mij´N¬O±q²{¦³ªº10»õªÑ¼W¥[¨ì50»õªÑ¡Aµ¥ªÑªF·|³q¹L¡A¨S¦³¥i¯à§é°J³o¥ó¨Æ..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/23 ¤U¤È 10:22:43
²Ä 6514 ½g¦^À³
|
Ó¤H²q´ú¥i¯à¨ÖÁʪÌ--- ªÑ»ù¶W¹L280¬ü¤¸ªº¤@®a«D¬ü°ê¥Í§Þ¤½¥q ( ¤j®a¥i¥H±q²³ø¤¤¥h²q´ú¥i¯à¨ÖÁʪÌ)
¨ÖÁʽͧP¹ê¤O : TREK-DX :(´Á«Ý©ú¦~¤¤µo¥¬³o¨Ç´¿¨Ï¥Î¹L dupilumab ªº±wªÌ¤¤¬ã¨seblasakimabªºÀø®Ä¼Æ¾Ú)
TREK-AD : TREK-AD ¬ã¨sªºµ²ªGªí©ú¡Aeblasakimab ¦³¼ç¤O¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ¤¤´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¦Ó¤£¼vÅT Àø®Ä¡A¨Ã¦¨¬° AD ªº»â¥ýÀøªk FAST-AA : (´Á«Ý©ú¦~¤¤µo¥¬´³¨r¬ã¨sªº¶i¤@¨B¼Æ¾Ú)
¨ä¥L¦³¼ç¤OType 2 driven diseases COPD : (ºC©Êªý¶ë©ÊªÍ¯f ´Á«Ý©ú¦~µo¥¬³o¨Ç¬ã¨sªº¶i¤@¨B¼Æ¾Ú ) Astma : ( ®ð³Ý ) CSU ( ëC³Â¯l )
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/23 ¤U¤È 09:36:01
²Ä 6513 ½g¦^À³
|
¸ê°T¨Ó·½ : Understanding the Increase in Authorized Share Capital: A Comprehensive Guide
¼W¥[ªk©wªÑ¥»ªºì¦]
1.ÂX±i©M¦¨ªø¾÷·|¡G¤½¥q¿ï¾Ü¼W¥[ªk©wªÑ¥»ªº¥Dnì¦]¤§¤@¬O¾AÀ³¥¼¨Óªº¦¨ªø©MÂX±ipµe¡C³z¹L´£°ªÃB¡A¤½¥q¥i¥H¦b¥¼¨Óµo¦æ§ó¦hªÑ²¼¡A±q¦Ó¦b»Ýn®ÉÄw¶°§ó¦h¸êª÷¡C³o¤@¦¨ªø´£¨Ñ¤FÆF¬¡©Ê¡A¨Ã½T«O¤½¥q³B©ó¦³§Q¦ì¸m¥H§ì¦í¥X²{ªº¦¨ªø¾÷·|¡C
2.§l¤Þ§ë¸êªÌ©M¸êª÷¡G¼W¥[ªk©wªÑ¥»¨Ó¥i¥H¨Ï¤½¥q¹ï¼ç¦b§ë¸êªÌ©M¶U´Ú¤H§ó¨ã§l¤Þ¤O¡C¸û°ªªºªk©w¸ê¥»·N¨ýµÛ¤½¥q¦³¯à¤Oµo¦æ§ó¦hªÑ²¼¡A³o·N¨ýµÛ§ó¤jªºªÑ¥»°ò¦¡CÂX¤jªº¸ê¥»°ò¦¥i¥HÀ°§U«Ø¥ß§ë¸êªÌªº«H¤ß¡A¨Ã¨Ï¤½¥q§ó®e©ö¬°¦UºØ±M®×©Î¥ø·~Àò±o¸êª÷¡C
3.¦X¨Ö»P¦¬ÁÊ¡G¦b¦X¨Ö©Î¦¬Áʪº±¡ªp¤U¡A¤½¥q³q±`»Ýn¼W¥[¨äªk©wªÑ¥»¡C§@¬°¥æ©öªº¤@³¡¤À¡A³o¤@¼W¥[¥i¯à¬O«P¶i·sªÑµo¦æ ©Ò¥²»Ýªº¡C³z¹LÄw¶°ªk©w¸ê¥»¡A¤½¥q½T«O¾Ö¦³¶¶§Q¡B¦³®Ä²v¦a¶i¦æ¦¹Ãþ¥æ©ö©Ò»ÝªºÆF¬¡©Ê¡C
4.û¤u«ùªÑpµe¡]ESOP¡^¡G¤½¥q¥i¥H¼W¥[ªk©wªÑ¥»¥H¹ê¬Iû¤u«ùªÑpµe¡]ESOP¡^¡CESOP ¦®¦b³z¹L¬°û¤u´£¨Ñ¥H¹w©w»ù®æÁÊ ¶R¤½¥qªÑ²¼ªº¾÷·|¨Ó¿EÀyû¤u¡C¼W¥[ªk©wªÑ¥»¨Ï¤½¥q¯à°÷µo¦æ±Mªù¥Î©ó³o¨Çp¹ºªºÃB¥~ªÑ¥÷¡A±q¦Ó¿EÀyû¤u¨Ã¨Ï¥L̪º§Q ¯q»P¤½¥qªº§Q¯q«O«ù¤@P
¼W¥[±ÂÅvªÑ¥»ªº¹Lµ{¡G ¼W¥[ªk©wªÑ¥»ªº¹Lµ{¦]¥qªkºÞÁÒ°Ï©M¤½¥q³¹µ{ªº¤£¦P¦Ó¦³©Ò¤£¦P¡CµM¦Ó¡A¥¦³q±`¯A¤Î¥H¤U¨BÆJ¡G 1.¸³¨Æ·|§åã¡G¤½¥q¸³¨Æ·|³q¹L¨Mij¡A«Øij¼W¥[ªk©wªÑ¥»¡C¸Ó¨MijÀH«á±N´£¥æªÑªF¤j·|§åã¡C
2.ªÑªF§åã¡GªÑªF¦¬¨ì¦³Ãö¼W¥[ªk©wªÑ¥»ªº«Øijªº³qª¾¡A¨Ã¦³¾÷·|¦bªÑªF¤j·|¤W´N¸Ó¨Mij¶i¦æ§ë²¼¡C¸Ó¨Mij¥²¶·Àò±oªÑªF¥² nªº¦h¼Æ§åã¤~¯àÄ~Äò¶i¦æ¡C
3.ºÊºÞ¦X³W©Ê¡G¤@¥¹Àò±oªÑªF§åã¡A¤½¥q¥²¶·¿í¦u¬ÛÃö¥qªkºÞÁҰϪºªk«ß©MºÊºÞn¨D¡C³o¥i¯à¯A¤Î´£¥æ¥²nªº¤å¥ó¨Ã¦V¾A·í ªººÊºÞ¾÷ºc¤ä¥I¥²nªº¶O¥Î¡C
4.ק綠¥q³¹µ{¡G¬°¤Ï¬M¼W¥[ªºªk©wªÑ¥»¡A¹ï¤½¥q³¹µ{¶i¦æ¬ÛÀ³×§ï¡C³o¨Ç×¥¿®×³q±`·|´£¥æµ¹ºÊºÞ¾÷ºc¡C
µ²½× ¼W¥[ªk©wªÑ¥»¬O¤@¶µµ¦²¤©ÊÁ|±¹¡A¨Ï¤½¥q¯à°÷¾AÀ³¤£Â_ÅܤƪºÀô¹Ò¡B´M¨D¦¨ªø¾÷·|¨Ã¼W±j¨ä°]°Èª¬ªp¡C³z¹LÂX¤j¥iµo¦æªÑ²¼¼Æ¶qªº¨î¡A¤½¥q¥i¥H¬°¥¼¨ÓªºÂX±i°µ¦n·Ç³Æ¡A§l¤Þ¼ç¦bªº§ë¸êªÌ¡A¨Ã«P¶i¦UºØ¤½¥q¦æ°Ê¡CµM¦Ó¡A¤½¥q¦b¹ï¨äªk©wªÑ¥»¶i¦æ¥ô¦óÅܧ󤧫e¡A¥²¶·¿í´`ªk«ßµ{§Ç¨ÃÀò±oªÑªF§åã¡C
±`¨£°ÝÃD (FAQ) Q1: ¤°»ò¬Oªk©wªÑ¥»¡H A1¡Gªk©wªÑ¥»¬O«ü¤½¥q¨Ìªk¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº³Ì¤j¼Æ¶q¡C¥¦¥Nªí¤½¥q¥i¥Hµo¦æªºªÑ²¼Á`»ùÈ¡C
Q2¡G¬°¤°»ò¤½¥q»Ýn¼W¥[ªk©wªÑ¥»¡H A2¡G¤½¥q¿ï¾Ü¼W¥[ªk©wªÑ¥»ªºì¦]¦³«Ü¦h¡C¥¦¥i¯à¬O¬°¤F¾AÀ³¥¼¨Óªº¦¨ªø©MÂX±ip¹º¡A§l¤Þ§ë¸êªÌ©M¸êª÷¡A«P¶i¨ÖÁÊ¡A©Î¹ê ¬Iû¤u«ùªÑp¹º¡]ESOP¡^¡C
°ÝÃD 3¡G¼W¥[ªk©wªÑ¥»¹ï¤½¥q¦³¦ó¦n³B¡H A3¡G¼W¥[ªk©wªÑ¥»¬°¤½¥q´£¨Ñ¤FÆF¬¡©Ê©M¥¼¨ÓÄw¶°§ó¦h¸ê¥»ªº¯à¤O¡C¥¦¨Ï¤½¥q¯à°÷§ì¦í¦¨ªø¾÷·|¡A§l¤Þ§ë¸êªÌ¡A«P¶i¤½¥q¦æ °Ê¡A¨Ã³z¹Lû¤u«ùªÑpµe¨ó½Õû¤u§Q¯q¡C
Q4¡G¼W¥[ªk©wªÑ¥»ªº¬yµ{¬O«ç¼Ëªº¡H A4¡G¼W¥[ªk©wªÑ¥»ªº¬yµ{¨Ì¥qªkºÞÁÒ°Ï©M¤½¥q³¹µ{ªº¤£¦P¦Ó¦³©Ò¤£¦P¡C¤@¯ë¥]¬AÀò±o¸³¨Æ·|§åã¡B³z¹LªÑªF·|´M¨DªÑªF§å ã¡B¿í¦uºÊºÞn¨D¡Bק綠¥q³¹µ{¡C
Q5: ªk©wªÑ¥»¼W¥[«á¥i¥H´î¤Ö¶Ü¡H A5¡G¬Oªº¡A¥i¥H³z¹LÀò±o¸³¨Æ·|©MªÑªF§å㪺Ãþ¦ü¬yµ{¨Ó´î¤Öªk©wªÑ¥»¡CµM¦Ó¡A¿í¦uªk«ßn¨D¨Ã¿í´`´î¤Öªk©wªÑ¥»ªº¥²nµ{ §Ç«D±`«n¡C
°ÝÃD 6¡G¼W¥[ªk©wªÑ¥»¹ï²{¦³ªÑªF¦³¦ó¼vÅT¡H A6¡G¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ùÈ¡CµM¦Ó¡A¦pªGµo¦æ·sªÑ¡A´N·|µ}ÄÀªÑÅv¡C²{¦³ªÑªF¦³Åv¥H¨ä ²{¦³«ùªÑ¤ñ¨ÒÁʶR·sªÑ¡A¥Hºû«ù¨ä«ùªÑ¤ñ¨Ò¡C
Q7¡G¼W¥[ªk©wªÑ¥»»Pµo¦æ·sªÑ¬Û¦P¶Ü¡H A7¡G¤£¬O ¼W¥[ªk©wªÑ¥»¬O«ü´£°ª¤½¥q¥i¥Hµo¦æªºªÑ²¼¼Æ¶qªº¨î¡C¥t¤@¤è±µo¦æ·sªÑ¯A¤Î¹ê»Ú³Ð«ØªÑ¥÷¨Ã±N¨ä¤À°tµ¹ªÑªF
Q8: ¼W¥[ªk©wªÑ¥»¬O§_¦³¥ô¦óªk«ßn¨D©Î¨î¡H µª8¡G¬Oªº¡A¤½¥q¦b¼W¥[ªk©wªÑ¥»®É»Ýn¿í¦u¨äºÞÁÒ½d³ò¤º¯S©wªºªk«ß©MºÊºÞn¨D¡C³o¨Çn¨D¥i¯à¥]¬A´£¥æ¥²nªº¤å¥ó¡B¤ä¥I ¶O¥Î¥H¤ÎÀò±oºÊºÞ¾÷ºc©MªÑªFªº§åã¡C
Q9¡G¼W¥[ªk©wªÑ¥»¬O§_·|¼vÅT¤½¥qªº°]°È³øªí¡H A9¡G¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT¤½¥qªº°]°È³øªí¡CµM¦Ó¡A·í¦]¼Wµo¦Óµo¦æ·sªÑ®É¡A¥i¯à·|¼vÅT¸ê²£t¶ÅªíªºÅv¯q³¡¤À©M¨CªÑ ¬Õ¾l¡]EPS¡^ªºpºâ¡C
Q10¡Gªk©wªÑ¥»¨Ó¥i¥H¦h¦¸¼W¥[¶Ü¡H A10: ¬Oªº¡Aªk©wªÑ¥»¨Ó¥i¥H®Ú¾Ú¤½¥qn¨D¦h¦¸¼W¥[¡CµM¦Ó¨C¦¸¼W¸ê³£»Ýn¿í¦uªk«ßµ{§Ç¨ÃÀò±oªÑªF©MºÊºÞ¾÷ºcªº¥²n§åã¡C
¸ê°T¨Ó·½ : Understanding the Increase in Authorized Share Capital: A Comprehensive Guide
¥H¤UÓ¤H¤À¨É:
A ¥»¦¸´£°ªªk©wªÑ¥»ªº½T»P¨ÖÁʦ³Ãö
B ¤½¥q¤½§i´£¨ìµø±¡ªp³q¹L¥H¤UªÑªF¨Mij ( ¥H«eªk©wªÑ¥»10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ )
¡]A¡^10,000,000 ¬ü¤¸¤À¬° 1,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±ÃB©Î²¼±»ùÈ 0.01 ¬ü¤¸¡C (B) 50,000,000 ¬ü¤¸¡A¤À¬° 5,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±ÃB©Î²¼±»ùÈ 0.01 ¬ü¤¸¡C
¥H¤W¨â®×³q¹Lªí¨M ( ¤]¦³¥i¯à¾Ü¤¤ )
°ÝÃD 6¡G¼W¥[ªk©wªÑ¥»¹ï²{¦³ªÑªF¦³¦ó¼vÅT¡H
A6¡G¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ùÈ¡CµM¦Ó¡A¦pªGµo¦æ·sªÑ¡A´N·|µ}ÄÀªÑÅv¡C²{¦³ªÑªF¦³Åv¥H¨ä ²{¦³«ùªÑ¤ñ¨ÒÁʶR·sªÑ¡A¥Hºû«ù¨ä«ùªÑ¤ñ¨Ò¡C
C ¬Ý§¹ Understanding the Increase in Authorized Share Capital: A Comprehensive Guide ½Ķª©
¦A¬Ý¤½¥q¥l¶}2024¦~1¤ë24¤éÁ{®ÉªÑªF¤j·|ªº¤½§i·|µo²{ ¦ü´¿¬ÛÃÑ «e«á©IÀ³
D ÁÙ¦n 0.7¥H¤U¦³¦A¤j¥[½X ¦¨¥»¤j°¤@¥b
E ¥æµ¹¤jªÑªF, ºÊ¹î¤H BVF Tang capital Vivo Capital Citadel ¥h§ë²¼¨M©w(À³¸Ó¤£·|ªí¨M¹ï¦Û¤v¤£§Qªº¨Æ)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/12/23 ¤U¤È 05:56:14
²Ä 6512 ½g¦^À³
|
«ç»ò·|¨S¦³§C»ù¥i¥H¦^¸É©O¡AªÑ»ù¤£´N¤S¯}©³¤F¶Ü......¡A³o¦¸ªk©wµn°OªÑ¼Æ¤@¦¸¼W¥[40»õªÑ¯uªº¬O¤Ó«ÕÀq¤F¡A¥Hasln¤½¥¬ªº2023Q3°]³øÅã¥Ü¡AÁöµMªk©wµn°OªÑ¼Æ¦³10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ¡A25ªÑ=1ads¨Óºâ¡A¤j¬ù¬°1720¸UªÑads¡Aµ¥©óÁÙ¦³2280¸UadsªºªÅ¶¡¥i¥H¼W¸ê¡A³o¦¸ª½±µ§âµn°OªÑ¼Æ¼W¥[¨ì50»õªÑ¡A¦pªG¯uªº¥þ³¡µo¦æ¥Nªí·|¦³2»õªÑªºads¡AÓ¤H¤£t³d¥ô²q´ú¥i¯à¬°¤F¥¼¨Ó¦X§@¹Ù¦ñ´£¨Ñ¤T´Á¸êª÷¦Ó¼W¸ê¤JªÑ¥ý°µ·Ç³Æ¡A¦ý¥Ñ©óªÑ»ù§C°g¡A©Ò¥H¼W¸êªÑ¼Æ¥u¯à¿±µÈªº¦p¦¹¥¨¤j¡A쥻2280¸Uadsªº®Ú¥»¤£¨¬¥H©Ó±µ¡A½Ö¥sªÑ»ùÄꦨ³o¼Ë¡A©Ò¥H¤~»¡ºÞ²z¶¥¼h¤£ª`«ªÑ»ù¡A¾ÉPÄw¸ê®É»Ýn¼Wµo¤j¶qªÑ²¼¡A즳ªÑªF«ùªÑ³Qµ}ÄÀ¨ìÃz¬µ¡A³oºØºÞ²z¶¥¼h®Ú¥»µLÃÄ¥i±Ï¡A§Y¨Ï³Ì«áUSD20»õ¤¸³Q¦¬ÁÊ¡A§éºâads¤@ªÑ10¤¸¡A¬Û«HÁÙ¬O¦³¤j³¡¤À¦Ñ·à¤Í¬O½ß¿úªº¡A²¦³ºn¬O¨S¦³¦b³Ìªñ¥[½XÅu¥ªº¸Ü¡A¯uªº¦Ñ·à¤Í«ùªÑ¦¨¥»À³¸Ó³£¤£§C¡A¨ººØ¦¨¥»0.5¥i¥H½´X¿ªº´N¤Ö»¡¤F§a¡A¤£µM²{¦b0.4¤SÁȦh¿°Õ¡A«ùªÑ¦¨¥»¬O¥i¥H¥Î³Ûªº´N¬O¤F¡I¡Hn¤£n¬Ý¬Ý±q¥xªÑ´N¶}©l¤@¸ôµe¤j»æªº®ÉԪѻù¦h¤Ö¡A³o»ò¬Ý¦nªº¸Ü¡AÁ`¤£·|¦´Á´N¨S«ù¦³¡A²{¦b¤~¤j¶q§C»ù¶R¶i§a¡AÁ`¤§¡A¯uªº¦Ñ·à¤Í̦h«O«¡A²{¦b³B¤À¤]¦¬¦^¤£¤F¤°»ò¤F¡A¥u¨D³Ì«áµ²ªG¯à¦^¥»´N¦n¡A¤jÁÈÀ³¸Ó¬O¨S«ü±æ¤F..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/12/23 ¤U¤È 05:19:29
²Ä 6511 ½g¦^À³
|
¤w¸g¨ì½T»{¥ë¦ñªº³Ì«á¶¥¬q¤F¡C¤£µM¤£¥Î¤j¶O©P±i¥hÂX±iªÑ¥»¡C¹w´ÁªÑªF·|¶}§¹´N·|ª¾¹D¥ë¦ñ¬O½Ö¡C¦Ó¥B¹ê»Ú»{ªÑªÑ»ù©MªÑ¼Æ¤½¥q³£ºâ¦n¤F,¥u¬O¥Ø«e¤£¯à»¡¡C³Ì«á,¥ë¦ñ©Òñªº«´¬ù¤@©w¬O»¡,¤T´ÁÁ{§É¼Æ¾Ú«Ü¦n®É,¦³Àu¥ý½Í§P¨ÖÁÊÅv§Q¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·RµL10148552 |
µoªí®É¶¡:2023/12/23 ¤U¤È 01:26:40
²Ä 6510 ½g¦^À³
|
To ¤p©ú¤j: 0.01¥u¬OªÑ²¼±ÃB¡A¹ê»Ú»{ªÑ»ù®æ¸òªÑ¼Æ¡A¤½¥q©|¥¼¤½¥¬¡H
µù1¡G¦¹¦¸¼W¥[40»õªÑ¥»¡A±À´ú¬O¥Î¨Ó¼W¸ê¡B3´Á¸ÕÅç¥Î. µù2¡G2024.1.24³q¹Lij®×«á¡A´N·|¦A¶i¦æ«á±ªº¼W¸ê»{ªÑ¡A³o®É«á´N·|ª¾¹D¬O½Ö§ë¸ê¡AÀRÀRµ¥«Ý3´Á¹êÅçµ²ªG¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/23 ¤W¤È 11:12:48
²Ä 6509 ½g¦^À³
|
Ãö©ó¥l¶}2024¦~1¤ë24¤éÁ{®ÉªÑªF¤j·|ªº¤½§i
2023¦~12¤ë22¤é¡AASLAN Pharmaceuticals Limited¡]¡u¥»¤½¥q¡v¡^µo¥X±N©ó2024¦~1¤ë24¤é¤W¤È9:00¦b²H°¨¿ü¤j¹D3¸¹¼h¥l¶}Á{®ÉªÑªF¤j·|ªº³qª¾¡]¡u³qª¾¡v¡^ 18 Centennial Tower, Singapore 039190 ¨Ñ¦Ò¼{¨Ãµø±¡ªp³q¹L¥H¤UªÑªF¨Mij¡G
¨Mij¤@¡G
(i) §@¬°¤@¶µ´¶³q¨Mij¡A¼W¥[¤½¥qªºªk©wªÑ¥»¡G
¡]A¡^ ¸ê®Æ¨Ó·½¡G10,000,000 ¬ü¤¸¤À¬° 1,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±ÃB©Î²¼±»ùÈ 0.01 ¬ü¤¸¡C (B) TO¡G50,000,000 ¬ü¤¸¡A¤À¬° 5,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±ÃB©Î²¼±»ùÈ 0.01 ¬ü¤¸¡C
¨Mij2¡G
(i) §@¬°¤@¶µ¯S§O¨Mij¡A¤½¥q²{¦³ªº²Õ´³¹µ{¤jºõ©M³¹µ{²Ó«h¡]§Y²Ä¤Q¤@¦¸×q©M«zªº¤½¥q²Õ´³¹µ{¤jºõ©M³¹µ{²Ó«h¡^¥þ³¡¥Ñ·sªº²Õ´³¹µ{¤jºõ©M³¹µ{²Ó«h¨ú¥N¡]¥»¤½¥q²Ä¤Q¤G¦¸×q¤Î«zªº²Õ´³¹µ{¤jºõ¤Î³¹µ{²Ó«h¡C
Ãö©óij®×¤Gªº»¡©ú¡G¹ï¤½¥q³¹µ{¤jºõ¤Î³¹µ{²Ó«hªº×§ï¶È©ó¤½¥q³¹µ{¤jºõ²Ä¤C±ø¸ü©ú¤½¥q¸ê¥»ªº×§ï¡A¥H¤Ï¬M¤Wzªk©wªÑ¥»ªº¼W¥[¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/23 ¤W¤È 09:53:03
²Ä 6508 ½g¦^À³
|
¦U¦ì¤j¤j
¨È·à±d1¤ë24¤éÁ{®ÉªÑªF·|¡A
¨Mij®×¤@¡A0.01¬ü¤¸¡A¬O¼W¸ê¶Ü
¬Ý¤£¤ÓÀ´ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/19 ¤U¤È 07:33:28
²Ä 6507 ½g¦^À³
|
¸Ø±i¤j ·PÁ§Aªº§ó¥¿»P¸É¥R¡AÅý¤j®a¦Y¤F©w¤ß¤Y¡Aªº½T¦pµL¤j©Ò»¡«K©y´N¬O³Ì¤j§Q¦h¡A³o¤äªÑ²¼¶^ªº²ö¦W¨ä§®¡A «ç»ò¤U¥h«ç»ò¤W¨Ó¡A³Ì«á·|ÁÙ¤©¤½¹D¡A©ö¸g´£¨ìé·¥¥²´_¤ñ³ë´c¦Hªº±¡ªp¨ì¹F·¥ÂI«á¡A¥²©wÂà¦n¡C µ¥¨ì§Q¦h¨ÓÁ{¡A¥X²{Á`¶R¶i¡A¨º»ò¦h¤H·mµÛ¦^¸É¡An¥Î¤°»ò»ù®æ¤~¯à¶R¨ì¡H ¤H±ó§Ú¨úªº¹D²z£¸ÂI¤]¤£ÃøÅ鮩¡C
«ö·Ó¨º´µ¹F§J³W©w¡A¥ø·~ªÑ»ù³s30¤Ñ§C©ó1¬ü¤¸·|¦¬¨ìĵ§i¡A¥¼¨Ó180¤Ñ¶·³]ªkÅýªÑ»ù¦^¤É¨ì1¬ü¤¸¡A§_«h´N·|±Á{¤U¥«©R¹B¡C¦ý¹ê»Ú±¡ªp¬O¡A³\¦h¤½¥q¥i¥H¥D±i¦AÀò±oÃB¥~¤@¦¸180¤Ñ¼e´Á¡A§Y«K¯uªº³Qn¨D¤U¥«¤]¥i¥H¤W¶D¡A¦b³o¬q´Á¶¡¨ÌµM¯àºû«ù±¾µP¦a¦ì¡C
¥H¤W¤À¨É¡A¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/12/19 ¤U¤È 05:22:41
²Ä 6506 ½g¦^À³
|
§ó¥¿: ªÑ»ù§C©ó1¬ü¤¸¡A¸g¹L30¤Ñ«á¡A±N³Qĵ§i©µ«á6Ó¤ë§ïµ½(§Y113¦~6¤ë«eªÑ»ùn°ª©ó1¬ü¤¸³sÄò10¤Ñ)¡A ¦Ó113¦~6¤ë©¡º¡(ÁÙ§C©ó1¬ü¤¸)ÁÙ¯à¦A©µ6Ó¤ë¡A§Y113¦~12¤ëYªÑ»ù¤´§C©ó1¬ü¤¸¡A¤~·|³Qn¨D¤U¥«¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·RµL10148552 |
µoªí®É¶¡:2023/12/19 ¤U¤È 01:56:58
²Ä 6505 ½g¦^À³
|
±q7¤ë¤G´Á¸Ñª¼¨´¤µ¡A¥¼¨£¥ô¦óªº§QªÅ¡AªÑ»ù¥Ñ4.X¶^¨ì0.43¤¸¡A¤w¸g¸y±Ù¤Q¤À¤§¤@¡C ¦Ó¶^¦h´N¬O³Ì¦nªº§Q¦h!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/18 ¤U¤È 05:11:30
²Ä 6504 ½g¦^À³
|
§CÀÉ¥X¤j¶q¡Aµ´«DÃa¨Æ¡A
¦p¦³¦^´ú¾ã²z¤£¯}«e§C0.43¡A¦³¾÷·|§Î¦¨²Ä2°¦¸}¡A
¦Aµ¥«Ý®ø®§°t¦X¡A
°µ¤@¬q¹³¼Ëªº¤Ï¼u¡A
¨ì¤F³o®ÉÔ¤]¨S¤°»ò¦n¿éªº¤F¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2023/12/18 ¤U¤È 02:46:51
²Ä 6503 ½g¦^À³
|
³oÓ¤pªi¬q³Ì§C¥Ñ0.43º¦¨ì0.66³Ì«á¦¬0.578...¦ý¬O«o¯d¤Fªøªøªº¤W¤Þ½u¥BÃzªñ´Á¤Ñ¶q140¸UªÑ,¦pªG2¤Ñ¤º¨S¦³¬ð¯}³oÓ0.66»ù¦ì,±N·|¶}©l©¹¤U¨«,¬Æ¦Üª½±µ¯}0.43ªº»ù¦ì©¹0.2«e¶i.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/16 ¤U¤È 10:44:14
²Ä 6502 ½g¦^À³
|
§ó¥¿»P¸É¥R
¥b¤s¸y¤j
1 TREK-AD¤G´Á§¹¦¨«á¥¿ÁÚ¦V¤T´ÁÁ{§É, ¦³¼ç¤O¤S¯àÁÚ¦V¤T´ÁÁ{§É¦ó¨Ó¥¢±Ñ, ªÑ»ù³QÄY«¿ù±þ»P§C¦ô, ¤w½æ¥X©Î¨S½æ¥X³£¬O Ó¤H¿ï¾Ü¨S¦³¹ï©Î¿ù, ®t§O¦b©ó¤w½æ¥X½T©wÁ«·l , ¥¼½æ¥XÁÙ¦³Â½Âà¾÷·| ¨Ì¾Ú¤½¥q12¤ë12¤é ¤½§i¸ê°T eblasakimab ªvÀø¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢ªº TREK-AD 2b ´Á¬ã¨s¨ú±o¦¨¥\«á¡A ¥Ø«e¥¿¦b½T»{¼ç¦b¦X§@¹Ù¦ñ¡C
2 TREK-DX°ò©ó TREK-AD ¬ã¨sµ²ªGªº§ó·s¼Ð·Ç(¥l¶ÒEASI ¦Ü¤Ö18¤À , IGA score 3 ©Î4 )¡A¦b¦³dupilumab¸gÅ窺±wªÌ¤¤¬ã¨seblasakimabÀø®Ä, ³oÓÁ{§É¸ÕÅçªvÀø16¶g¡A°lÂÜ8¶g¡AÁ`¦@24¶g( 6Ó¤ë)¡A¥ý«e¦¬¤Jªº¨ü¸Õ«Ü¦h¤w¹FEASI 18¤À¥H¤W ¡A¬Æ¦Ü¤j©ó21¤À¡A«á±¦¬®×¥u¬O¦b¸É¨¬²Å¦X¦¬®×¼Ð·Ç(Ó¤H¹w¦ô2024¦~¤¤¤½§i¨ä¤¤¼Æ¾Ú) ( 2023¦~11¤ë30¤é²³øP42 ¬Ý¥XTREK-DXÄ~Äò¦¬®× TREK-DX: phase2 study in dupilumab-experienced patients on going )
3 63% ªºdupilumab ªvÀø±wªÌ¦b16 ¶g«á¥¼¯à¹F¨ì³z©ú©Î±µªñ³z©úªº¥Ö½§¡]¬ã¨sªÌÁ`Åéµû¦ô[IGA] µû¤À¬°0 ©Î1¡^¡A¨Ã¥B¦b¹F¨ì³oºØ¤ÏÀ³ªº±wªÌ¤¤36¶g«á¤j¬ù¤@¥b¦bÀH«áªºªvÀø«áµLªkºû«ù³oºØ¤ÏÀ³ , ©Ò¥H³o¬O¤@Ó¬Û·í¤jªº±wªÌ¸sÅé¡A¯Ê¥F¦w¥þ¡Bªø´Áªº´À¥NªvÀø¿ï¾Ü¡C TREK-DX ªÓt«¤j¨Ï©R
4 Farudodstat ªvÀø´³¨rªº FAST-AA ¬ã¨s¤¤¦w¥þ©Ê¼Æ¾Úªº¼f¬dÅã¥Ü¨S¦³¥X²{¨xŦ©Î¨ä¥L¦w¥þ©Ê°ÝÃD¡A¤ä«ùÂX¤j¤J²Õ¼Ð·Ç¥H ¥]¬A¤£¤ÓÄY«ªº±wªÌ¡C¦]¬°ÂX¤j¦¬®×´Á¤¤¼Æ¾Ú±N¦b2024 ¦~¤¤¤½§G
5 ¨Ì¾Ú¨º´µ¹F§J¥æ©ö©Ò«h³W©w¡A¦pªG¤½¥qªÑ»ù³sÄò30Ó¥æ©ö¤é (30¤Ñ)§C©ó1 ¬ü¤¸¡A©Î¥¼º¡¨¬¨ä¥Ln¨D®É¡AÃÒ¨é¥æ©ö©Ò´N·| µo¥Xĵ§i¡A¥²¶·¦b180 ¤Ñ¤º«ì´_ªÑ»ù¡AY¥¼¹F¦¨«K·|³Q±j¨î¤U¥«©ÎÂಾ¨ì¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò (¤j®a¥[ªo 30Ó¥æ©ö ¤é¤º¦¬½L¤j©ó1¬ü¤¸ ¦M¾÷´N¸Ñ°£ «·spºâ ( ¬ù12¤ë29¤é¥ª¥k )
6 ·í¤@¤äªÑ²¼¦]¤£²Å¦Xn¨D¦Ó³QºKµP®É¡A¥¦¨Ã¤£·|´N¦¹®ø¥¢¡C¬Û¤Ïªº¥¦¶}©l¦b³õ¥~¥æ©ö (OTC) ¥«³õ¶i¦æ¥æ©ö ªÑªF¨ÌµM¬O¤½¥qªÑªF, ¾Ö¦³ªÑªFÅv·¸(¥]¬A±ÂÅv¨ÖÁʤ]¦³§A¤@¥÷)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/12/16 ¤W¤È 12:52:10
²Ä 6501 ½g¦^À³
|
·Q»¡nˤF ¤S¬ðµMº¦25% ¦Ñ¦´N©ñ±ó¥[½X¤F ½Ð°Ý¥¼º¡1¬ü¤¸¦h¤[´N¤Sn±Á{¤U¥«? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/15 ¤U¤È 11:24:12
²Ä 6500 ½g¦^À³
|
¸É¥R»¡©ú
·Pı¨S¦³§C»ù¥i¥H¦^¸É Recruitment in TREK-DX, studying eblasakimab in dupilumab-experienced patients, using updated criteria based on findings from TREK-AD, has commenced at US sites, with additional sites in Europe expected to open in the first half of 2024.
Recruitment³oÓ¦r¬O ¥l¶Ò·s¦¨û¡A¥l¶Ò·s§L¡A¸É¥Rªº·N«ä¡A¤w¦¬®×ªº²Å¦X¼Ð·Ç¯d¥Î¡A¦A¸É¨¬¤£²Å¦X¼Ð·Ç¡]EASI ¤p©ó18¤À¡^ªº¤H¼Æ¡A¤£¬O ±q·s¦¬®×¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/15 ¤U¤È 08:39:07
²Ä 6499 ½g¦^À³
|
¤p©ú¤j Trek-dx 쥻2024¦~²Ä¤@©u¤½§iÁ{§É¼Æ¾Ú¡A¦]¬°Trek-ADµo²{¥l¶ÒEASI¤j©ó18¤À¡A¤j©ó21¤À¡A¹ï·Ó²Õ»P¹êÅç²Õ®t¶Z¤~¯à©Ô¤j¡A¤]´N¬O»¡ ¹êÅç²ÕÀø®Ä¤£·|§ïÅÜ¡A¦ý¹ï·Ó²Õ·|¦]¯e¯fÄY««×¼W¥[¦ÓµLªkÅã²{Àø®Ä¡ATREK-DX ªº©Û¶Ò¤u§@¤Q¤G¤ëªì¤w¦b¬ü°ê±Ò°Ê¡A(°ò©ó TREK-AD ¬ã¨sµ²ªGªº§ó·s¼Ð·Ç¡A¦b¦³dupilumab¸gÅ窺±wªÌ¤¤¬ã¨seblasakimabÀø®Ä¡A¼Ú¬wªº¨ä¥L¯¸ÂI¹wp±N©ó 2024 ¦~¤W¥b¦~±Ò°Ê)¡A³oÓÁ{§É¸ÕÅçªvÀø16¶g¡A°lÂÜ8¶g¡AÁ`¦@24¶g¡AÓ¤H»{¬°¬O§ó·s¦¬®×¼Ð·Ç¡A¥ý«e¦¬¤Jªº¨ü¸Õ«Ü¦h¤w¹FEASI 18¤À¥H¤W¡A¬Æ¦Ü¤j©ó21¤À¡A«á±¦¬®×¥u¬O¦b¸É¨¬²Å¦X¦¬®×¼Ð·Ç¡A±ß´XӤ뤽§i¼Æ¾Ú¨Ã¤£«n¡A«nªº¬OÀø®Än¦n¨ÖÁÊ»ù½X¤~·|°ª¡A¥t¥~쥻¦b¬ü°ê¦¬®×¡A³o¦¸ÂX¤j¨ì¼Ú¬w¡AÂX¤j¼Ú¬w¥«³õªº¥ø¹Ï¤ß±j¯P¡AThe study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms. (¹w¦ô2024¦~²Ä¤G©u¤½§iÁ{§É¼Æ¾Ú¡A AA 2024¦~²Ä¤@©u¤½§i¡^
³Ìªñ¤½§i°T®§ª`·N³o¨âÓ^¤å³æ¦r (±À´ú¦X§@¹Ù¦ñ¦b°µ³Ì«á½T»{¡A³Ì«á¿ï¾Ü) 1 process is underway to identify potential partners ¡] Identify¬O½T»{ªº·N«ä¡A¥¿¦b½T»{¦³¼ç¤O¹Ù¦ñ ¡^ 2 Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications. Selection¿ï¾Üªº·N«ä¡A ¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡A±Neblasakimab¦b²§¦ì©Ê¥Ö½§ª¢»P¨ä¥L¾AÀ³¯g±À©¹²Ä¤T´ÁÁ{§É¸ÕÅç 3¦pªGÁÙ¦b§ä¦X§@¹Ù¦ñ·|¥Î find , seekµ¥^¤å¦r ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/14 ¤W¤È 12:24:08
²Ä 6498 ½g¦^À³
|
²§¦ì©Ê¥Ö½§ª¢AD ¨r´³AA¡AºC©Êªý¶ë©ÊªÍ¯fCOPD, ¹L±Ó®ð³Ý¡A³o¥|Ó¾AÀ³¯g³£¬O¤jÃÄ¡AºÝ¬Ý¨ÖÁʪ̥X»ù¡A·Pı¥Ø«e³B¦b¦h¤èºW±Û½Í§P¤¤¡A ·íµMn¥ý§â·íªì±ÂÅv¹L¨Ónµ¹CSLªº¨½µ{ª÷»P¾P°âÅv§Qª÷¥ýCover±¼¡A¤½¥qn²bÁȦh¤Ö¡AÓ¤Hµû¦ô¦³3~10»õ¬ü¤¸»ùÈ,¤£·|¦³¤Ñ©R¤j²q´úªº¤Ñ»ù¨ÖÁÊ¡A¤£n§Ñ¤F¤½¥q°õ¦æªø±Mªø¬O¨ÖÁÊ¡C
¥H¤W¨â«h¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/13 ¤U¤È 11:49:29
²Ä 6497 ½g¦^À³
|
Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications.
¥ÎSelection ³oÓ¦r¬O¿ï¾Üªº·N«ä¡A¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡A±Neblasakimab¦b²§¦ì©Ê¥Ö½§ª¢»P¨ä¥L¾AÀ³¯g±À©¹²Ä¤T´ÁÁ{§É¸ÕÅç¡A ¸É¥R»¡©ú¡G¤w§¹¦¨¤G´Á¡A¨ä¥L¾AÀ³¯g¦pCOPD,¥i¥Hª½±µ¶i¤J¤T´ÁÁ{§É¡Aªí¥Ü¤w¦³¦h®a¥Í§Þ¤½¥q¦b½Í§P¤¤¡A¤½¥qn±q¤¤¿ï¥X±ø¥ó³Ì¦nªº¨ÖÁʪ̡A ³Ì«nªº¬O¨ÖÁÊ»ù®æ¡A»P¥Ø«eªÑ»ùµLÃö¡A³Q¨ÖÁʤ½¥q·íµMn¤U¥«¡A¤U¥«¤££¸©w¬OÃa¨Æ¡A¥i¯à¬O¦n¨Æ¡C ²×©ó·Q³q¨º¨Ç§ë¸ê¾÷ºc¬°¦ó¨S¦b©È¡A³Ì«nªº¬O¨CªÑ¨ÖÁÊ»ù®æ¡A¤£¬O¥Ø«eªÑ»ù¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/13 ¤U¤È 06:40:35
²Ä 6496 ½g¦^À³
|
¦U¦ì¤j¤j
¨Ì¥H«eºD¨Ò¤Î¤½¥q¸Û«H¡A
¨È·à±d¥¼¨Ó¨Ã¤£¼ÖÆ[¡A
Trek-dx¨ì²{¦b¦~©³¤F¡AÁÙ¦b§ó§ï±µ®×¼Ð·Ç¡A³s¼Ú¦{±µ®×n¨ì©ú¦~¤W¥b¦~¤~¶}©l¡A´Nºâ±µ®×¶¶§Q¨ì¸ÕÅ秹¦¨¡A¤w±µªñ©ú¦~¦~©³¡A¸ò¤§«e»¡©ú¦~¤W¥b¦~¸Ñª¼¡A®Ú¥»¤£¤@¼Ë¡A³o¶BÄF¶°¹Î¨S±Ï¤F¡A
²{¦bªÑ»ù¶È0.47¤¸¡A©ú¦~¦~¤¤´N¤U¥«¤F¡AÁÙ¦³¥¼¨Ó¶Ü¡A
³s¼Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/12/13 ¤W¤È 11:26:32
²Ä 6495 ½g¦^À³
|
´«¥y¸Ü»¡¡G ´N¬O¤w¸g¦³§ä¨ì¦X§@¹Ù¦ñ¡A¨Ãñ¦³·N¦V®Ñ¡C¦ý®a¼Æ©Îª÷ÃB¤£²z·Q¡A©Ò¥Hn¦h§ä´X®a¡A ¦]¬°Ã±¦³·N¦V®Ñ¡AK2 HealthVentures LLC¤~¦P·N±NÁÙ´Ú´Á®i©µ¦Ü«á¦~¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/12/13 ¤W¤È 10:39:39
²Ä 6494 ½g¦^À³
|
§Y¨Ï¤½¥q¦b¦~²×»¡©ú¥Ø«e¸ÕÅ窺´Áµ{¡A»ù®æÁÙ¬O¨S¦³°_¦â¡A¥NªíÁÙ¬O¨S¤H·Q»{¦P¥¦¡F³o¼Ë¬Ý¨Ó«ùªÑ°ªªº·à¤ÍÌ¡A¹wp3¤ë¤Sn¦A¥I¬Û·íª÷ÃBªº«OºÞ¶O¡A¤j®aÁÙ¬On«ù¬Õ«O®õ! «ö³Ì·sªº»¡©ú¨Ó¬Ý¡A©ú¦~¤W¥b¦~¶È¦³003ªº2A¼Æ¾Ú¥i¨Ñ°Ñ¦Ò¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/12 ¤U¤È 09:53:51
²Ä 6493 ½g¦^À³
|
ASLAN Pharmaceuticals¨ÖÁÊ»ù®æ°ª§C¬Ý²£«~¼Æ¶q»P¼ç¤O( 1- 4 ÂIÅýASLAN Pharmaceuticals¨ÖÁÊ»ù®æ´£°ª¬O¦X²zªº)
1 FAST-AA ¬ã¨s¦w¥þ¸ê®Æ¨S¦³µo²{·s¥X²{ªº¨xŦ©Î¨ä¥L¦w¥þ°ÝÃD (JAK §í¨î¾¯ ³Ì¤j¦w¥þ©Ê¬O¨x·l¶Ë) FAST-AA ¬ã¨sÅã¥Ü¦w¥þ¥i¥H¬°±wªÌ´£¨Ñ¦³»ùȪºªvÀø¿ï¾Ü ( ¨S¦³µo²{¨x·l¶Ë) ( ¦w¥þ©Ê+ ¦³®Ä©Ê)
2 ®Ú¾ÚTREK-AD ¬ã¨sªºµ²ªG¡ATREK-DX ¯Ç¤J¼Ð·Ç¤w¶i¦æקï¡A¥H¯Ç¤JEASI µû¤À¦Ü¤Ö¬°18 ªº±wªÌ¡A¨Ã¥B¿W¥ßµû¼fû¹ï°ò½u EASI µû¤Àªº½T»{¤w±o¨ì¹ê¬I (TREK-DX ¦b¥l¶ÒEASI µû¤À¦Ü¤Ö¬°18¤Àªº±wªÌ«á¼Æ¾Ú¹w´Á·|«Ü«GÄRȱo´Á«Ý )
3 ¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡A±Neblasakimab±À¶i AD ©M¨ä¥L¾AÀ³¯gªº²Ä¤T´ÁÁ{§É¸ÕÅç ( ¤w¸gµo²{¦¬®×¼Ð·Ç°ò½uÀã¯l±¿n©MÄY«µ{«×«ü¼Æ EASIµû¤À¦Ü¤Ö 21¤À Åý¤T´Á¦¨¥\²v¤j´T´£¤É )
4 ¸êª÷À£¤O¤j´T´î»´
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2023/12/12 ¤U¤È 08:22:13
²Ä 6492 ½g¦^À³
|
¼ÐÃÑ ©Ò¦³§Y®É¥«³õ·s»D ASLAN Pharmaceuticals ´£¨Ñ¨ä Eblasakimab ©M Farudodstat ±M®×ªº¦~²×§ó·s 20 ¤ÀÄÁ«e¤U¤È8:00 [GMT+8] ³z¹L Àô²y³q°TªÀ ªü´µ¯S±¶§Q±d¯«¸gºôµ¸ ¤À¨É Ä~eblasakimab ªvÀø¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢ªº TREK-AD 2b ´Á¬ã¨s¨ú±o¦¨¥\«á¡A¥Ø«e¥¿¦b´M§ä¼ç¦b¦X§@¹Ù¦ñ¡C TREK-DX ªº©Û¶Ò¤u§@¤w¦b¬ü°ê¯¸ÂI¶}©l¡A¸Ó¯¸ÂI¨Ï¥Î°ò©ó TREK-AD ¬ã¨sµ²ªGªº§ó·s¼Ð·Ç¡A¦b¦³dupilumab¸gÅ窺±wªÌ¤¤¬ã¨seblasakimab¡A¼Ú¬wªº¨ä¥L¯¸ÂI¹wp±N©ó 2024 ¦~¤W¥b¦~¶}©ñ¡C ¹ïFarudodstatªvÀø´³¨rªº FAST-AA ¬ã¨s¤¤¥X²{ªºª¼ªk¦w¥þ©Ê¼Æ¾Úªº¼f¬dÅã¥Ü¨S¦³¥X²{¨xŦ©Î¨ä¥L¦w¥þ©Ê°ÝÃD¡A¤ä«ùÂX¤j¤J²Õ¼Ð·Ç¥H¥]¬A¤£¤ÓÄY«ªº±wªÌ¡C¥Ø«e¹wp¤¤´Á¼Æ¾Ú±N¦b 2024 ¦~¤¤´Á¤½§G¡C Âà¤Æ¤u§@ÃÒ©ú¤Feblasakimab¦b COPD ¤¤ªº¼ç¤O¡AÀY¹ïÀY¼Æ¾Úªí©ú¥i¯àÀu©ódupilumab¡A¤ä«ùeblasakimab¸Ñ¨M¼sªxªº AD ¦X¨Ö¯gªº¼ç¤O¡C ¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 12 ¤ë 12 ¤é¡]Àô²y³q°TªÀ¡^- ASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ´£¨Ñ·~°È§ó·s¥H¤Î»P¨äµ{¦¡eblasakimab©Mfarudodstat¬ÛÃöªº§ó·s¡C
°õ¦æªø Carl Firth ³Õ¤hªí¥Ü¡G¡u2023 ¦~¡AASLAN ¦b¦hӤ豨ú±o¤F«¤j¶i®i¡X¡X¦b²Ä¤G¶¥¬q´ú¸Õ¤¤±À¶i§Ú̪º¨âÓ¥D¾É¶µ¥Øeblasakimab©Mfarudodstat¡A¨Ã«Ø¥ß·~°È¶}µo¦X§@¥H¶i¤@¨B¶}µo©M§Q¥Îeblasakimab ¡¨ ¡Aªü´µÄõ»sÃÄ¡C¡uTREK-AD ¬ã¨sªºµ²ªGªí©ú¡Aeblasakimab¦³¼ç¤O¦b¤£¼vÅTÀø®Äªº±¡ªp¤U¬°²§¦ì©Ê¥Ö½§ª¢AD ´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¨Ã¦¨¬°AD ªº»â¥ýÀøªk¡C¦¹¥~¡A±qÀY¨ì§Àªº¼Æ¾ÚÅý§Ú̲`¨ü¹ª»R¡C- ÀY½Ķ¬ã¨sªí©ú¡A»Pdupilumab¬Û¤ñ¡A eblasakimab°w¹ïIL-13¨üÅ骺¿W¯S§@¥Î¾÷¨î¤Þ°_¤F¤£¦Pªº¤ÏÀ³©M²ÓM¦]¤l¯S¼x¡C³o¬°eblasakimabªº®t²§¤ÆÁ{§É¯S¼x´£¨Ñ¤F°ò¦¡A¨Ãªí©ú¥¦¥i¯à¹ï±wªÌ¦³®Ä¡C¨º¨Ç¹ïdupilumab¡X¡X§ÚÌ¥¿¦b TREK-DX ¸ÕÅ礤´ú¸Õ³o¤@ÂI¡C¥O¤H¿³¾Äªº¬O¡A¦b¨Ï¥Î¤HÃþ COPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅ礤¡A§ÚÌÆ[¹î¨ìeblasakimab¤ñdupilumab¨ã¦³§ó±jªº®ÄªG¡A¨Ã¥B§ÚÌ´Á«Ý©ú¦~µo¥¬³o¨Ç¬ã¨sªº§ó¦h¼Æ¾Ú¡C
Firth ³Õ¤hÄ~Äò»¡¹D¡G¡§2024 ¦~¡A§Ú̱NÄ~Äò±À¶ifarudodstat§@¬°´³¨r (AA) ªº·s«¬ªvÀø¤èªk¡C ¡¨ ¡u»P¨ä¥LDHODH §í¨î¾¯¤£¦P¡A¦b¼f¬dFAST-AA ¬ã¨sªºª¼ªk¦w¥þ¸ê®Æ®É¡A§Ų́S¦³¬Ý¨ì·s¥X²{ªº¨xŦ©Î¨ä¥L¦w¥þ°ÝÃD¡C§Ú̬۫H¡A¾Ö¦³¤@ºØ¦³®ÄªºÃĪ«¡A¥B¤£¦s¦bJAK §í¨î¾¯ªº¦w¥þ³d¥ô¡A¥i¥H´£¨Ñ¦³»ùȪºÃĪ«¡C¦b¦¹°ò¦¤W¡A§ÚÌÂX¤j¤F¤J²Õ¼Ð·Ç¡A±N¤£¤ÓÄY«ªºAA ±wªÌ¯Ç¤J¨ä¤¤¡A§ÚÌ»{¬°³o¨Ç±wªÌ¤]¥i¯à¨ü¯q¡A¦ý¥i¯à¤£²Å¦X¥Ø«e§å㪺¨t²ÎªvÀø©Î¨ä¥L¥¿¦b¶i¦æªº¸ÕÅ窺¸ê®æ¡C³Ì«á¡A§@¬°§Ú̧V¤Oªº¤@³¡¤À¬°¤F´î¤Ö 2024 ¦~ªº²{ª÷®ø¯Ó¡A§Ú̳̪ñקï¤F»P K2 HealthVentures ªº¶U´Ú¨óij±ø´Ú¡A¥H¤j´T´î¤Ö¥¼¨Ó 12 Ӥ몺¨ì´Á¥I´ÚÁ`ÃB¡C¡¨
¨Ì¥¬©Ô¦N³æ§Ü§ó·s
ASLAN is conducting clinical trials of its lead program, eblasakimab, in adult, moderate-to-severe AD patients. In July, ASLAN announced positive topline results from a Phase 2 TREK-AD study that demonstrated eblasakimab¡¦s potential as the first biologic in moderate-to-severe AD to demonstrate a competitive efficacy profile with once-monthly dosing from initiation. In October, new data was presented from an analysis of patients with severe disease (baseline Eczema Area and Severity Index [EASI] score at least 21), showing a marked widening in placebo-adjusted efficacy. ASLAN has engaged Seth J. Orlow, MD PhD, of the specialist firm, Pharus, with deep and extensive industry relationships in dermatology, to advise on global partnership discussions for eblasakimab.
ASLAN is also evaluating eblasakimab in the Phase 2 TREK-DX study in dupilumab-experienced, moderate-to-severe AD patients. 63% of dupilumab-treated patients fail to achieve clear or nearly clear skin (Investigator¡¦s Global Assessment [IGA] score of 0 or 1) after 16 weeks1, and around half of those patients that do achieve this response do not maintain it after the subsequent 36 weeks2, so this is a sizable patient population that lacks safe, long-term alternative treatment options. Based on findings from the TREK-AD study, which highlighted the changing patient population in the US, the TREK-DX inclusion criteria have been modified to enroll patients with an EASI score of at least 18 and independent reviewer confirmation of baseline EASI scores has been implemented. US sites are now recruiting according to the updated criteria and additional sites in Europe are expected to open in the first half of 2024. ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024.
For the first time, ASLAN demonstrated the potential utility of eblasakimab in an indication beyond AD. Data generated in a human translational model of COPD demonstrated that eblasakimab was effective in reducing IL-4 and IL-13 driven airway hyperresponsiveness. Unlike drugs targeting the IL-13 cytokine, eblasakimab blocks signaling of both IL-4 and IL-13 through the type 2 receptor, which may provide for utility in a broader range of indications, including those not solely driven by IL-13. New, promising data of head-to-head comparison with dupilumab in this translational model will be presented at an upcoming scientific meeting.
Farudodstat update
Farudodstat, a highly selective dihydroorotate dehydrogenase (DHODH) inhibitor, is being investigated for the treatment of AA in the FAST-AA Phase 2 trial. Blinded safety data emerging from the study has shown no liver or other major safety concerns to date in patients enrolled supporting farudodstat¡¦s improved safety profile compared to the first-generation of approved DHODH inhibitors. Farudodstat could, therefore, provide an important treatment option for patients with less severe disease looking for a safe systemic therapy. ASLAN has received approval from the study¡¦s Institutional Review Board to expand the enrollment criteria to include patients with 30% or greater hair loss, a milder patient population who currently lack approved systemic treatment options, and is implementing the change to the protocol. JAK inhibitors, which carry several boxed warnings, were recently approved only to treat patients with severe AA. Due to the recent increased availability of approved therapies in severe AA and the expansion of the trial to include moderate AA patients, ASLAN expects topline interim data from the study to be available in mid-2024.
Corporate updates
ASLAN amended the terms of its loan agreement with K2 HealthVentures. In order to substantially reduce the total payments due to K2 HealthVentures over the next 12 months and extend the date from which the Company is required to make monthly repayments to January 2025, ASLAN made a prepayment of $12.0 million which has been applied to the outstanding principal under the loan agreement. $13.0 million of principal now remains outstanding under the loan agreement. The prepayment allows the Company to reduce total cash burn through 2024.
2024 expected milestones
Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications. Topline readout from the TREK-DX study of eblasakimab. Topline interim data readout from FAST-AA study of farudodstat in AA in mid-2024. Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses. Upcoming conference attendance
ASLAN¡¦s management team will be participating in the Dermatology Summit in San Francisco on January 7, 2024, at the Hyatt Regency, and the LifeSci Corporate Access Event at the Beacon Grand Hotel, San Francisco, from January 8-10, 2024.
Thaci et al (2019) J Dermatol Sci 94(2):266-275 Worm et al (2020) JAMA Derm 156(2):131-143 About eblasakimab
Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. Eblasakimab¡¦s unique mechanism of action enables specific blockade of the Type 2 receptor and has the potential to improve upon current biologics used to treat allergic disease. By blocking the Type 2 receptor, eblasakimab prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) ¡V the key drivers of inflammation in AD. Positive results from the Phase 2b TREK-AD study in moderate-to-severe AD support eblasakimab¡¦s potential to deliver a monthly dosing regimen from initiation in AD without compromising on efficacy and with an encouraging safety profile demonstrated to date, with preparations for Phase 3 underway. ASLAN is also investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.
About farudodstat
Farudodstat is a potent, oral dihydroorotate dehydrogenase (DHODH) inhibitor that suppresses immune cell proliferation and IFN-£^ secretion by blocking de novo production of pyrimidines required for DNA replication. Compared to first-generation DHODH inhibitors, farudodstat has been shown to be approximately 30 times more potent in its inhibition of DHODH and T cell activity and has demonstrated a well-tolerated safety profile. ASLAN has generated data showing that farudodstat can potentially protect against the loss of immune privilege in hair follicles, supporting its potential as a first-in-class treatment option for alopecia areata (AA). A Phase 2a proof-of-concept trial in AA is currently underway with an interim readout expected in mid-2024.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in mid-2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the Website or follow ASLAN on LinkedIn.
Forward-looking statements
This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the Company). These forward-looking statements may include, but are not limited to statements regarding the Company¡¦s business strategy and clinical development plans; the Company¡¦s plans to develop and commercialize eblasakimab and farudodstat; the safety and efficacy of eblasakimab and farudodstat; the Company¡¦s plans and expected timing with respect to manufacturing activities, clinical trials, clinical trial enrolment and clinical trial results for eblasakimab and farudodstat; the potential of eblasakimab as a first-in-class treatment for atopic dermatitis and of farudodstat as a first-in-class treatment for alopecia areata; the potential benefits, capabilities and results of the Company¡¦s collaboration efforts; and the Company¡¦s cash runway. The Company¡¦s estimates, projections and other forward-looking statements are based on management¡¦s current assumptions and expectations of future events and trends, which affect or may affect the Company¡¦s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; the fact that results of earlier studies and trials may not be predictive of future trial results; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic, the ongoing conflict between Ukraine and Russia and bank failures on the Company¡¦s business and the global economy; general market conditions; changes in the competitive landscape; and the Company¡¦s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company¡¦s US Securities and Exchange Commission filings and reports (Commission File No. 001- 38475), including the Company¡¦s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on March 24, 2023. All statements other than statements of historical fact are forward-looking statements. The words believe, may, might, could, will, aim, estimate, continue, anticipate, intend, expect, plan, or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.
Media and IR contacts
ASLAN Media and IR contacts
Emma Thompson
Spurwing Communications
Tel: +65 6206 7350
Email: ASLAN@spurwingcomms.com Ashley R. Robinson
LifeSci Advisors, LLC
Tel: +1 (617) 430-7577
Email: arr@lifesciadvisors.com
¥Dn¼Ð»x
·j¯Á¡A¨Ò¦p AAPL ©Î¦¬¯q Show advanced search Markets Latest News Analyst Ratings Earnings Call Transcripts SPACs & IPOs FDA Approvals Show more Sector News Healthcare Technology ¬¡¤O ¤u·~ ®ø¶OªÌ¨¾¿m ®i¥Ü§ó¦h ³Ì·s¨Ó¦Û ¬ü°ê¥þ°ê¼s¼½¤½¥q°]¸gÀW¹D ¸ô³zªÀ ´^³ÕªÀ ¬ü³qªÀ µØº¸µó¤é³ø ®i¥Ü§ó¦h ¬ü°ê¬F©² ¬ü°êÃÒ¨é¥æ©ö©eû·|³Æ®× Á{§É¸ÕÅç ±M§Q¥Ó½Ð»P®Öã FDA - ÃÄ«~®Öã FDA - ·s»D½Z ®i¥Ü§ó¦h API¡B¶}µo¤Hû API¤å¥ó API©w»ù Discord ·s»D¾÷¾¹¤H ±b¤á µn¤J «Ø¥ß§K¶O±b¤á ±ø´Ú | Áô¨p ·ÀI´¦ÅS¡Gª÷¿Ä¤u¨ã©M/©Î¥[±K³f¹ô¥æ©ö¯A¤Î°ª·ÀI¡A¥]¬A·l¥¢³¡¤À©Î¥þ³¡§ë¸êª÷ÃBªº·ÀI¡A¥i¯à¤£¾A¥Î©ó©Ò¦³§ë¸êªÌ¡C¥[±K³f¹ôªº»ù®æªi°Ê·¥¤j¡A¥i¯à·|¨ü¨ìª÷¿Ä¡BºÊºÞ©Î¬Fªv¨Æ¥óµ¥¥~¦b¦]¯Àªº¼vÅT¡C«OÃÒª÷¥æ©ö¼W¥[¤Fª÷¿Ä·ÀI¡C¦b¨M©w¥æ©öª÷¿Ä¤u¨ã©Î¥[±K³f¹ô¤§«e¡A±zÀ³¸Ó¥R¤À¤F¸Ñ»Pª÷¿Ä¥«³õ¥æ©ö¬ÛÃöªº·ÀI©M¦¨¥»¡A¥J²Ó¦Ò¼{±zªº§ë¸ê¥Ø¼Ð¡B¸gÅç¤ô¥©M·ÀI°¾¦n¡A¨Ã¦b»Ýn®É´M¨D±M·~«Øij¡C§ÚÌÂÔ´£¿ô±z¡A¥»ºô¯¸©Ò¥]§tªº¼Æ¾Ú¤£¤@©w¬O§Y®Éªº¡A¤]¤£¤@©w¬O·Ç½Tªº¡Cºô¯¸¤Wªº¼Æ¾Ú©M»ù®æ¤£¤@©w¥Ñ¥ô¦ó¥«³õ©Î¥æ©ö©Ò´£¨Ñ¡A¦ý¥i¯à¥Ñ°µ¥«°Ó´£¨Ñ¡A¦]¦¹»ù®æ¥i¯à¤£·Ç½T¡A¨Ã¥B¥i¯à»P¥ô¦ó¯S©w¥«³õªº¹ê»Ú»ù®æ¦³©Ò¤£¦P¡A³o·N¨ýµÛ»ù®æ¬O«ü¥Ü©Êªº¡A¨Ã¤£¥Nªí»ù®æ¡C¾A¦X¥æ©ö¥Øªº¡C¹ï©ó¦]±zªº¥æ©ö©Î±z¹ï¥»ºô¯¸©Ò§t¸ê°Tªº¨Ì¿à¦Ó³y¦¨ªº¥ô¦ó·l¥¢©Î·l®`¡A§ÚÌ©M¥»ºô¯¸©Ò§t¸ê®Æªº¥ô¦ó´£¨ÑªÌ§¡¤£©Ó¾á¥ô¦ó³d¥ô¡C¥¼¸g§ÚÌ©M/©Î¸ê®Æ´£¨ÑªÌ©ú½T¨Æ¥ý®Ñ±³\¥i¡A¸T¤î¨Ï¥Î¡BÀx¦s¡B½Æ»s¡B®i¥Ü¡Bקï¡B¶Ç¿é©Î´²§G¥»ºô¯¸©Ò¥]§tªº¸ê®Æ¡C©Ò¦³´¼¼z°]²£Åv§¡¥Ñ´£¨Ñ¥»ºô¯¸©Ò§t¸ê®Æªº´£¨ÑªÌ©M/©Î¥æ©ö©Ò«O¯d¡C®Ú¾Ú±z»P¼s§i©Î¼s§i°Óªº¤¬°Ê¡A§ÚÌ¥i¯à·|±qºô¯¸¤W¥X²{ªº¼s§i°Ó¨º¸ÌÀò±o¸ÉÀv¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/12/12 ¤U¤È 12:30:55
²Ä 6491 ½g¦^À³
|
2023¦~12¤ë9¤é¨È·à±d¤½§i »P K2 HealthVentures LLC ñqªº¶U´Ú¨óijץ¿
2021¦~7¤ë12¤é¡A®Ú¾Ú¶}°Ò羣®qªk«ß²Õ«ØªºÁŧK¤½¥qªü´µÄõ»sÃĦ³¤½¥q¡]¥H¤U²ºÙ ¡§¤½¥q¡¨¡^©M¯S©ÔµØ¦{ªº¤@®a¤½¥q¨È´µÄõ»sÃÄ¡]¬ü°ê¡^¦³¤½¥q¡]¡§¨È´µÄõ¬ü°ê¡¨¡^§@¬°É´Ú¤H»P¨È´µÄõ»sÃĨp¤H¤½¥qñq¤F¶U´Ú¡B¾á«O©M¾á«O¨óij¡]¡§¶U´Ú¨óij¡¨¡^¡CLtd.¡A¤@®a®Ú¾Ú·s¥[©Y¦@©M°êªk«ß¦¨¥ßªº¨p¤HªÑ¥÷¦³¤½¥q¡]¡§·s¥[©YASLAN¡¨¡A»P¤½¥q©MASLAN USA¤@°_¡A¦U¬° ¡§¶U´Ú¤è¡¨¡A¦XºÙ ¡§¶U´Ú¤è¡¨¡^¡A§@¬°¾á«O¤H¡A¶U´Ú¤H¡A¨ä·í¨Æ¤è¡AK2 HealthVentures LLC§@¬°¦æ¬F¥N²z¤H¡A§@¬°©è©ã¥N²z¤HªºAnkura Trust Company, LLC¡A¸g¸Ó×¥¿®×ªº¬Y¨Ç²Ä¤@×¥¿®××q¶U´Ú¡B¾á«O©M¾á«O¨óijªº¤é´Á¬°2023¦~6¤ë30¤é¡C¡m¶U´Ú¨óij¡n³W©w³Ì¦h¤À¥|§å´£¨Ñ°ª¹F4,500¸U¬ü¤¸ªº©w´Á¶U´Ú¡A¨ä¤¤¥]¬A¦b¥æ©öµ²§ô®Éª`¸êªºªì©l2,000¸U¬ü¤¸©w´Á¶U´Ú¡C¨´¤µ¬°¤î¡A¸Ó¤½¥qÁ`¦@ɤJ¤F2,500¸U¬ü¤¸¡A¤À§O¬O²Ä¤@©M²Ä¤G§å©w´Á¶U´Ú¡C
2023¦~12¤ë6¤é¡A¤½¥qñq¤F¶U´Ú¨óijªº×¥¿®×¡]¡§²Ä¤G×¥¿®×¡¨¡^¡A®Ú¾Ú¸Ó×¥¿®×¡A¶U´Ú¤H¦P·N©µªø¡m¶U´Ú¨óij¡n³W©wªº´Á¡A¦b¸Ó´Á¤º¡A¤½¥qµL»ÝÀvÁÙ¥¼ÀvÁÙªº¥»ª÷¡]¦b¦¹´Á¶¡¡A§Q®§¥I´Ú±NÄ~Äò®Ú¾Ú¶U´Ú¨óijªº±ø´Ú¨ì´Á©M¤ä¥I¡^¡C²{¦b¡A¤½¥q³Qn¨D«ö¤ë¤ä¥I¥»ª÷ªº²Ä¤@Ó¤é´Á¬O2025¦~1¤ë1¤é¡C
¦¹¥~¡A®Ú¾Ú²Ä¤G×¥¿®×¡A¡]i¡^¤½¥q¦VºÞ²z¥N²z¤H¤ä¥I¤F1,200¸U¬ü¤¸¡A³oµ§´Ú¶µ¤w¾A¥Î©ó¶U´Ú¨óij¤Uªº¥¼Àv¥»ª÷¡]¡§¹w¥I´Ú¡¨¡^¡F¡]ii¡^¶U´Ú¤H©MºÞ²z¥N²z¤H§K°£¤F¶U´Ú¨óij¤¤ì¥»n¨Dªº2.0¢Hªº¹wÁÙ´Ú¶O¡C¹w¥I´Ú¥Í®Ä«á¡A®Ú¾Ú¶U´Ú¨óij¡A1,300¸U¬ü¤¸ªº¥»ª÷¤´¥¼ÀvÁÙ¡C
Ãö©ó²Ä¤G×¥¿®×¡A¶U´Ú¤H¤wÀò±o¶U´Ú¤è¾Ö¦³ªº¬Y¨Çª¾ÃѲ£Åvªº¯d¸mÅv¡A¦ýºD¨Ò°£¥~¡C
²Ä¤G×¥¿®×ªº°Æ¥»§@¬°ªþ¿ý4.1ªþ©ó¦¹¡A¨Ã¥H¤Þ¥Î¤è¦¡¯Ç¤J¦¹³B¡C¤Wz¹ï²Ä¤G¥óªº´yz¨Ã¤£§¹¾ã¡A¦Ó¬O°Ñ·Ó¦¹ÃþÃÒª«¶i¦æ¤F¥þ±©w¡C
************************************************************************************************* ÅÞ¿è«ä¦Ò(¥H¤U¦C3ÂI¬°«e´£)¡G 1.¨È·à±d112¦~12¤ë9¤é¤½§i»PK2 HealthVentures LLCñq¶U´Ú«´¬ùªºÁٴڤ驵ªø¦Ü2025(114)¦~1¤ë1¤é¡C 2.¨È·à±d²Ä¤T©u°]³ø¬ÒÅS²{ª÷¥u°÷¥Î¨ì113¦~¤U¥b¦~¡C 3.112¦~12¤ë20¤éªÑ»ù§C©ó1¤¸©¡º¡30¤Ñ¡A±NÂಾ¦Ü¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò(¬°´Á180¤Ñ§Y113¦~6¤ë16¤é¤î)¡C --------------------------------------ÅÞ¿è«ä¦Ò¦p¤U--------------------------------------------------- ¤@¯ë¶U´Ú»È¦æ¬Ý°]³ø¡A²{ª÷¬y¥u°÷¥Î¨ì113¦~©³¡A¦´N«B¤Ñ¦¬³Ê¤F¡A ¦Ó¥B¨È·à±d±N³Q²¾¦Ü¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò(¬°´Á180¤Ñ)¡A§Y113¦~6¤ë16¤é«e§ä¤£¨ì°]·½±N³Q¤U¥«¡C ¤Wz¸ê°TK2 HealthVentures LLC³£ª¾¹D¡A«ç¥i¯àÁÙ¦P·N®i©µ¦Ü114¦~1¤ë1¤é¡C ¦^ÅU¤µ¦~6¤ë22¤éªº¤é¥»±ÂÅv®É¶¡(¤£¥i¯à¥u°Q½×¤@¬P´Á(7¤Ñ)¡A6¤ë22¤é´N¹ï¥~¤½§i)¡A ¹w¦ô3~6Ӥ몺°Q½×¬O¥²nªº¡A ¹w¦ô112¤ë12¤ë¤w¸g¦b±µ¬¢¬ÛÃö±ÂÅv©Î¨ÖÁÊÃÄ°Ó¡A©ú¦~²Ä2©uªº¬Y¤Ñ±N¹ï¥~¤½§i(¦p¦P6¤ë22¤é¤½§i¤é¥»±ÂÅv) ¦]¬°¤w¸g¦b¸òÃÄ°Ó°Q½×±ÂÅv©Î¨ÖÁʨƩy¡A¾á¥ôºÊ¹î¤Hªº§ë¸ê¤½¥qª¾¹D¨È·à±d¤½¥q¤º³¡ª¬ªp¡Aª¾¹D°]·½¨S°ÝÃD¡A©Ò ¥H¤~´±¦P·NÁÙ´Ú´Á®i©µ¡C (²{ª÷¤£°÷(§tÁ{§É¤T´Á)¡BªÑ»ù§C©ó¬üª÷1¤¸³Q¤U¥«µ¥°ÝÃD±N¤£·|µo¥Í)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/11 ¤U¤È 10:49:31
²Ä 6490 ½g¦^À³
|
°¶¤jªº¦L«×¸Ö¤H®õ¤àº¸¬°¬ü¦n¥@¬Éªº³Ð§@µL¼Æ¨Î¥y¦W¨¥¡AÅý¤H¼È®É§Ñ«o¤F¹Ð¥@ªº¯ÉÂZ¡A¦p²M²Dµ¯ë¡C
~¤£nþÓ«æ¡A³Ì¦nªºÁ`·|¦b³Ì¤£¸g·Nªº®ÉÔ¥X²{¡C
¡ã¶È¶È¯¸¦b¨º¨à±æµÛ¤j®ü¡A§A®Ú¥»¨Sªk¾î´ç¥¦¡C
~¥Í¦p®Lªá¤§µºÄê¡A¦º¦p¬î¸¤§ÀR¬ü¡C
~·í§A¿ù¹L¤Ó¶§¦Ó¬y²\¡A§A¤]±N¿ù¹L¸s¬P¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/5 ¤U¤È 10:05:29
²Ä 6489 ½g¦^À³
|
¤p©ú¤j ¦³¤H¬ÝªÅ¦³¤H¬Ý¦h¥»À³µ¹¤©´L«¡A§Ú¦b©³³¡²z©Ê¬Ý¦n¡A¤ÀªRªº¤º®e¾¨¶q¨Ï¥Î¤½¶}¼Æ¾Ú¡A ¥t¥~§Ú¤À¨É·®æ»P¤Ñ©R¤j§¹¥þ¤£¦P¡A§A·Q¤Ó¦h¤F¡A§Ú·Pı§A¤w¦^¸É¡A¯¬ºÖ§A¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/5 ¤U¤È 09:26:54
²Ä 6488 ½g¦^À³
|
¥xÁÞ¤j
Á¿¥y¶}§¹¯ºªº¸Ü¡A§A§O¤¶·N¡A
§Ú¦³ÂIÃhºÃ§A¬O¤Ñ©R¤jªº¤À¨¡A
«¢«¢¡A·PÁ§Aªº¤ÀªR |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/5 ¤U¤È 08:40:57
²Ä 6487 ½g¦^À³
|
¤p©ú¤j @ ¤p¤½¥q³£¬O±q¥¢±Ñ¤¤§l°_¸gÅç³vº¥²æL´«°©Åܦ¨¤j¤½¥q ( Áx¹DÀù©ñ±ó¬ãµoºâ¬O¥¢±Ñ 003Âà´«¾AÀ³¯g (¨r´³)¨S¦³¥¢±Ñ Eblasakimab 2B ¯à¶i¤J¤T´ÁÁ{§Éªí¥Ü¦³¦¨¥\¼ç¤O, 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|µ¹¤©¤fÀY³ø§i§ó¥YÅã¨ä¿W¯S©Ê»P ®t²§¤Æ ( ¨C¤ë¤@°w ) @ 7¤ë6¤é¼Æ¾ÚÓ¤H»{¬°¬O´Á¤¤¤ÀªR, 2023 ¦~ 10 ¤ë 13 ¤é¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº±ß¶¡³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú ( §¹¾ã¼Æ¾Ú ) ²Ä¥|©u±N¤½§i¥Íª«¼Ð°O Eblasakimab reduced airway constriction and enhanced dilation in ex vivo model of COPD (2b ´Á¬ã¨s§¹¾ã¼Æ¾Ú½Ð°Ñ¦Ò2023¦~11¤ë³Ì·s²³ø )
@ ¦pªGEblasakimab ¦bITT»P¸ûÄY«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯µû¤À¤j¤j°§C ( «ümean change frm baseline IGA 0/1 EASI-75 EASI-90 ) ³oÃÒ©úEblasakimab¦³ÅãµÛÀø®Ä, ¦pªGEblasakimab ¦b¸ûÄY«ªº±wªÌ¤¤ªí²{¥X¦â¡A¦w¼¢¾¯¤]ªí²{¦P¼Ë¥X¦â¡A³oÃÒ©úEblasakimab Àø®Ä¤£¦p¹w´Á, ¨Æ«á¤ÀªRÃÒ©ú Eblasakimab ¦bITT»P ¸ûÄY«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯¦b¸ûÄY«ªº±wªÌµû¤À«o¤j¤j°§C
ITT mean change frm baseline ¹ï·Ó²Õ Q2W -51.1 % Patients with EASI >18 ¹ï·Ó²Õ Q2W -42.3 % Patients with EASI >21 ¹ï·Ó²Õ Q2W -38 % µo²{¹ï·Ó²Õ¦U²ÕÀø®ÄÅܰʫܤj
ITT mean change frm baseline ¹êÅç²Õ 600mg Q4W -73 % Patients with EASI >18 ¹êÅç²Õ 600mg Q4W -75 % Patients with EASI >21 ¹êÅç²Õ 600mg Q4W -74.5% Eblasakimab ¦bITT»P ¸ûÄY«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯¦b¸ûÄY«ªº±wªÌµû¤À«o¤j¤j°§C ¨ä¥LIGA 0/1 EASI-75 EASI-90 ¤]¦³¦P¼Ë±¡ªp (°Ñ¦Ò2023¦~¤Q¤ë²³ø )
@ ¥H¤U¬O2023¦~ 11¤ë²³ø»¡©ú¬°¦ón°µ¨Æ«á¤ÀªR • TREK-AD ¬O¤@¶µ¦b 9 Ó°ê®a¶i¦æªº¥þ²y¾¯¶q½d³ò¬ã¨s¡A´ú¸Õ eblasakimab¬ù300¦W¤¤«×¦Ü««×AD±wªÌ ¬ã¨sµ²ªG¬O¥¿± ªº¡A¨Ã®i¥Ü¤F¨C¤ëµ¹ÃĪº¼ç¤O¬ã¨s¦b 3 ÓÃöÁ侯¶q¤¤¹F¨ì¤F ITT ±Ú¸sªº¥Dn²×ÂI©MÃöÁ䦸n²×ÂI 600mg Q4W ²Õ¦b¼ÆȤW¬Oªí²{³Ì¦nªº²Õ§O¡]EASI ¤À¼Æ°§C 73%¡Ap=0.001¡^ Eblasakimab °_®Ä§Ö (Page 23 2¶g¹FÅãµÛ®t²§)¡A@¨ü©Ê¨}¦n¡Aµ²½¤ª¢©Mª`®g³¡¦ìµo¥Í²v§C • ¨Æ«á¤ÀªRÃÒ©ú¦w¼¢¾¯½Õ¾ã¤À¼Æ¦³¥i¯à¶i¤@¨BÂX¤j¨ä¥L´X¶µ³Ìªñªº¬ã¨s¤@P¡A¦w¼¢¾¯¤ÏÀ³°ª©ó¤Q¦~«e¶i¦æªºdupilumab ¬ã¨s ¦b¬ü°ê¡A°ª¤ñ¨Òªº»´«×±wªÌ«P¦¨¤F¸û°ªªº¦w¼¢¾¯¤ÏÀ³¡]¶W¹L¤T¤À¤§¤@ªº±wªÌ¬ü°ê±wªÌªº EASI µû¤À§C©ó 18¡^ Eblasakimab ¦bITT»P¸ûÄY«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯¦b¸ûÄY«ªº±wªÌµû¤À«o¤j¤j°§C
@ 1 Top shareholders include BVF, Tang Capital, Vivo Capital, Citadel ( ¨Ì¾Ú10¤ë 11¤ë¤½¥q²³ø³o¥|®a§ë¸ê¾÷ºc¾á¥ôSurveyor ºÊ¹î¤H) ºÊ¹î¤H¦³Åv½Õ¬d¤½¥q·~°È¤Î°]°Èª¬ªp¡A¤½¥q¬ÛÃö³¡ªùÀ³°t¦X´£¨Ñ¬d®Ö©Ò»Ý¤§Ã¯¥U¤å¥ó¥H«O»ÙªÑªFÅv¯q
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/5 ¤W¤È 01:44:26
²Ä 6486 ½g¦^À³
|
°O±o¡A
³o®a¤½¥q¦¨¥ß¦Ü¤µ¡A
¨S¦³¦¨¥\¹L¤@¦¸¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/5 ¤W¤È 01:36:48
²Ä 6485 ½g¦^À³
|
¥xÁÞ¤j
³o´X¤Ñ¦¨¥æ¶q¥[Á`¡A ¤£¨ì1M¡A
´Nºâ¦³¤ß¤H¥þ¦Y¡A
ÁÙ¤£¨ì5%¡A
¤£¨¬¼vÅT¥þ§½¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/5 ¤W¤È 01:26:44
²Ä 6484 ½g¦^À³
|
¥xÁÞ¤j
§Ú¨S¦³¨º»ò¼ÖÆ[¡A¬Ý¸Ó¤½¥q¤½¥¬¼Æ¾Ú«áÁÙ·|ק諸§@ªk¡A´N¥Nªí¥L¬O«H¥Î¯}²£ªº¤½¥q¡Aceo¤]¬O¦L«×ªü¤T«á¥N¡A
®g½b«á¤~µe¹v¡A½Ö«H¡A
§Ú»{¬°¤§«e«Ü¦h¸ÕÅç¼Æ¾Ú¡A¤@©w¦³¥LÌ¥ô·N¤W¤U¨ä¤â¡AJ¶Ã×¥¿ªº±¡ªp¡A ³y¦¨²{¦b¤½¥q»¡¤°»ò¡A³£¨S¤H¬Û«H¥L̪º°¸Ü¡A¥«³õ¤]²@¤£¶R±b¡A
¶^¨ì¥«È¤ñ²{ª÷ÁÙ¤Öªº±¡§Î¡A
§Ú»{¬°©ú¦~²Ä¤@©uDX¸ÕÅç¡A¬O¤£·|¦¨¥\ªº¡A¤½¥q·|¦A½s¤@¨Ç²z¥Ñ°¸Ü¡A»¡n°µ²Ä3´Á¡A¦A¨Ó·dÓ´î¸ê¼W¸ê§âÀ¸¡AÄF¤@¨Ç¸êª÷¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/5 ¤W¤È 12:49:40
²Ä 6483 ½g¦^À³
|
³o´X¤Ñ§CÂI©³³¡¥X¶q¡A³o¬O½Ö¶Rªº? µª®×«Ü²M·¡·íµM昰¦³¤ß¤H¦b¶R
¶q¥ý»ù¦æ¡A¤£n¥u¬Ý»ù¦Ó¤£¬Ý¶q
»ù®æ¥i¥HÄF¤H¡B¦ý¦¨¥æ¶q¤£·|ÄF¤H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/12/4 ¤U¤È 11:50:22
²Ä 6482 ½g¦^À³
|
¤p©ú¤j 1«¢«¢¡I§Ú²qµ¥¤Ñ©R¤j¶R¦n¶Rº¡´N·|¥X¨Ó¡H «Øijª©¤Í¦³½æ¥X«á¦³»ù®t¥i¦Ò¼{¦^¸É¡A¨S¦^¸É½T©wÁ«·l¡A¦³¦^¸É·|¤ñ¨S¦^¸É¥¼¨Ó³Óºâ¤j ¦pªG¥¼¨Ó¤½¥q³Q¨ÖÁÊ¡A¦b¨ÖÁÊÁ`ª÷ÃB©T©w±¡ªp¤U¡A»P¥Ø«eªÑ»ù°ª§CµLÃö¡A»PMarket cap¦³Ãö Market Cap ¶V°ª¡A¨ÖÁÊ»ù¶V§C¡AMarket Cap ¶V§C¡A¨ÖÁÊ»ù¶V°ª¡A²{¦bMarket cap§C¨ì¬ù900¸U¬ü¤¸¡A»·§C©ó¤½¥q²Ä¤T©u²{ª÷4080¸U¬ü¤¸ªº©_¯S²{¶H¡A«O¦u¨Ó¬Ý¥un¦³Lebrikizumab¨ÖÁÊÁ`ª÷ÃB参¦Ò»ù11»õ¬ü¤¸ªº£¸¥b¡A¨CªÑ¨ÖÁÊ»ù·|Åý¤pªÑªF»P§ë¸ê¾÷ºc¬Û·íº¡·N¡C
2 ¤Ñ©R¤j2023¦~6¤ë23¤é¤À¨É»¡¥@¬É«e¤¤jÃļt·|«æµÛ§äASLN ½Í¨ÖÁÊ¡A³o¬O50»õ¬ü¤¸¦y®p¾P°â¤jÃÄ¡C 27.7»õ±ÂÅvª÷¤Q20%¤À¼í⋯Áô§t¦y®p¾P°â¬ù55»õ¬ü¤¸¡C
3 Lebrikizumab¨ÖÁÊ参¦Ò»ù11»õ¬ü¤¸
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2023/12/4 ¤U¤È 11:29:32
²Ä 6481 ½g¦^À³
|
¥»·Q¤£µo¨¥¤F~¦ý¬OªÑ»ù¥O¤HÅå³Y¨ì·Qµo¤@¤U¼o¤å....¶ZÂ÷¤W¦¸µo¤å¨ì¤µ¤Ñ¤~µuµu60¤Ñ , ´N¥Ñ1.62¶^¨ì0.51 , ¦pªG·í®É¤£´î¸ê²{¦bªº»ù®æ´Nè¦n0.1,·Q·í®É´î¸ê«e2.4¥þ³¡¥X²æªºµ¦²¤¬O¹ïªº , ¤@¨Ó¤@¦^¸ê²£®t²§24¿ !
¦pªG·í®É§ë¸ê120¸U²{¦b»ùÈ5¸U ¦pªG·í®É§ë¸ê240¸U²{¦b»ùÈ10¸U ¦pªG·í®É§ë¸ê480¸U²{¦b»ùÈ20¸U ¦pªG·í®É§ë¸ê720¸U²{¦b»ùÈ30¸U ¦pªG·í®É§ë¸ê960¸U²{¦b»ùÈ40¸U ®¥³ß«Ó°¶¤j1.4»ù¦ì§Y®É¥X²æ !!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2023/10/5 ¤U¤È 11:29:35²Ä 6435 ½g¦^À³ ¶ZÂ÷¤W¦¸¸Ñª¼¥¢±Ñ«á...¤S¹L¤TÓ¤ë~ 2023/7/5ªÑ»ù3.8¶ô¦ý¨ì¤µ¤Ñ¥u³Ñ¤U1.62¤F,¦A¹L¤TÓ¤ëÀ³¸Ó´N·|¯}1¶ô,¦pªGn¨ÖÁʦ´N³Q¨ÖÁʤF,½Ð¤j®a¤£n¥Õ¤é¹Ú¤F! 2021¦~§Ú´N¬Ý³z³o¤äªÑ²¼¤F!¥u·|¼W¸êÄF¿ú..ªÑ»ù¶^¨ì1¤¸¦A´î¸ê,«nªºÁ{§É«o¨S±Ë¦nµ²ªG!¤§«á´N·|¹³Âû³J¤ô»åªÑ0.1ªº»ù®æ ! ¤£«H¶Ü? 2024¦~¨Ó¬Ý
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2023/7/6 ¤U¤È 10:41:26²Ä 6353 ½g¦^À³ ±Nªñ¤@¦~¨S¨Óµo¨¥¤F~¤µ¤Ñ¤S¬O¸Ñª¼¥¢±Ñ...¾ú¸g¤F´î¸ê¤À©îÁקK¤U¥«,ªÑ¼Æª½±µ°£¤W6,ÁöµMÁקK¤U¥«©R¹B...¦ý¼Æ¾ÚÁÙ¬O¤£ª§®ð,´N§ÚªºÆ[¹îªÑ»ù¦b¥¼¨Ó¥b¦~ÁÙ·|«ùÄò±´§C¨ì1¬ü¤¸¤§¤U~¤d¸U¤£n¤£¬Û«H...©^ÄU¤j®a¤£n¦Aª±³o¤@¤ä¤F!!§ß¤£°_ªºªü¤æ
¤£¬Û«Hªº¥h¬Ý§Ú¥H¤Uªºµo¨¥§a !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/5/27 ¤U¤È 03:08:40²Ä 5352 ½g¦^À³ ¥Ø«e¤w¸g¤U±´0.4¤§¤U¤F,´«ºâ¦¨¥xªÑ»ù®æ¤j¬ù2.4¶ô¥ª¥k,ªñ´Á¤º¨S¦³«¤j§Q¦h®ø®§ªº¸Ü,ªÑ»ù´N·|¬O¦b©¹¤U¾_Àú,¤£¹L©¹¤U¦h¤Ö¤w¸g¤£«n¤F!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/3/2 ¤U¤È 11:16:14²Ä 5145 ½g¦^À³ ¤§«e¥»¤Hªº¯d¨¥³£¤w¸g¤@¤@ÅçÃÒ.......ªÑ»ù¤w¸g©¹0.8¾aªñ ! ±µ¤U¨Ó·|ºCºC¤U±´¨ì0.4¥ª¥k ! ³ÌºGªº¬O¦pªG30¤Ñ¤ºªÑ»ù³£¯¸¤£¤W1¶ô¿ú~ÁÙn±Á{¤U¥«·ÀI ~ ¤£¹L¬üªÑ«Ü¬y¦æ¤À©îªÑ²¼´î¤Ö§AªºªÑ¥÷µM«á¼W¥[ªÑ²¼±È¨ÓÁקKªÑ²¼¤U¥«...§Æ±æ¨È·à±d¤£n¨«¨ì³o¤@¨B
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/1/19 ¤W¤È 09:59:39²Ä 5061 ½g¦^À³ ¶ZÂ÷¤W¦¸¯d¨¥(2021/12/28)¹L¤F¤j¬ù20¤Ñ~¨ì¤F¤µ¤Ñ¥Ø«e¤w¸g¶^¸¨1¶ô¤§¤U... (2021/9/29)¸Ñª¼¤j¶^¤§®ÉÁÙ¦³2.5¶ô,¥B·í®É¥»¤H¤w¸gÂ_¨¥¤§«áÁÙ·|«ùÄò¤j¶^... ¬Ýªk¨Ì¤£ÅܱNÄ~Äò©¹0.8¾aªñ~¦A¨Ó´N¬O©¹0.5»ù¦ì¾aÃl.... ¤d¸U¤£n¬Û«H±Ë»ò³o·sÃĤñ±Ë»òÁÙn¦nªº°¸Ü ? §Aª¾¹D¥«±¤W¾AÀ³©Ê¥Ö½§ª¢·sÃĦ³¦h¤Ö¶Ü ? ª¾¹D¤F§A´N¤£·|Ä~Äò§ë¸êASLN¤F....
³¯¤j§Aªºµo¨¥¨S¦³°ÝÃD~¤£»Ýn³Q¤H«Â¯Ù~~¤]¤£·|¦³ªk«ß³d¥ô !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/12/28 ¤U¤È 01:43:58²Ä 5008 ½g¦^À³ ¥H¤U¬O2021/9/29¸Ñª¼¨ì¤µ¤Ñªº¬Ýªk.... ¥»¤H1´Á¸Ñª¼¤j¶^·í¤Ñ¬å¥X»ù¦ì2¶ô5¥ª¥k!!¨ì¤µ¤Ñ¤S¶^¨ì1¶ô¿ú¤W¤U~²{¦bªºªÑ»ù¤w¸gÅçÃÒ·í®Éªº¬Ýªk~ ¤§«áÁÙ·|©¹0.8¾aªñ~¤£«H¶Ü ? ½Ð±µµÛ¬Ý !! ºô¸ô°g´öªGµMÁÙ¬O·|¨R©ü¤@°ï¤H°Ú~½Ð¦Û¤v¤p¤ß!!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/23 ¤U¤È 05:55:34²Ä 4784 ½g¦^À³ ¬Q¤é«ùÄò¤j¶^7%¤¤~«Ü¼y©¯¥»¤H¦b¨È·à±d¬ü¤Æªº1´Á¸Ñª¼¼Æ¾Ú..¦ý¥«³õ¤£»{¦P¤j¶^«á...¦b2¶ô¦h´N¥þ¼Æ¥X²æ.. ¤§«e¤w¸g»¡¹LªGµM¤j¶^«áÁÙ·|«ùÄò³Ð·s§C...¥¼¨Ó±NºCºC½w¶^¨ì¤@¶ô¤§¤U..¤d¸U¤£n¤£¬Û«H ?
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/15 ¤U¤È 07:49:46²Ä 4750 ½g¦^À³ ¥H¤U§ó¥¿¬°004 ¤j®aÁÙ°O±o¶Ü¡H ¨È·à±d³£¬O¤@³eªº§@·¡A¤§«eÁx¹DÀù¤T´Á¥¼¸Ñª¼¤§«e¤]¬O³£«Ü¼ÖÆ[¡AµM«á³oÃ䪺ºô¤Í±M·~¤ÀªR¤å³¹³sµo¡I»¡¦³¦h¼F®`¤@©w·|¹L¤T´Á¡Aµ²ªG¤@¸Ñª¼¥¢±ÑªÑ»ù¤j¶^¡A³oÃ䪺ªº°l±·¤å³¹ÃÒ¾Ú¤]³£¤@°_¬å±¼¤F¡AµM«á²{¦b¦A¨ÓÓ004¡K ¬Ý¦ü«Ü±M·~¼Æ¾Ú¤å³¹Ä~Äò°l±·¡A¦ý¨Æ¹ê004´N¬O¼Æ¾Ú¤£¦n¡AÃø¤£¦¨¨gµo¬Ý¦ü±M·~ªº¤å³¹¡A¨È·à±d´N·|ùL¤G´Á¶Ü¡HµM«á³Q¦¬ÁÊ¡H ·í§½ªÌ°g¡A®ÇÆ[ªÌ²M¡A½Ð¤T«ä¡K
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/12 ¤U¤È 03:24:19²Ä 4709 ½g¦^À³ Ó¤Hı±o³o¦¸¤£¬OÀ£§C¥X³f¸ÑŪ, ¦U¦ì¦³¬Ý¹L¼Æ¾ÚÀu¦ý¬OªÑ»ù¶^±¼¤@¥bªºªº¨Ò¤l¶Ü? ³q±`¼Æ¾ÚÀu³£¬Oº¦¤@¿!¤£·|À£§CÅý§A¦Y³fªº©Ô! ¨S·N¥~ªÑ»ù·|½w¶^¨ì1¶ô¤§¤U~
¥H¤U¬O9¤ë©³ªº¬Ýªk¦Ü¤µ¤£ÅÜ...½w¶^¨ì§A¤ß·W·N¶Ã...
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51²Ä 4668 ½g¦^À³ ¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W, ¦pªG¯uªº¦p³oÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ? ¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/4 ¤U¤È 09:40:37
²Ä 6480 ½g¦^À³
|
«Ó¤j
µL©Ò¿×¤F¡A´N·í¹J¨ì¤F¶BÄF¶°³QÄF¤F¡A
¤£¹L³s¤Ñ©R¤j³£¤£¨£¤F¡A
¦³ÂI©_©Ç¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/12/4 ¤U¤È 09:11:54
²Ä 6479 ½g¦^À³
|
¦Û±q½æ¥X¨È·à±d«á´N¨S¦bª`·N èè¬ðµMÂI¨ì·à¤lªÑ»ù¯u¬OÅå§b¤F ©~µM¥u³Ñ0.6 (·íªì1.4©ñ±ó½æ¥ú¯u¬O½æ¹ï) ¤j®a«O«ªü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/11/29 ¤U¤È 10:25:49
²Ä 6478 ½g¦^À³
|
¤p©ú¤j
«ùªÑÃøºâ ª¾¹D«ùªÑµ²ºc¤ñ¸û«n
«ùªÑµ²ºc 0.08% % of shares held by all insiders 39.13% % of shares held by institutions 39.16% % of float held by institutions 17 Number of institutions holding shares
Top institutional holders Holder Shares / Date reported /% out /Value Tang Capital Management, LLC 1,901,552 29 Sept 2023 25.03% 1,293,055 BVF Inc. 1,049,999 29 Sept 2023 13.82% 713,999 Velan Capital Investment Management LP 625,000 29 Sept 2023 8.23% 425,000 Vivo Capital, LLC 568,182 29 Sept 2023 7.48% 386,363 Parkman Healthcare Partners LLC 372,741 29 Sept 2023 4.91% 253,463 Temasek Holdings (Private) Limited 335,615 29 Sept 2023 4.42% 228,218 Sio Capital Management, LLC 254,150 29 Sept 2023 3.34% 172,822 Citadel Advisors Llc 172,478 29 Sept 2023 2.27% 117,285 Schonfeld Strategic Advisors Llc 91,500 29 Sept 2023 1.20% 62,220 Millennium Management Llc 80,456 29 Sept 2023 1.06% 54,710
¥H¤U³o¤T®aÄå°£¥H25¤~¬O¯u¥¿ªÑ¼Æ K2 HealthVentures Equity Trust LLC 26,466,126/25 13G 2023/03/20 BIOTECHNOLOGY VALUE FUND L P 42,440,000/25 13G 2023-03-06
TANG CAPITAL PARTNERS LP 26,824,625/25 13G/A 2023-02-14
¬°ªü´µÄõ»sÃĦ³¤½¥q´£¨Ñ 12 Ó¤ë»ù®æ¹w´úªº 3 ¦ì¤ÀªR®vªº¤¤¦ì¼Æ¥Ø¼Ð¬° 15.00¡A³Ì°ª¦ôp¬° 17.00¡A³Ì§C¦ôp¬° 15.00¡C ¹w¦ô¤¤¦ì¼Æ¸û¤W¦¸»ù®æ 0.69 ¬ü¤¸ ¦³ 2,073.91%¤Wº¦¼ç¤O
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦³¿ù½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/29 ¤W¤È 01:26:03
²Ä 6477 ½g¦^À³
|
¥xÁÞ¤j
§A¦CÁ|ªº¨º¨Ç¤j©@«ùªÑÁ`p
¤w¶W¹L¥Ø«e¤½¥q²{¦³ªÑ²¼Á`¼Æ¡A 16,350,000ªÑ¡A
¥i¯à¦³¨Ç¬O´î¸ê«e«ùªÑ¡A »Ý°£¥H5¡A
§Ú¬d¤£¨ì¥¿½T¸ê®Æ¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/11/28 ¤U¤È 10:37:50
²Ä 6476 ½g¦^À³
|
³o´X®a«ù¦³ASLAN Pharmaceuticals ºâ¬O¤j©@¤¤ªº¤j©@
Tang Capital Management, LLC 1,901,552 13F 2023 /09/29 BVF Inc. 1,049,999 13F 2023 /09/29
K2 HealthVentures Equity Trust LLC 26,466,126 13G 2023/03/20 BIOTECHNOLOGY VALUE FUND L P 42,440,000 13G 2023-03-06
TANG CAPITAL PARTNERS LP 26,824,625 13G/A 2023-02-14
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/11/28 ¤W¤È 10:11:29
²Ä 6475 ½g¦^À³
|
©ú(113)¦~¤W¥b¦~¨½µ{¸O¦p¤U: 2¤ë15¤é¦U°òª÷¤½¥q¤½¥¬112¦~Q4«ùªÑ©ú²Ó 3¤ëTREK-DX¡BAA¸Ñª¼ 4¤ë¤½§i113¦~Q1°]³ø(²{ª÷¥i¤äÀ³¨ì113¦~8¤ë) 4¤ë»P¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)¥l¶}Á{§É¤T´Á«e·|ijEnd-of-Phase 2 (EOP2) meeting 5¤ë°Ñ¥[¤é¥»²Ä2©¡°ê»Ú¥Ö½§¯f¬ã¨s¾Ç·|(ISID)(TREK-DX¡BAA¸Ñª¼¼Æ¾ÚÀ³¸Ó¨Óªº¤Î°e¥X) 5¤ë15¤é¦U°òª÷¤½¥q¤½¥¬113¦~Q1«ùªÑ©ú²Ó 6¤ë©³«e¤½¥q·|¶i¦æ¨p¶Ò¡B±ÂÅv¡B³Q¨ÖÁʩΤU¥«
½Ð¦U¦ì¤j¤j¸É¥R©Î«ü¥¿.ÁÂÁ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/11/28 ¤W¤È 08:30:13
²Ä 6474 ½g¦^À³
|
whalewisdom.com/stock/asln ¸Óºô¯¸´£¨Ñ2021¦~Q3¦Ü¤µ(2023¦~Q3)¦U°òª÷¹ï¨È·à±d¼W´îªÑ¼Æ¼Æ¾Ú ¦Ó¥B²{¦b¬Ý¨ìªº2021¦~Q3¦Ü2023¦~Q3ªº«ùªÑ¼Æ¡A³£¬O¤w¸g´î¸ê(¤µ¦~2¤ë´î¸ê)§¹ªº¼Æ¾Ú ¦U¦ì¥i¥H±q2021¦~Q3¶}©l¬d¨C©uTang Capital Management, LLCªº¶i¥X¶q Tang Capital Management, LLC¬O±q2021¦~Q3¶}©l¶R¶i¨È·à±d ¦U¦ì¥i¥H¬d¨ìTang Capital Management¤½¥qt³d¤H¦P®É¥H TANG CAPITAL PARTNERS LP ©M TANG CAPITAL MANAGEMENT LLC ³o¨â®a°òª÷¤½¥q¤j¶q¶R¶i¨È·à±d
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/11/27 ¤U¤È 11:15:41
²Ä 6473 ½g¦^À³
|
¤p©ú¤j ¬Ý°_¨ÓTang Capital Management, LLC«ùªÑ¦û¤ñ¦³»~¡A¦³¤H¥i¥H´£¨Ñ§ë¸ê¾÷ºc¯u¹êªº«ùªÑ»P¦û¤ñ¡HÁÂÁ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/27 ¤U¤È 10:43:13
²Ä 6472 ½g¦^À³
|
Tang Capital Management, LLC 1,901,552 29 Sept 2023 25.03% (13F)
§Ú»{¬°¸ê®Æ¦³»~¡A 1,901,552/16,350,000=11.63% «D 25.03% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/11/27 ¤U¤È 10:21:19
²Ä 6471 ½g¦^À³
|
¸Ø±i¤j
whalewisdom.com/stock/asln
VIVO CAPITAL, LLC ½æ¤F 2,272,726ªÑ ¯d 568,182 ªÑ (¥i¯à¬O¬Ý¨ì·s¼Æ¾Ú¤£½æ¤F ¦p¤Ï¦V¶R¦^ ¤£ª¾¹D·|«ç¼Ë?)
«ùªÑ¨º»ò¦h§ë¸ê¾÷ºc¤@ÂI¤]¨S¦b©È ¤Ï¦Ó¬O¤pªÑªF©È¨ì¤£p¦¨¥»±þ¥X 7¤ë6¤é¶^¨ì²{¦b§â003 004 ªº»ùÈ¥þ³¡¶^¥ú¥úªº«D¦X²z¶W¶^ , «ç»ò¤U¥h «ç»ò¤W¨Ó ! ´²¤á¥Ã»·¬O³Ì¤j¿é®a
«e¤Q¤j Holder Åܰʤ£¤j
«e¤Q¤j Holder / Shares / ¦û¤ñ
Tang Capital Management, LLC 1,901,552 29 Sept 2023 25.03% (13F) BVF Inc. 1,049,999 29 Sept 2023 13.82% (13F) Velan Capital Investment Management LP 625,000 29 Sept 2023 8.23% (13F) Vivo Capital, LLC 568,182 29 Sept 2023 7.48% (13F) Parkman Healthcare Partners LLC 372,741 29 Sept 2023 4.91% (13F) Temasek Holdings (Private) Limited 335,615 29 Sept 2023 4.42% (13F) Sio Capital Management, LLC 254,150 29 Sept 2023 3.34% (13F) Citadel Advisors Llc 172,478 29 Sept 2023 2.27% (13F) Schonfeld Strategic Advisors Llc 91,500 29 Sept 2023 1.20% (13F) Millennium Management Llc 80,456 29 Sept 2023 1.06 (13F)
¥t¥~ÁÙ¦³13G/A §ë¸ê¾÷ºc ( ¬Ý¤£À´«ùªÑ¦û¤ñ«ç»òºâ? ) ( «ùªÑ¨º»ò¦h ¤@ÂI¤]¨S¦b©È Åܰʤ£¤j ) Shares / ¦û¤ñ K2 HealthVentures Equity Trust LLC 26,466,126 6.20 13G 2023/03/20 BIOTECHNOLOGY VALUE FUND L P 42,440,000 9.99 13G 2023-03-06
TANG CAPITAL PARTNERS LP 26,824,625 7.80 13G/A 2023-02-14
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/25 ¤W¤È 01:44:16
²Ä 6470 ½g¦^À³
|
¤½¥q³£§Ö¦º¤F¡A
µe¤j»æ¦ó¥Î¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/11/24 ¤U¤È 04:46:29
²Ä 6469 ½g¦^À³
|
1.²§¦ì©Ê¥Ö½§ª¢¯f±w¥þ²y2»õ¤H¡A¥Ø«e¥u¦³¦Ê¤À¤§8 ¯f±w¨Ï¥ÎDupilumab¡A¨Ï¥ÎDupilumabªº¯f±w¤¤¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä¡A¬OÄY«¥¼³Qº¡¨¬ªº¯e¯f¡C 2.eblasakimab ©M dupilumab ¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¥Ö½§¬¡Àˤ¤ªºÀY¹ïÀY¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î¡C 2.¨Ï¥Î¤w«Ø¥ßªº¤HÃþªÍ¤Á¤ù COPD ¼Ò«¬¡A·s¼Æ¾ÚÃÒ©ú eblasakimab ¨ã¦³´î¤Ö®ð¹D¦¬ÁY©M¼W±jÂX±iªº¼ç¤O¡C
Å޿軡©ú«Ø¥ß¦b¤Wz3ÂI«e´£½T©w¤U¡C 1.ÀY¹ïÀY¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î¡C§Yeblasakimab·|·m¨«ì¥ÎdupilumabªvÀøªº¯f±w¡Cµ¹ÃÄÀW²v¥Ñ¨â¶g¤@¦¸§ï¦¨¤@Ӥ뵹ÃĤ@¦¸¡C 2.¨Ï¥ÎDupilumabªº¯f±w¤¤¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä¡C§Y»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|¤£¥u¦³¤@ºØ¡A¦ý¤w¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä¡A©Ò¥H¹w¦ô¤£·|¦³¤Ó¦hºØ»¤µo¸ô®|(¹w¦ô¦³¤TºØ¤£¦Pªº»¤µo¸ô®|ºâ®t¤£¦h)¡CDupilumab§í¨î¤F¨ä¤¤¤@ºØ»¤µo¸ô®|¡C 3. TREK-DX¬On§ä¥ÎDupilumabªvÀø¨S®Äªº¯f±w¡A§Y§ä«e±¥t¥~¨âºØ»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|ªº¯f±w¡A³o¬O¤@ºØ¬D¾Ô(TREK-DX©ú¦~²Ä¤@©u¸Ñª¼¥¢±Ñ¤]¨SÃö«Y¡A¦]¬°¨È·à±dÁ{§É¤T´Á¥i¥H§äAD·UÄY«ªº¯f±w¨Ó¸ÕÅç)¡C 4.¤G´ÁÁ{§É¸ÕÅçÅã¥Ü¡AAD·UÄY«ªº¯f±w¡A¨Ï¥ÎeblasakimabªºÀø®Ä·U¦n¡C(AD·UÄY«ªº¯f±w¡A»¤µo¦]¤l¬O¤£¬O¨«¨ä¥L»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|?¤£ª¾¹D)¨È·à±dÀ³¸Ó¦bTREK-DX¸ÕÅ礤·|¼W¦¬¥ÎDupilumabªvÀø¨S®Ä¦ý¯f±¡ÄY«ªº¯f±w¡C 5.ÀY¹ïÀY¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î¡C(¦pªG»¤µo¦]¤l¨«IL-13R »P IL-4R¬O¨â±ø¤£¤@¼Ëªº»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|¡A¨º¨È·à±d¦¨¥\¤F¡A¦]eblasakimab¥i¥H¦P®É§í¨î³o¨âºØ¤£¤@¼Ëªº»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|)¡C 6. COPD¥ÎeblasakimabªvÀø¡Cµ¹ÃÄÀW²v¦³·Q¹³ªÅ¶¡¡C
¦³½Ð¦U¦ì¤j¤j«ü¥¿
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/21 ¤U¤È 10:54:01
²Ä 6468 ½g¦^À³
|
¸Ó¿ô¤F§a¡A
³Ð¾ú¥v·s§C0.92¡A«Ü§Ö´N¤U¥«¡A
3´Á¸ÕÅç¡A¸g¶O©O¡A½Ö´±§ë¸ê¡A
³Ìªñ¤@ª½©ñ§Q¦h®ø®§¡A
¨ä¤¤¥²¦³¶B
³s¦hÀY¤Ñ©R¤j¤]¥¢Áp¤F¡A
³o¤½¥q¨S±Ï¡AÄF¤F«Ü¦h¦~¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/11/16 ¤U¤È 04:56:51
²Ä 6467 ½g¦^À³
|
§ë¸ê¨È·à±dªº¹ï¨R°òª÷¤Î¸ê²£ºÞ²z¤½¥q¡A«ùªÑ©ú²Ó(²Ä¤T©u)¦p¤Uºô¯¸: whalewisdom.com/stock/asln
7¤ë6¤é¤j½æªÑ²¼¬O ºû¨U¸ê¥»¦³³d¥ô¤½¥q ½æ¥X2,272,726ªÑ (³Ñ568,182ªÑ)
¦Ó ºû¨U¸ê¥»¦³³d¥ô¤½¥q ¦b¤µ¦~²Ä¤@©u ´N¬O¶R¶i2,272,726ªÑ (¶R½æªÑ¼Æ¤@¼Ë) (²Ä¤@©u¤À¶¥¬q¶R¶i,¦A7¤ë6¤é¤@¦¸½æ¥X,¤~¯àÀ~¥X¤@°ï´²¤á) (¬Ý¤£¦n´N¥þ½æ§a,¬°¦óÁÙ¯d568,182ªÑ)
¥t¥~ 𤽥q¦b²Ä¤T©u¦A¶R¶i773,484ªÑ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/14 ¤U¤È 07:07:41
²Ä 6466 ½g¦^À³
|
¨Ì¨È·à±dªº«e¬ì°O¿ý¡A
§Ú»{¬°¨S¦³¾÷·|·ÓTempest |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2023/11/14 ¤W¤È 06:31:04
²Ä 6465 ½g¦^À³
|
Tempest Therapeutics¾ÌÔ£1¤Ñ±q18¼h¦aº»¤É¨ì¤Ñ°ó¡H
2023.10.11-¬üªÑ¤SÅå²{¤@©]ötº¦ªñ40¿¤j¤ûªÑ www.fx168news.com/article/326113 ±q24¤p®É«eªº¨CªÑ30¬ü¤Àªº»ù®æ¤Wº¦¨ì¤F¥Ø«eªº6.40¬ü¤¸¡Cº¦´T¶W¹L2,000¢H¡A³Ì°ª飙¨ì39.7¿..... -------------------------------------------------------------------------------------------- ¨È·à¹wp©ó2024 ¦~²Ä¤@©u¤½§GTREK-DX¸ÕÅ窺¥Dn¼Æ¾Ú(Eblasakimab¦b¥ý«e±µ¨ü Dupilumab ªvÀøªº¨k©Ê©Î¤k©Ê¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤¤ªº¬ã¨s) ¸U¤@¼Æ¾Ú¥¿±¡A«ö¥Ø«eªÑ»ù1¤é¤S¸Ó½º¦´X¿? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/11/14 ¤W¤È 12:22:44
²Ä 6464 ½g¦^À³
|
³o¦ìµoªíºtÁ¿ªÌ¬O¤½¥qÂàĶ¬ì¾Ç³¡¥D¥ô¡A¨Ó¦Û¥[¦{¡AªA°È¹LLebrikizumab ¬ãµo¤½¥qDermira»PLily «á¨ÓLebrikizumab ³QLily¥H11»õ¬ü¤¸¨ÖÁÊ¡A¦]¬°Lily·Ç³Æ¨ÖÁʦ³¼ç¤OªºAD¶}µo¤¤ÃĪ«¡A·Ç³Æ»PDupilumab ¥¿±¤j¹ï¨M¡C ¹³Aslan Pharmaceuticals ³oºØÁ`¥«È¬ù1800¸U¬ü¤¸¤S¦³Ävª§¼ç¤O¡A¥i¥H¶i¤J¤T´ÁÁ{§É¡AªÑ»ù·|¶^ªº²z¥Ñ³Ì¤j¥i¯à¬OªÎ¤ô¤£¸¨¥~¤H¥Ð¡A¥xÆWªÑªFÄw½X³QÀ~¥X«á(½æÀ£¨Ó¦Û¥xÆWªÑªFªº¥i¯à©Ê³Ì¤j)¡A¸¨¤J¤jªÑªF¤â¤¤«á´N¬OªÑ»ù¤ÏÂ઺¶}©l¡AªÑ¼Æ¤Ö¡AÁ`¥«È¤p¡A¥¼¨Ó¼WÈ¿¼Æ¦p§ë¸ê¾÷ºc¹w¦ô¬Û·í¥iÆ[¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/13 ¤U¤È 11:38:46
²Ä 6463 ½g¦^À³
|
¦p©ú¤Ñ¤j©Ò¨¥¡A¤µ¤Ñ¥¿¦¡¶^¯}¤@¤¸¡A
¨C¤Ñ¯}©³¡AÂ÷¤U¥«´N§Ö¤F¡A
³o¤½¥q³s¸ÕÅç«á³ø§i³£¯à×¥¿¡A
Moa¦³®Ä¥i¯à¤]¬OÓ§¾¡A¥i¯à³y°²ªº
³o¤½¥q¥»¨Ó´NµL¸Û«H¡A ³Ìªñ¦h¦¸½Ð±M®a°¸Ü³s½g¡A¥«³õ¤]¤£¶R³æ¡A
¨Ì¦¹»ù¦ìÁÙ°ø¨¥n°µ¤T´Á¸ÕÅç¡A¯u¬O¤Ñ¯u¦n¯º¡A¿ú¨ºÓ¥Õè¥I¡A
¤@ÄF¦AÄF¡A±q¥xÆWÄFˬü°ê¡A
¯u½M¤F²´¡A²{¥u¯àÅ¥¤Ñ©R»{¿é |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2023/11/11 ¤U¤È 07:31:00
²Ä 6462 ½g¦^À³
|
¸Ø±i¤j¡ã½Ð°Ý¤@¤U¦³µL½Ķ¡A¬O¦b»¡©ú¤°»ò«ÂI¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/11/11 ¤U¤È 06:19:41
²Ä 6461 ½g¦^À³
|
m.youtube.com/watch?v=HvJGBLvuYmo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/11/11 ¤U¤È 06:11:16
²Ä 6460 ½g¦^À³
|
Dr. Ferda Cevikbas, Aslan Therapeutics - YouTube
m.youtube.com/watch?v=HvJGBLvuYmo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/11/8 ¤U¤È 02:26:28
²Ä 6459 ½g¦^À³
|
¤K¤ë©³¤w¥X²Maslan«ùªÑ¡A¦³©¯³B¤À»ù®æÁÙ¦b2¤¸¥H¤W¡A±q¥xÆW¨ì¬ü°ê¡A¤@¸ô¶R¶i¡A³B¤À«e¥Ø«eADR«ùªÑ¦¨¥»¬ù¬°USD12.5~13¤¸¥ª¥k(´«ºâ¦^·íªì¥xªÑ¤j·§¬O¤@ªÑTWD14~15¤¸¥ª¥k)¡A³o¤@µ§§ë¸ê¤]ºâ¬O¥H-85%¦¬³õ¡A§Ú¬Û«H§Úªº«ùªÑ¦¨¥»¦b¦Ñ·à¤Í¸ÌÀ³¸Óºâ¬O¬Û¹ï§Cªº¤F¡A¸Ü¤£¦h»¡¤F¡A¤j·§¤]¬O³Ì«á¤@½g¤F¡A¥Ø«e³o¼Ë¬Ý¤U¨Ó¤j·§¥u¦³©ú¤Ñ¹L«á¤j¤j»¡ªº¸û¬°·Ç½T¡A¨ä¥Lµe¤j»æªº´Nºâ¤F¡A11¤ë»ù®æ¤]¹Gªñ1¤¸¤U¥««O½Ã¾Ô¡A¸ò©ú¤Ñ¹L«á¤j¤j¹w¦ôªº¤@¼Ë³o´N¤£¦h»¡¤F¡A¥Ø«e²{ª÷°÷ºÙ¨ì2024¤U¥b¦~¡A¦ý2024¤W¥b¦~¦³¤°»ò©O?¥u¦³ASLAN003ªº´Á¤¤¼Æ¾Ú¡AASLAN004ªº¤G½u¦]¬°×§ï¸ÕÅ窺½t¬G¡A¤w¸g¤£ª¾¹D¦ó®É·|§¹¦¨¤F¡A¥u¯d¤U©ú¦~·|¶}©l¶i¦æ¤T´Á¤Î¤é¥»¤@´Á¡A¦ý¤é¥»¤@´Á»¡¹ê¦bªº¦³¨S¦³°µ±o¤£¼vÅT¤j§½¤F¡A¤½¥q¨S¿ú°µ¤T´Á¡A¦ý¥H¥Ø«e¨Ó»¡¡A¨ì¤F©ú¦~¤U¥b¦~¡AASLAN004¤]¨S¤°»ò·s¶i«×¤F¡An§ä¤jÃļt¦X§@¤T´Á¡A¯uªº¦³³o»ò®e©ö?¥H¥Ø«e¥«È¨Ó»¡¡AUSD5»õ¤¸¬O25¿¡AUSD10»õ¤¸¬O50¿¨S¿ù³â¡A¦ý¥HASLANªÑ»ù¤@ª½¦b¯}©³¨Ó»¡¬O¦³½Öªº¥D¤O³¡¦ì«ù¦³¦¨¥»USD1.2¤¸ªº³â¡A¨º°®¯Üµ¥¨ìªÑ»ù0.5¤¸¦A¨Ó»¡¤£´NÅܦ¨50¿¡B100¿§ó§l¤Þ¤H?¥H¥Ø«eªÑ¥»¨Óºâ(«áÄò¨S¦³¼W¸ê¿±µÈªº¸Ü)¡A¥«È1»õ¤¸¤j·§¬OADR1ªÑ6¤¸(´«ºâ¦^¥xªÑ¤j¬ù1ªÑ7~8¤¸)¡A¦Ñ·à¤Í¥i¥Hµû¦ô¤@¤U¡A«ù¦³³o»ò¦h¦~¡AÁÙn«_µÛ¤U¥«ªº·ÀI¡A³ø¹S²vn§ì¦h¤Ö?¦¬ÁÊ»ù®æ°_½Xn¹F¨ì¦h¤Ö¤~¯à±µ¨ü?§Ú¦Û¤vµû¦ô«á¬Oı±oºâ¤F¡AÄêªd§ß¤£¤WÀð¡A®É¶¡¸ò¿ú³£µ¹¤F¡A¥u¥æ¥X³oºØ¦¨ÁZªº¸Ü¡A§Ú¤£»{¬°¥¼¨Ó·|¦³©Ò§ïµ½¡AÁ`¤§¦Ñ·à¤ÍÌ«O«....... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/11/6 ¤U¤È 11:11:15
²Ä 6458 ½g¦^À³
|
·s»D½Z¤¤¦³´£¨ìÀY¹ïÀYÁ{§É¸ÕÅç Head-to-Head trial ¡]¥Dn¬O»Pdupilumab¶i¦æ¤ñ¸û¡^ ³oºØÁ{§É¸ÕÅç·s¤è¦¡昰n»P¤w¤W¥«ÂÂÃĶi¦æÃĪ«Àø®Ä»P¦w¥þ©Ê¶i¦æ§óª½±µ¤ñ¸û¡A¥Øªº¦b©ó¥[§ÖÁ{§É¸ÕÅç»PÃĪ«¼f¬d®Éµ{
¥i参¦Ò¡G ·sÃÄÂÂÃĽ֤ñ¸û¦n¡HÀY¹ïÀYÁ{§É¸ÕÅç PK ¸Ñ±K |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/11/6 ¤U¤È 10:21:08
²Ä 6457 ½g¦^À³
|
¥þ¤å½Ð°Ñ¦Ò¤½¥q·s»D½Z ASLAN PHARMACEUTICALS PRESENTS NEW DATA ON EBLASAKIMAB IN ATOPIC DERMATITIS AND COPD TRANSLATIONAL MODELS AT THE 7th DERMATOLOGY DRUG DEVELOPMENT SUMMIT
ªü´µÄõ»sÃĤ½¥q¦b²Ä¤C©¡¥Ö½§¯fÃĪ«¶}µo°ª®p·|¤W®i¥Ü Eblasakimab ¦b²§¦ì©Ê¥Ö½§ª¢©MºC©Êªý¶ë©ÊªÍ¯fÂà¤Æ¼Ò«¬¤¤ªº·s¼Æ¾Ú ªü´µÄõ»sÃĪѥ÷¦³¤½¥q 2023 ¦~ 11 ¤ë 3 ¤é¬P´Á¤±ß¤W 7:00
eblasakimab©Mdupilumab¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¥Ö½§¬¡Àˤ¤ªºÀY¹ïÀY¬ã¨sÃÒ¹ê¤Feblasakimab¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î
¨Ï¥Î¤w«Ø¥ßªº¤HÃþªÍ¤Á¤ù COPD ¼Ò«¬¡A·s¼Æ¾ÚÃÒ©úeblasakimab¨ã¦³´î¤Ö®ð¹D¦¬ÁY©M¼W±jÂX±iªº¼ç¤O
µ²ªGº¦¸ÃÒ©úeblasakimab¦b AD ¥H¥~ªº¨ä¥L¾AÀ³¯gªº¼ç¦b¥Î³~
¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~11 ¤ë3 ¤é¡]Àô²y³q°TªÀ¡^- ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¨Ó§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬±À¥X·s²£«~¼Æ¾Ú©ó2023 ¦~10 ¤ë31 ¤é¦Ü11 ¤ë2 ¤é¦b°¨ÂĽѶë¦{ªi¤h¹yÁ|¦æªº¥Ö½§¯fÃĪ«¶}µo°ª®p·|(DDDS) ¤W¤½§G¡C³o¨Ç¼Æ¾Ú¶°´£¨Ñ¤F±j¤ÆÃÒ¾Ú¡AÃÒ©úeblasakimab ¦b²§¦ì©Ê¥Ö½§ª¢(AD) ¤¤ªº®t²§¤Æ§@¥Î¾÷¨î¡A¥H¤Îº¦¸®i¥Ü¤F¨ä¦b·s¾AÀ³¯g¡X¡XºC©Êªý¶ë©ÊªÍ³¡¯e¯f (COPD) ¤¤ªºÀ³¥Î¡A¸Ó¯e¯f¥i¥Ñ 2 «¬µoª¢ÅX°Ê¡C
¦b AD ±wªÌªº¥Ö½§¬ï¨ë¬¡Àˤ¤¶i¦æªºeblasakimab ©Mdupilumab¤§¶¡ªºÀY¹ïÀY¬ã¨sÅã¥Ü¡A§½³¡¥Ö½§²Õ´¤Àªcªºµoª¢²ÓM¦]¤lªºªí¹F¦s¦b®t²§¡A eblasakimabªvÀø§ó¦³®Ä¦a°§CTh2 ²ÓM¦]¤lIL-13¡BIL-4©MIL-13 ªºªí¹F¡C»PªvÀødupilumab ¡C³o¨Çªì¨Bµ²ªGÅçÃÒ¤F¥ý«eµo¥¬ªº¨Ó¦Û AD ±wªÌ¥~©P¦å³æ®Ö²ÓMªº¼Æ¾Ú1 ¡A³o¨Ç¼Æ¾Ú¨Ó¦ÛASLAN »PShawn Kwatra ³Õ¤h¡]¬ù¿«ÀN´¶ª÷´µ¤j¾ÇÂå¾Ç°|¡^©MMadan Kwatra ³Õ¤h¡]§ù§J¤j¾Ç¡^ªº¬ã¨s¦X§@¡C³o¨Ç¼Æ¾Ú¦@¦PÃÒ©ú¤Feblasakimab»Pdupilumab¬Û¤ñªº®t²§¤Æ§@¥Î¡A¨Ã±j½Õ¤Feblasakimab¹v¦V IL-13R ªº¼ç¦bÀu¶Õ¡A³o¥i¯à¾ÉP§ó¦³®Ä¦aªýÂ_ 2 «¬°T¸¹¶Ç¾É¡A¦P®É¤£¼vÅT 1 «¬¨üÅé¡C
ASLAN ¤]§Q¥Î¤w«Ø¥ßªº¤HÃþ¨ÑÅéºë±K¤Á³ÎªÍ¤Á¤ùÂ÷Åé¼Ò«¬¡A´£¨Ñ¤F¬ã¨seblasakimab¦b COPD ¤¤§@¥Îªº·s¼Æ¾Ú2¡C¸Ó¼Ò«¬¨Ï¥Î IL-4 ©M IL-13¡]°Ñ»P COPD ¯e¯f¯f²z¾ÇªºÃöÁä Th2 ²ÓM¦]¤l¡^´ú¸Õ¤FªÍ²Õ´¤¤ªº®ð¹D°ª¤ÏÀ³©Ê (AHR) 3¡CEblasakimab¥i³z¹L´î¤Ö®ð¹D¦¬ÁY¡AÅãµÛ°§C IL-4 ©M IL-13 »¤¾Éªº AHR¡C¦¹¥~¡AIL-4 ©M IL-13 ¨Ï®ð¹D¹ï¾L¥ÒÁxÆPªº¤ÏÀ³¶i¤@¨B¦¬ÁYÅܱo±Ó·P¡A¦ý³oºØ±Ó¤Æ³QeblasakimabªvÀøªýÂ_¡C¬°¤FÀˬd¹ï®ð¹DÂX±iªº¼vÅT¡A¨Ï¥ÎºÖ²ö¯Sù»¤¾É¤ä®ðºÞÂX±i¡CIL-4 ©M IL-13 ¹w³B²z¦bªvÀø«á 5 ¤ÀÄÁ¤ºÅãµÛ°§C¤FºÖ²ö¯Sù¤Þ°_ªºÂX±i¡A¦ý³o¨Ç®ÄÀ³³Qeblasakimab¦³®Ä°fÂà¡A«ì´_¤F®ð¹Dªº¥¿±`¤ÏÀ³¡C¦]¦¹¡Aeblasakimab¦¨¥\ªýÂ_¤FªÍ²Õ´¤¤IL-4/IL-13»¤¾ÉªºAHR¡A«ì´_¤F®ð¹D¦¬ÁY©MÂX±iªº¥¿±`¤ÏÀ³¡A³o¦bCOPD¤¤¨ã¦³Á{§É·N¸q¡CEblasakimab³z¹L 2 «¬¨üÅéªýÂ_ IL-4 ©M IL-13¡A»P¶È°w¹ï IL-13 ²ÓM¦]¤lªºÃĪ«¬Û¤ñ¡A¥¦¦³¥i¯à¦b§ó¼sªxªº¾AÀ³¯g¤¤§ó¦³®Ä¡C
¡uºC©Êªý¶ë©ÊªÍ¯f¬O¥þ²y²Ä¤T¤j±`¨£¦º¤`ì¦]4¡A¨Ã¥B¬O¤@ºØ²§½è©Ê¯e¯f¡A«Ü¤j¤@³¡¤À±wªÌ¨ü¨ì 2 «¬ÅX°Ê¯f²zªº¼vÅT¡A¦Ó³o¨Ç±wªÌªº°w¹ï©ÊªvÀø¿ï¾Ü½d³ò¦³¡C§Ú̦bÂà¤Æ¼Ò«¬¤¤´£¨Ñªº¼Æ¾Ú¹ï©ó±´¯Áeblasakimab¦b AD ¥H¥~ªº¨ä¥L¾AÀ³¯g¤¤ªº¼ç¤O¦ÜÃö«n¡A§Ú̬۫Heblasakimab¨ã¦³¥¨¤jªº¼ç¤O¡A¥i¥H¬° COPD ´£¨Ñ¦³®Ä¥B®t²§¤ÆªºªvÀø¿ï¾Ü¡A¸Ó¥«³õ¹wp±N¨ì2032¦~±N¹F¨ì 300 »õ¬ü¤¸¡A¡vASLAN »sÃĤ½¥q°õ¦æªø Carl Firth ³Õ¤h»¡¡C¡§ÁöµMeblasakimab¤w¸g¦b AD ¤¤®i¥Ü¤F¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¥B¤£¼vÅTÀø®Ä¡A¦ý¦b¥Ñ 2 «¬ª¢¯gªº±`¨£¼ç¦b¥Íª«¾ÇÅX°Êªº¨ä¥L¯e¯f¤¤¡AÁÙ¦³¥¨¤jªº¥¼¶}µo¼ç¤O¡C¡¨
ASLAN Pharmaceuticals Âà¤Æ¬ì¾Ç¥DºÞ Ferda Cevikbas ³Õ¤hªí¥Ü¡G¡§§ÚÌ´£¨ÑªºÂà¤Æ¼Æ¾Ú´£¨Ñ¤Feblasakimab¿W¯S§@¥Î¾÷¨îªºÃÒ¾Ú¡A¨Ã±j½Õ¤F¨ä»P°w¹ï IL-4R ªºÃĪ«ªº°Ï§O¡C¡¨ ¡§§ÚÌ«Ü°ª¿³¨üÁܦb¥»¦¸¦æ·~·|ij¤W®i¥Ü³o¨ÇÂà¤Æ¼Ò«¬¡A¨Ã®i¥Üeblasakimab¦b¸Ñ¨M AD ©M COPD ¤¤ 2 «¬ÅX°Êª¢¯gªº¼ç¤O¡C¡¨
¹ï³o¨âºØÂà¤Æ¼Ò«¬ªº¬ã¨s¥¿¦b¶i¦æ¤¤¡AALSAN p¹º´£¥æ¥þ±ªº¼Æ¾Ú¶°¥H¦b§Y±NÁ|¦æªº¬ì¾Ç·|ij¤Wµo¥¬¡CÃĪ«¶}µo°ª®p·|ªºÂ²³ø¥i³z¹L ASLAN ºô¯¸¦s¨ú¡C
Ãö©óeblasakimab Eblasakimab¬O¤@ºØ¼ç¦bªº¤@¬y³æ®è§ÜÅé¡A°w¹ï 2 «¬¨üÅ骺 IL-13 ¨üÅé¨È°ò¡A³o¬OÅX°Ê¦hºØ¹L±Ó©Êµoª¢¯e¯fªºÃöÁä³~®|¡CEblasakimab¿W¯Sªº§@¥Î¾÷¨î¯à°÷¯S²§©ÊªýÂ_ 2 «¬¨üÅé¡A¨Ã¦³¥i¯à§ïµ½¥Ø«e¥Î©óªvÀø¹L±Ó©Ê¯e¯fªº¥Íª«»s¾¯¡C³z¹LªýÂ_ 2 «¬¨üÅé¡Aeblasakimab¥iªý¤î¥Õ²ÓM¤¶¯À4 (IL-4) ©M¥Õ²ÓM¤¶¯À13 (IL-13) ªº«H¸¹¶Ç¾É¡A¦Ó¥Õ²ÓM¤¶¯À4 (IL-4) ©M¥Õ²ÓM¤¶¯À13 ( IL-13) ¬OAD µoª¢ªºÃöÁäÅX°Ê¦]¤l¡C¤¤«×¦Ü««× AD ªº 2b ´Á TREK-AD ¬ã¨sªº¿n·¥µ²ªG¤ä«ùeblasakimab±qAD ªvÀø¶}©l´N´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×ªº¼ç¤O¡A¦Ó¤£¼vÅTÀø®Ä¡A¨Ã¥B¨´¤µ¬°¤îÃÒ©ú¤F¥O¤H¹ª»Rªº¦w¥þ©Ê¡A¬°2 ´ÁÁ{§É¸ÕÅç°µ¦n¤F·Ç³Æ3 ¶i¦æ¤¤¡CASLAN ¤]¦b 2 ´Á¸ÕÅç TREK-DX ¤¤¬ã¨seblasakimab¦b¸g¾ú¹Ldupilumab ªº¤¤«×¦Ü««× AD ±wªÌªºÀ³¥Î¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/4 ¤W¤È 12:46:58
²Ä 6456 ½g¦^À³
|
ªü´µÄõ»sÃĤ½¥q¦b²Ä¤C©¡¥Ö½§¯fÃĪ«¶}µo°ª®p·|¤W
®i¥Ü Eblasakimab ¦b²§¦ì©Ê¥Ö½§ª¢©MºC©Êªý¶ë©ÊªÍ¯fÂà¤Æ¼Ò«¬¤¤ªº·s¼Æ¾Ú
eblasakimab ©M dupilumab ¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¥Ö½§¬¡Àˤ¤
¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î
¨Ï¥Î¤w«Ø¥ßªº¤HÃþªÍ¤Á¤ù COPD ¼Ò«¬¡A·s¼Æ¾ÚÃÒ©ú eblasakimab ¨ã¦³´î¤Ö®ð¹D¦¬ÁY©M¼W±jÂX±iªº¼ç¤O
µ²ªGº¦¸ÃÒ©ú eblasakimab ¦b AD ¥H¥~ªº¨ä¥L¾AÀ³¯gªº¼ç¦b¥Î³~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/11/2 ¤U¤È 10:58:37
²Ä 6455 ½g¦^À³
|
§Æ±æ Piper Sandler¤ÎH.C. Wainwright³o2®a¤½¥q¯à¬Ý¹ï¤@¦¸¡A
Piper Sandler «¥Ó¹ï Aslan Pharmaceuticals (ASLN) ªº¶R¤Jµû¯Å ¡A ¶ø´µ¥Å¦w¦N¬¥ 2023¦~10¤ë30¤é ¤U¤È 6:56
|¦b¤µ¤Ñµo¥¬ªº¤@¥÷³ø§i¤¤¡APiper Sandler ªº Edward Tenthoff
«¥Óªü´µÄõ»sÃĤ½¥q¡]ASLN ¡V ¬ã¨s¡^ªº¶R¶iµû¯Å
³ø§i¡^¡A¥Ø¼Ð»ù¬° 15.00 ¬ü¤¸¡C ¤½¥qªÑ²¼¤w¦¬½L
¤W¶g¤»ù®æ¬° 1.07 ¬ü¤¸¡C
¥Ø«e¡A¤ÀªR®v¹ï¨È·à±d»sÃĪº¦@ÃѬO±j¯Pªº
¶R¤J¥§¡¥Ø¼Ð»ù¬° 15.67 ¬ü¤¸¡A
¦b¤µ¤Ñµo¥¬ªº¤@¥÷³ø§i¤¤¡A
H.C. Wainwright·Å¿à¯SÁÙ«¥Ó¹ï¸ÓªÑªº¶R¤Jµû¯Å¡A¥Ø¼Ð»ù¬° 17.00 ¬ü¤¸¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/31 ¤U¤È 09:25:35
²Ä 6454 ½g¦^À³
|
©t¨àÃĤj §A»¡ªº¨S¿ù --- ¬Ý¨ì«Ü¦h¦Ñ·à¤Í̳£µ´±æ¤F! Åý¤Hı±oÃø¨ü ¡K¡K.
Ó¤H»{¬° «Ü¦h§ë¸ê¤H·|»{¬°ªÑ»ù¤U¶^»PÀø®Ä¤£¦n²£¥ÍÁp·Q, ¨Æ¹ê¤W¬O³o¼Ë¶Ü? ¥i¯à¹ï¤]¥i¯à¿ù, ¥¢±æ©Ê±þ½LÅýªÑ»ùÄY«¶W¶^ ¤G´Áµ²§ô¥i¥H°µ¦¸±Ú¸s¤ÀªR¥H§ä¥X¤T´Á³Ì¨ÎÀø®Äµ¦²¤ , ¤T´Á´Áµ²§ô´N¤£¥i¥H¦A°µ¦¸±Ú¸s¤ÀªR
¤Ñ©R¤j7¤ë6¤é¶K¤å´£¨ì¨Ì¤µ±ß³ø§i,¥§¡EASI°´T«e6¶g¤ô·Ç¬O¦p¹w´Á,¦ý7~16¶g¶]¤£°Ê¡K.
¨Æ¹ê¤W¤£¬O¦p¦¹, «Øij¤Ñ©R¤j¬ÝIQVIA Biotech & ASLAN Pharmaceuticals KOL Panel Discussion (21¤À15¬í--24¤À15¬í¹Ïªí) ( §â¹Ïªí¥Î¤â¾÷©ç¤UºCºC¬Ý )
¥H¤U¬O¼Æ¾Ú¬O¨Ì¾Ú 2023 ¦~ 10 ¤ë 13 ¤éªü´µÄõ»sÃĤ½¥q¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú»P2023 ¦~ 10 ¤ë 24 ¤éªü´µÄõ»sÃĤµ¤Ñ±N¦@¦P¥D¿ì KOL ¤p²Õ°Q½×¡A°Q½×²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅç©MªvÀø®æ§½ªºÅܤÆ
¦¬®×¤ÀªR ( IQVIA Biotech & ASLAN Pharmaceuticals KOL Panel Discussion) ITT EASI 16- 66 ¦@289¤H(100%) EASI score mean 27.9 IGA3/4 58.8%/41.2% EASI 18- 66¦¬®×231¤H (80%) EASI score mean 30.7 IGA3/4 51.5%/48.5% EASI 21- 66¦¬®×181¤H (63%) EASI score mean 33.8 IGA3/4 40.3%/59.7% ( EASI¤j©óµ¥©ó21 IGA/4 ´N¬O¦¬««×¯f±w ¥H¤U¼Æ¾Úµo²{ ¯f±w¶VÄY«Àø®Ä¶VÅãµÛ IGA3/4 40.3%/59.7% IGA 4¯f±w¤ñIGA3ÄY« (dupilumab¤T´ÁIGA3/4 51%/49%) dupilumab¤T´ÁIGA4 ¦û49% eblasakimab ¤GB IGA4 ¦û59.7% ¤S¬O¥|¶g¤@°w ³o¬O§Ú¬Ý¥X¼ç¤Oªºì¦], eblasakimab ¥¼¨ÓAD ¥«³õ¥þ²yª§¹ÜÁÉ (¿z¿ï1 ²Å¦X¥Íª«¼Ð°O¯f±w 2 EASI score ¤j©óµ¥©ó 21¤À 600mg ¥|¶g¤@°w «O¦u¤@ÂI600mg ¨â¶g¤@°w«Øij¦C¤JÁ{§É³]p 240»õ¬ü¤¸ªºAD ¥«³õ¤£n¦³·Qn¿W¦û¥«³õªº©ÀÀY , ¯dÂI¥«³õµ¹§OªºÃÄ ) (dupilumab¤T´Á¬O³]p300mg¤@¶g¤@°w »P ¨â¶g¤@°w)
A 600mgQ4w ¤£°µ¦¸±Ú¸s¤ÀªR¦b²Ä4¶g´N¹F¨ìÅãµÛ®t²§¤@ª½¨ì²Ä10¶g»P¹ï·Ó²Õ¹F¨ì³Ì¤j®t¶Z , ²Ä11¶g¤~¨«¥Ä~Äò©¹¤Uª½¨ì16¶g B 600mgQ4w ¦¸±Ú¸s¤ÀªREASI¤j©óµ¥©ó18 ¦b²Ä2¶g´N¹F¨ìÅãµÛ®t²§¤@ª½¨ì²Ä16©P(»P¹ï·Ó²Õ¶V©Ô¶V»· , 300mg Q2w 400mg Q2w ¤]¤@¼Ë¦b²Ä2¶g´N¹F¨ìÅãµÛ®t²§¤@ª½¨ì²Ä16©P»P¹ï·Ó²Õ¶V©Ô¶V»· 400mg Q4w ªí²{¸û®t²Õ Áö¦³¹F¨ìÅãµÛ®t²§ ¦b²Ä6¶g¥H«á´N¨«¥
C ITT EASI 16- 66 ¦@289¤H(100%) EASI score mean 27.9 IGA3/4 58.8%/41.2%
600mg Q4W ( 59¤H) -73.0% /--51.1%) p=0.001 400mg Q4W ( 59¤H) -61.9% /--51.1%) p=0.1054 ( ªí²{¤í¨Î²Õ ) 400mg Q2W( 56¤H) -65.8% /--51.1%) p=0.029 300mg Q2W( 58¤H) -69.8 % /--51.1%) p=0.005 ¦w¼¢¾¯²ÕQ2W( 57¤H) --51.1%
D EASI 18- 66¦¬®×231¤H (80%) EASI score mean 30.7 IGA3/4 51.5%/48.5% ¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°18 ªº±wªÌ ( 231¤H) ¨È²Õªº¤ÀªR¤¤¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G 600mg Q4W ( 47¤H) -75% /-42.3 %¡]p<0.0001¡^ 400mg Q4W ( 49¤H) -60.4% /-42.3 %¡]p<0.0098¡^ 400mg Q2W( 46¤H) -73.5%/ -42.3 %¡]p<0.0001¡^ 300mg Q2W( 44¤H) -71.8%/-42.3 %¡]p< 0.0001¡^ ¦w¼¢¾¯²ÕQ2W( 45¤H) -42.3 %
E EASI 21- 66¦¬®×181¤H(63%) EASI score mean 33.8 IGA3/4 40.3%/59.7%
¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ( 181¤H ) ªº±wªÌ¨È²Õªº¤ÀªR¤¤¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G 600mg Q4W( 31¤H) -74.5% /38.0%¡]p<0.0001¡^¡A 400mg Q4W ( 39¤H) -60.2% /-38 %¡]p<0.0068¡^( ªí²{¤í¨Î²Õ ) 400mg Q2W( 41¤H) -72.7%/38.0%¡]p<0.0001¡^¡A 300mg Q2W( 32¤H) -69.8%/38.0%¡]p<0.0001¡^¡A ¦w¼¢¾¯²ÕQ2W( 38¤H) -38 %
¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õ¤ÀªR¤¤¡A¹F¨ìEASI-75 ªº±wªÌ¦Ê¤À¤ñ¬°¡G¹êÅç²Õ/¦w¼¢¾¯²Õ 600mg Q4W ( 31¤H)53.6%/12.9% (p=0.009)¡A 400mg Q4W ( 39¤H)36.1%/12.9%¡]p=0.0328¡^( ªí²{¤í¨Î²Õ ) 400mg Q2W ( 41¤H)49.7% / 12.9% (p=0.0014)¡A 300mg Q2W( 32¤H) 52.1%/12.9% ( p=0.001) ¦w¼¢¾¯²ÕQ2W( 38¤H) 12.9%
¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌÀò±oÅçÃÒªº²§¦ì©Ê¥Ö½§ª¢¬ã¨sªÌ¾ãÅéµû¦ô(vIGA-AD) µû¤À¬°0/1 ªº±wªÌ¦Ê¤À¤ñ¦p¤U¡G¹êÅç²Õ /¦w¼¢¾¯²Õ 600mg Q4W( 31¤H) 29.8% /6.8% (p=0.0172)¡A 400mg Q4W ( 39¤H) 9.6%/6.8% ( ªí²{¤í¨Î²Õ ) 400mg Q2W( 41¤H) 37.6% /6.8%(p=0.0030) ¡A 300mg Q2W ( 32¤H)27.1%/6.8%¡]p=0.0297¡^¡A ¦w¼¢¾¯²ÕQ2W( 38¤H) 6.8 %
¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦p¦³¿ù»~½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/10/31 ¤U¤È 04:50:18
²Ä 6453 ½g¦^À³
|
ªü´µÄõ§Y¨È·à±d¡A½Ķ³nÅéÃö«Y¡A·Pı¨È·à±d¿¤¦b¦b¥´¼s§i¦p¤UĶ¤å
How ASLAN Pharmaceuticals Limited is Revolutionizing the Pharma Industry
ªü´µÄõ»sÃĦ³¤½¥q¦p¦ó¹ý©³§ïÅÜ»sÃÄ·~
ªü´µÄõ»sÃĦ³¤½¥q¤w¦¨¬°»sÃÄ·~ªº¹CÀ¸³W«h§ïÅܪ̡A¹ý©³§ïÅܤFÃĪ«ªº¶}µo¤è¦¡¡A¬°¥þ²y±wªÌ±a¨Ó¤F§Æ±æ¡C ¾ÌÂǨä³Ð·s¤èªk©MP¤O©ó¸Ñ¨M¥¼º¡¨¬ªºÂåÀø»Ý¨D¡A¨È·à±d»sÃĦ³¤½¥q¹ï»sÃÄ·~²£¥Í¤F«¤j¼vÅT¡C
¨È·à±d»sÃĦ³¤½¥q¹ý©³§ïÅܲ£·~ªºÃöÁä¤è¦¡¤§¤@¬O±Mª`©óºë·ÇÂåÀø¡C ³z¹L§Q¥Î¦yºÝ§Þ³N©M¥ý¶iªº¤ÀªR¡A¸Ó¤½¥q¯à°÷ÃѧO³Ì¦³¥i¯à±q¨äªvÀø¤¤¨ü¯qªº¯S©w±wªÌ¸sÅé¡C ³oºØ¦³°w¹ï©Êªº¤èªk¤£¶È¼W¥[¤FÁ{§É¸ÕÅ窺¦¨¥\¾÷·|¡AÁÙ½T«O±wªÌ¦b¥¿½Tªº®É¶¡±µ¨ü¥¿½TªºªvÀø¡C
°£¤Fºë·ÇÂåÀø¤§¥~¡Aªü´µÄõ»sÃĦ³¤½¥q¤]¾Ö©ê¨ó§@ªº¤O¶q¡C ¤½¥q¿n·¥´M¨D»P¾Ç³N¾÷ºc¡B¬ã¨s²Õ´©M¨ä¥L»sÃĤ½¥qªº¦X§@Ãö«Y¡A¥H¥[³t·sÀøªkªº¶}µo¡C ³z¹L¶×¶°¸ê·½©M±M·~ª¾ÃÑ¡A¨È·à±d»sÃĦ³¤½¥q¯à°÷§ó¦³®Ä¦aÀ³¹ï½ÆÂøªºÂåÀø¬D¾Ô¡C
¦¹¥~¡Aªü´µÄõ»sÃĦ³¤½¥q¦b¸~½F¾Ç»â°ì¨ú±o¤F«¤j¶i®i¡C ¸Ó¤½¥qªº³Ð·s²£«~½u¥]¬A¤@¨t¦C°w¹ï¦UºØÀù¯gªº¼Ð¹vÀøªk¡A¥]¬AGÀù¡B¨ÅÀù©M¤j¸zÀù¡C ³o¨ÇÀøªk¦bÁ{§É¸ÕÅ礤Åã¥Ü¥X¦³§Æ±æªºµ²ªG¡A¬°¥ý«eªvÀø¿ï¾Ü¦³ªº±wªÌ±a¨Ó¤F·sªº§Æ±æ¡C
ªü´µÄõ»sÃĦ³¤½¥qP¤O©ó¥H±wªÌ¬°¤¤¤ß¡A³o¬O¨ä°Ï§O©ó¶Ç²Î»sÃĤ½¥qªº¥t¤@Ӥ象C ¸Ó¤½¥q¿n·¥»P±wªÌÅv¯q¹ÎÅé¦X§@¡A¨Ã±N±wªÌªºÆ[ÂI¯Ç¤J¨äÃĪ«¶}µo¹Lµ{¡C ³oºØ¤èªk½T«O±q¬ã¨sªº¦´Á¶¥¬q¨ì·sÀøªkªº³Ì²×§åã¡A³£¦Ò¼{±wªÌªº»Ý¨D©M°¾¦n¡C
¦¹¥~¡Aªü´µÄõ»sÃĦ³¤½¥q¦b¥þ²y¾Ö¦³±j¤jªº¼vÅT¤O¡A¦b¨È¬w¡B¼Ú¬w©M¬ü°ê¶}®i·~°È¡C ³oºØ¥þ²y¼vÅT¤O¨Ï¸Ó¤½¥q¯à°÷¶i¤J¤£¦Pªº¥«³õ¨ÃÀò±o¼sªxªº¸ê·½¡C ³z¹LÂX¤j·~°È½d³ò¡Aªü´µÄõ»sÃĦ³¤½¥q¯à°÷±N¨ä³Ð·sÀøªk±aµ¹¥@¬É¦U¦aªº±wªÌ¡AµL½×¥L̨¦b¦ó³B¡C
ªü´µÄõ»sÃĦ³¤½¥q¹ï»sÃÄ·~ªº¼vÅT¤£®e¤pòó¡C ¸Ó¤½¥qªºÃĪ«¶}µo³Ð·s¤èªk¡B¹ïºë·ÇÂåÀøªºÃöª`¡B¹ï¨ó§@ªº«µø¥H¤Î¹ï¥H±wªÌ¬°¤¤¤ßªº©Ó¿Õ³£¬°¨ä¦¨¥\°µ¥X¤F°^Äm¡C ³z¹L¬D¾Ô¶Ç²Î³W½d©M¾Ö©ê·s§Þ³N¡A¨È·à±d»sÃĦ³¤½¥q¥¿¦b¬°§ó¦³®Ä²v¡B§ó¦³®Äªº»sÃÄ·~¾Q¥¹D¸ô¡C
Á`¤§¡Aªü´µÄõ»sÃĦ³¤½¥q¥¿¦b³z¹L¨ä³Ð·s¤èªk¡B¨ó§@«äºû©M¥H±wªÌ¬°¤¤¤ßªºµJÂI¡A¹ý©³§ïÅÜ»sÃÄ·~¡C ¾ÌÂǺë·ÇÂåÀø¤èªk¡A¸Ó¤½¥q¯à°÷¶}µo¥X¼Ð¹vÀøªk¡A¬°±wªÌ±a¨Ó·sªº§Æ±æ¡C ³z¹L¿n·¥´M¨D¦X§@¹Ù¦ñÃö«Y¨Ã»P±wªÌÅv¯q¹ÎÅé¦X§@¡A¨È·à±d»sÃĦ³¤½¥q¥¿¦b¥[³t·sÀøªkªº¶}µo¡C ¨ä¥þ²y¼vÅT¤O¶i¤@¨B¨Ï¸Ó¤½¥q¯à°÷±µÄ²¨ì¥@¬É¦U¦aªº±wªÌ¡C ªü´µÄõ»sÃĦ³¤½¥q¹ï»sÃÄ·~ªº¼vÅT¬O¤£¥i§_»{ªº¡A¨ä¹ï³Ð·s©M±wªÌÅ@²zªº©Ó¿Õ¬°¾ãÓ¦æ·~¾ð¥ß¤F·s¼Ð·Ç¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2023/10/31 ¤U¤È 04:40:29
²Ä 6452 ½g¦^À³
|
¥[¤W§Ú̹ï±wªÌ©MÂå⽣ªº½Õ¬dµ²ªG¡A⽀«ù§Ú̹ïeblasakimab ªº 3 ´Á¬ã¨sp¹º¡A§Ú̹wp±N©ó 2024 ¦~»P¥þ²y°Ó·~¦X§@¹Ù¦ñ⼀°_±Ò°Ê¸Ó¬ã¨s¡A¡v Firth ³Õ⼠¸É¥R¹D¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/10/31 ¤W¤È 11:50:10
²Ä 6451 ½g¦^À³
|
¬Ý¨ì«Ü¦h¦Ñ·à¤Í̳£µ´±æ¤F! Åý¤Hı±oÃø¨ü¡F¹ï©ó¥Ø«eªºª¬ªp¡Aı±o¥u¦³¤½§G¤G½u´Á¤¤¼Æ¾Ú¡AÅý¤j²³¤F¸Ñ¦bªA¥Î¹L§ù¥²ª¢ªºI´ºÈ¤U¡A004ÁÙ¦³ªvÀø®ÄªG¡A³o¼Ë004³oÁûÃĤ~¦³¾÷·|«·s³Q»{¦P¡A¤£µMÀ³¸ÓÁÙ¬O¹³©ú¤Ñ¤j¤À¨Éªº¤@¼Ë¡A´Â¦V¯}1¶ôªº¸ô«e¶i¦Ó¤w¡C
¤j®a¬Ã«¦Û¤vªº¤f³U°Ú!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/30 ¤U¤È 11:43:21
²Ä 6450 ½g¦^À³
|
¤p©ú¤j 1 ¨º´µ¹F§J¥æ©ö©Ò«h³W©w¡A¦pªG¤½¥qªÑ»ù³sÄò30 ¤Ñ§C©ó1 ¬ü¤¸¡A©Î¥¼º¡¨¬¨ä¥Ln¨D®É¡AÃÒ¨é¥æ©ö©Ò´N·|µo¥Xĵ§i¡A¥²¶·¦b180 ¤Ñ¤º«ì´_ªÑ»ù¡AY¥¼¹F¦¨«K·|³Q±j¨î¤U¥«©ÎÂಾ¨ì¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò (³Q¨ÖÁʪº¾÷²v»·¤j©ó¤U¥«¾÷²v)
2©ú¦~²Ä¤@©u¼Æ¾Ú¥þ³¡¥X¨Ó¬O¨ÖÁʦn®É¾÷ , ¤T´ÁÁ{§Éªº¿ú¬O¨ÖÁʤ½¥q¥Xªº , ¤£¥Î¾á¤ß¤T´ÁÁ{§É¸g¶O , ¦]¬°®Ú¾Ú×q¦X¬ù±ø´Ú¡A¨È·à±d-KY±N©óASLAN004¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥ICSLºµ§´Ú¶µ3,000¸U¬üª÷¡CCSL±N¥i¦¬¨ú³Ì°ª¹F9,500¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F6.55»õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü10%¤§Åv§Qª÷ (¬ù¦Ê¤À¤§7.5) ½Ð°Ý¤j®a¤Sn¦b¼Ú¬ü¨È±Ò°Ê¤T´ÁÁ{§É ¤Sn¥ýµ¹3,000¸U¬üª÷, ¿ú±q¦ó¦Ó¨Ó ? (³Q¨ÖÁʪº¾÷²v»·¤j©ó¤U¥«¾÷²v)
3 ©ú¦~²Ä¤@©u¼Æ¾Ú«G²´, ¤é¥»¦³±Ò°Ê¤@´ÁÁ{§É , eblasakimab¼Ú¬ü¨È¦³±Ò°Ê¤T´ÁÁ{§É ¬O¥¿±«ü¼Ð
4 Piper Sandler Companies¬O¤@®a¬ü°ê¸ó°ê§ë¸ê»È¦æ©Mª÷¿ÄªA°È¤½¥q¡A±Mª`©ó¨ÖÁÊ¡B°]°È«²Õ¡B¤½¶}µo¦æ¡B¤½¦@ª÷¿Ä¡B¾÷ºc¸g¬ö¡B§ë¸êºÞ²z©MÃÒ¨é¬ã¨s¡C¸Ó¤½¥q³z¹L¨ä¥Dn¤l¤½¥q Piper Sandler & Co¡A±¦V¥ø·~¡B¾÷ºc§ë¸êªÌ©M¤½¦@¹êÅé¡C û¤uªñ2000¤H ¤µ¤Ñ«¥Ó¹ïªü´µÄõ¤½¥q¶R¤Jµûµ¥ ¥Ø¼Ð»ù15¬ü¤¸, »P H.C. Wainwright & Co. ¤K¤ë¤¤«¥Ó¹ïªü´µÄõ¤½¥q¶R¤Jµûµ¥ ¥Ø¼Ð»ù15¬ü¤¸-17¬ü¤¸ «Ü±µªñ
5 Æ[¹î«ÂI: ¤µ¦~ 11 ¤ë 2 ¤éÁ|¦æªº²Ä¤C©¡µoª¢©Ê¥Ö½§¯f¥Ö½§¯fÃĪ«¶}µo¦~«×°ª®p·|¤W¡A¤¶²Ð¤F eblasakimab ¦bºC©Êªý ¶ë©ÊªÍ¯f (COPD) ¤HÃþÂà¤Æ¼Ò«¬¤¤ªºªì¨Bµ²ªG¡C • Farudodstat ªº FAST-AA ¬ã¨sªº¥Dn¤¤´Á¼Æ¾Ú¹wp±N©ó 2024 ¦~²Ä¤@©u«×¤½§G¡C TREK-Dx study 2024 ¦~²Ä¤@©u«×¤½§G¼Æ¾Ú ( 75¤H ¨Ï¥Îdupilumab ¤¤Â_¯f±w §ï¥Îeblasakimab ) • ¹wp ASLAN ªº¦X§@¹Ù¦ñ Zenyaku Kogyo Co. ±N¦b¤é¥»±Ò°Ê eblasakimab ªº 1 ´Á¸ÕÅç¡C 2024 ¦~¤W¥b¦~ASLAN ¥¿¦b¹ï TREK-AD ¬ã¨s¶i¦æ«ùÄò¤ÀªR¡A¨Ãp¹º´£¥æ¥Íª«¼Ð°O¼Æ¾Ú©M±wªÌ³ø§iªºµ²ªG¡A¥H«K¦b¥¼¨Óªº ¬ì¾Ç¤j·|¤Wµoªí¡C ¹wp±N»P¬ü°ê¹«~ÃĪ«ºÞ²z§½Á|¦æ²Ä 2 ¶¥¬qµ²§ô·|ij¡AÀH«á eblasakimab ªº²Ä 3 ¶¥¬qÁ{§Épµe¹wp±N©ó2024¦~±Ò°Ê¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/10/28 ¤W¤È 12:14:39
²Ä 6449 ½g¦^À³
|
¥xÁÞ¤j
§Ú§Æ±æ§A¬O¹ïªº¡A
¥u¤£¹L±q¥xÆW¿é¨ì¬ü°ê¡A§Ú¤w¤£©ê§Æ±æ¡A
¤½¥q¤@¦A±j½Õ·|¦b©ú¦~°µ3´Á¡A°ÝÃD¬O¥H¦¹ªÑ»ù¦p¦ó¦A¶Ò´Ú¼W¸ê¡A
¦Ó¥BªÑ»ù¯}1¬ü¤¸¤S¦³¤U¥«¦M¾÷¡A
¸g¶O±q¦ó¦Ó¨Ó¡AÁÙ¨Sºân¥ICSLªº±ÂÅvª÷¡A
¥xÁÞ¤j¤Ñ©R¤j§A̪º¬Ýªk©O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/27 ¤U¤È 11:55:09
²Ä 6448 ½g¦^À³
|
¸É¥R»¡©ú ¤p²Õ°Q½×·|¤¤ eblasakimab 2b TREK-AD study ¹Ï¤ù´£¨ì ¦b²Ä¥|¶g®É¹êÅç²Õ»P¹ï·Ó²Õ¦±½u´N©Ô¶}¹F¨ìÅãµÛ®t²§¡A¤ÀªREASI>18¤À ¹êÅç²Õ»P¹ï·Ó²Õ¦b²Ä¤G¶g¦±½u´N©Ô¶}¹F¨ìÅãµÛ®t²§¡A§e²{¶VÄY«¯f±wÀø®Ä¶V¦nªºÁͶաA³o¬O«¤jµo²{ ±q¹Ï¤ùµo²{¥»¦¸¹êÅç±q EASI±q16¤À¦¬¨ì66¤À¡A«D±`ÄY«¯f±wEASI 50¤À¥H¤W¬ù¦³¦Ê¤À¤§10 .
·Pı¦³¤H¦bÀ£§CªÑ»ù¦¬Äw½X¡A¥Ø«eÁ`¥«È¬ù2000¸U¬ü¤¸(ªÑ»ùxªÑ¼Æ)¡A´«ºâªÑ¼Æ¬ù16666000ªÑ¡A¤jªÑªF¬ù´x±±6¦¨¡A¥|¦¨´²¤á¡AÄw½X³Q¦¬±o®t¤£¦h¤F ¤»õ¬ü¤¸³Q¨ÖÁÊ¡A·|¦³25¿º¦´T¡A¤Q»õ¬ü¤¸³Q¨ÖÁÊ¡A·|¦³50¿º¦´T¡A·Q¤£³q´²¤á½æ¥úªÑ²¼¡A¤½¥q¦A¤½§G¦n¼Æ¾Ú昰¤£¬On¾ã¸JºÝ¨«¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/27 ¤U¤È 10:41:04
²Ä 6447 ½g¦^À³
|
¤p©ú¤j: ¦³»ù®t«Øij»°§Ö¶R¦^
¤G´ÁÁ{§É: ¥i¥H¥ý®g½b«á¦A½Õ¾ã¨¤«× ×¥¿¶Õ¶Õ ( ¤G´ÁÁ{§É¥Dn¬O±´¯Á¦w¥þ©Ê»P¦³®Ä¾¯¶q¡A±´¯Áµ¹ÃÄÀW²v»P¦p¦ó§ó¦³®Ä¿z¿ï¨ü¸Õ¡A ±´¯Á¦p¦ó¼W¥[¤T´ÁÁ{§É¦¨¥\¾÷²v)
¤T´ÁÁ{§É: ½Õ¾ã¦n¨¤«× ×¥¿¦n¶Õ¶Õ®g¥X«á´N¨S¦³×¥¿¾÷·|¤F (¤@½¨âÀü²´)
¨È·à±d»sÃÄ2023 ¦~ 10 ¤ë 24 ¤é¤W¤È 11:00¡]¬ü°êªF³¡®É¶¡) ±N¦@¦P¥D¿ìÃö©ó²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅç©MªvÀø®æ§½Åܤƪº KOL ¤p²Õ°Q½× ASLAN ºÞ²z¼h±N®i¥Ü TREK-AD ¬ã¨sªº·s¼Æ¾Ú¥H¤Î¨Ó¦Û±wªÌ©M³B¤èªÌ½Õ¬dªº AD ªvÀø«e´ºªº·s¥«³õ¬ã¨s¼Æ¾Ú
TREK-AD ¬ã¨s:¥l¶Ò¯f±wEASI score ¤j©óµ¥©ó21¤À¦@181¤H EASI score ¥§¡¤À¼Æ 33.8¤À ¬ü°ê¯f±w45¤H EASI score ¥§¡¤À¼Æ 34.3¤À (dupilumab¤T´Á EASI score ¥§¡¤À¼Æ31.8-33¤À) ( ¯e·ª¾«l¯óªO¿ºÃÑ©¾¦Ú)( ¥l¶Ò¯f±w¶VÄY«Àø®Ä¶V¦n)
IGA score : eblasakimab 2b IGA 3 (¤¤«×) (73 ¤H 40.3%) IGA 4 (««×) ( 108 ¤H 59.7% ) (dupilumab¤T´Á IGA score IGA 3 (¤¤«×) ( 51%- 52 % ) IGA 4(««×) ( 48% -49% ) (¯e·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY«Àø®Ä¶V¦n )
Mean change from baseline : ITT 289¤H eblasakimab 2b 600mg Q4w -73 / - 51.1 EASI score ¤j©óµ¥©ó18¤À 600mg Q4w -75 / - 42.3 EASI score ¤j©óµ¥©ó21¤À 600mg Q4w -74.5 / - 38 (¯e·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY«Àø®Ä¶V¦n)
EASI 75 : eblasakimab 2b ITT 289¤H 600mg Q4w 52% /24.4% EASI score ¤j©óµ¥©ó18¤À EASI 75 600mg Q4w 55.6% /15.4% (dupilumab¤T´Á 300mg Q2w 50.3%/15.2%
(¯e·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY«Àø®Ä¶V¦n)
IGA 0/1 eblasakimab 2b ITT 289¤H 600mg Q4w 31.2% /15.1 %
EASI score ¤j©óµ¥©ó18¤À 600mg Q4w 30.6% / 8 % dupilumab¤T´Á 300mg Q2w 34.7 % / 10.2% (¯e·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY«Àø®Ä¶V¦n)
¥»¦¸¥l¶Ò ITT 289¤H 100% EASI score ¤j©óµ¥©ó18¤À ¦û80% EASI score ¤j©óµ¥©ó21¤À ¦û63% ¤p©ó21¤À ¦û37%
»P·|±M®a¥«³õ¹w¦ô : eblasakimab 1L 17% ( AD 40.8 »õ¬ü¤¸) 2L 26% ( ¹L±Ó ®ð³Ý COPD 62.4 »õ¬ü¤¸ )
¥»¦¸KLO ¤p²Õ°Q½× TREK-AD ¬ã¨sªº·s¼Æ¾Ú¥H¤Î¨Ó¦Û±wªÌ©M³B¤èªÌ½Õ¬dªº AD ªvÀø«e´ºªº·s¥«³õ¬ã¨s¼Æ¾ÚÀò±o°Ñ»y·|¬Ì±M®a ¦nµû»PÀò±o³\¦hÄ_¶Q«Øij ( ¥»¦¸KLO ¤p²Õ°Q½× ¦³¶W¹L¤@¥b¯f±wÄ@·N´«ÃÄ )
( ²§¦ì©Ê¥Ö½§ª¢¯f±w¥þ²y2»õ¤H( ¬ü°ê4140¸U¤H ¼Ú·ù3070¸U¤H ¤¤°ê 3560¸U¤H¤é¥»500¸U¤H) ¥Ø«e¥u¦³¦Ê¤À¤§8 ¯f±w¨Ï¥ÎDupilumab , ¨Ï¥ÎDupilumabªº¯f±w¤¤¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä,¬OÄY«¥¼³Qº¡¨¬ªº¯e¯f
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/10/26 ¤W¤È 09:50:03
²Ä 6446 ½g¦^À³
|
¥«³õ¤ÏÀ³¥Ã»·¬O¹ïªº
¨ì²{¦b¤S¦AקïDX¦¬®×¼Ð·Ç¡A
¥i¨£¤½¥q¦³¦hÄê¡A¥¢±Ñ¦h¦¸ÁÙ·d¤£²Mª¬ªp¡A
¨ì²{¦b¤´¦b®g½b«á¦Aµe¹v¡A ¥«³õ¤£¶R³æ¨S±Ï¤F¡A
±q¥xÆW¶BÄF¨ì¬ü°ê |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/24 ¤U¤È 09:26:10
²Ä 6445 ½g¦^À³
|
¤G´ÁÁ{§É¸ÕÅçPhase 2 昰¥H¤p³W¼Ò¤§¯f¤H¨ü¸ÕªÌ¬°¹ï¶H¡A©Ò»Ý¤H¼Æ¬ù¼Æ¤Q¦Ü¼Æ¦Ê¤H¡A¥Ø¼Ð¬Oµû¦ô¤£¦P¾¯¶q¹ï¯f¤HªºÃĮĻP¦w¥þ©Ê¡A§@¬°²Ä¤T´ÁÁ{§É¸ÕÅ羯¶q¤§¨Ì¾Ú¡A¥Õ¸Ü»¡ ´N¬O±´¯Á¦w¥þ©Ê»P¦³®Ä¾¯¶q¡A±´¯Áµ¹ÃÄÀW²v»P¦p¦ó§ó¦³®Ä¿z¿ï¨ü¸Õ¡A±´¯Á¦p¦ó¼W¥[¤T´ÁÁ{§É¦¨¥\¾÷²v ¡Aeblasakimab 2b ´ÁTREK-AD study ¥u昰±µÄò£¸´ÁÁ{§É¦A±´¯Á¦w¥þ©Ê»PÀø®Ä¡A¨S¦³©Ò¿×ªº¦¨¥\©Î¥¢±Ñ¡A§ë¸ê¤H§â¤G´ÁÁ{§É¬Ýªº¤Ó¦n©Î¤£¦n¬O«D²z©Êªº¸ÑŪ¡AªÑ»ù¤w³QÄY«±þ¹LÀY¡A ¤½¥qµû¦ô¦³¶}µo¼ç¤O´N·|Ä~Äò©¹¤T´Á¨«¡A ³Ì«nªº¬O§ë¸ê¤Hnª`·NÆ[¹î¤½¥q°Ê¦V¡C
EASI ÄY«©Ê¤À§O¦p¤U¡G 0 = ²M´· 0¡P1-1¡P0 = ´X¥G²M´· 1¡P1-7¡P0 = »´«× 7¡P1-21¡P0 = ¤¤«× 21¡P1-50¡P0 = ÄY«50¡P1-72¡P0 = «D±`ÄY«
¥»¦¸¦¸±Ú¸s¤ÀªREASI¤À¼Æ21¤À¥H¤W¡]««×¡^¥i¥HÀò±o·¥¨ÎÀø®Ä¡A²q´ú¤T´ÁÁ{§É¤£·|¥l¶Ò¤Ó¦h¤¤«×¯f±w¡A¥H««×¯f±wEASI¤À¼Æ 21¤À¥H¤W¬°¥Dn¹ï¶H¡A ¹êÅç²Õ»P¹ï·Ó²Õ®t¶Z¤~·|©Ô¤j, ¤~·|Àò±o·¥¨ÎÀø®Ä¡C
¤½¥q«n°T®§ 2023 ¦~ 10 ¤ë 18 ¤é ¨È·à±d»sÃıN¦@¦P¥D¿ìÃö©ó²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅç©MªvÀø®æ§½Åܤƪº KOL ¤p²Õ°Q½× ASLAN ºÞ²z¼h±N®i¥Ü TREK-AD ¬ã¨sªº·s¼Æ¾Ú¥H¤Î¨Ó¦Û±wªÌ©M³B¤èªÌ½Õ¬dªº AD ªvÀø«e´ºªº·s¥«³õ¬ã¨s¼Æ¾Ú ¦b¦¹µù¥U§Y¥i°Ñ¥[ 2023 ¦~ 10 ¤ë 24 ¤é¤W¤È 11:00¡]¬ü°êªF³¡®É¶¡¡^Á|¦æªººô¸ô¬ã°Q·| ¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 10 ¤ë 18 ¤é ¡V ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬±N¦@¦P¥D¿ì»P»â¥ýªºÁ{§É¬ã¨s²Õ´ (CRO) ¶i¦æ¤p²Õ°Q½×¡A¡§²§¦ì©Ê¥Ö½§ª¢ªºÅܤƱ»ª¡GDupilumab ±À¥X«á¤C¦~¤¤Á{§É¸ÕÅç©MªvÀø®æ§½µo¥Í¤F«ç¼ËªºÅܤơ¨¡A¨ä¤¤ÃöÁä·N¨£»â³S(KOL) Jonathan Silverberg ±N¥X®uMD¡BPhD¡BMPH¡]³ìªvµØ²±¹y¤j¾ÇÂå¾Ç»P°·±d¬ì¾Ç¾Ç°|¡^©M April W. Armstrong¡AMD¡BMPH¡]¥[¦{¤j¾Ç¬¥§üÁF¤À®Õ°·±d¤¤¤ß¡^¡C
³o¶µºô¸ô¬ã°Q·|¬¡°Ê±N¥]¬A ASLAN ©M CRO ªººtÁ¿¡AÀH«á»P¨â¦ì KOL ¶i¦æ¤p²Õ°Q½×¡A°Q½×²§¦ì©Ê¥Ö½§ª¢ (AD) Á{§É¸ÕÅç©MªvÀø®æ§½ªºÅܤơB³o¨ÇÅܤƹïÁ{§É¼Æ¾Ú©M·sÀøªkªº¼vÅT¡A¥H¤ÎÀu¤ÆAD ¸ÕÅ窺¼ç¦b¸Ñ¨M¤è®×¡C
ASLAN ºÞ²z¼h±N°Q½×eblasakimab 2b ´Á TREK-AD ¬ã¨sªº¼Æ¾Ú¡A¨Ã±N¤¶²Ð°w¹ï AD ±wªÌ©M³B¤èÂå¥Í¹ï·í«e©M¥¼¨ÓªvÀøªº¬Ýªkªº½Õ¬dªº·s¥«³õ¬ã¨s¡C
½Ð¦b¦¹³Bµù¥U¡A°Ñ¥[ 2023 ¦~ 10 ¤ë 24 ¤é¬P´Á¤G¤W¤È 11:00 ¦Ü¤¤¤È 12:00¡]¬ü°êªF³¡®É¶¡¡^ªººô ¸ô¼s¼½¡A©ÎÆ[¬Ý¬¡°Ê«¼½
¤°»ò¬OÃöÁä·N¨£»â³S¡H
½Ð·j´M Key Opinion Leader (KOL) What is a key opinion leader?
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/10/24 ¤U¤È 04:42:53
²Ä 6444 ½g¦^À³
|
¤Ñ©R¤j¤Î¦U¦ì¤j¤j
³o¤½¥q¥¼¨ÓÁÙ¦³§Æ±æ¶Ü¡A
±q7¤ë6¤é°_¦Ü¤µ¤w³s¶^§Ö4Ó¤ë¡A¤£ª¾¨äì¦]¡A¼Æ¾ÚÁö¤£¨Î¡A¦ý¤£¦Ü¿éCntb¡A²{¦b¤S¦^1¤¸¡A¬Ý¨Ó¤£¼ÖÆ[¤F¡A
·Pı¤½¥q¤w¨S±Ï¤F¡A·|¦A¦¸¤U¥«¡A ¨È·à±d°ª¼hÁȨ찪Á~¡A¤£¦b¥G§ë¸êªÌ¡A·íªì¦b¥x¤W¥«¤~´X¦~¡A´N¥ô·NºM¥X¥xÆW¡A´NÀ³¸Óı®©¡A³o¬O¤@®aµL¸Û«H¤½¥q¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/15 ¤W¤È 09:31:35
²Ä 6443 ½g¦^À³
|
«ÃĸɥR
1 ¤½¥q¹w©w¥»©u±N»P¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)¥l¶}Á{§É¤T´Á«e·|ijEnd-of-Phase 2 (EOP2) meeting
2 EOP2 meeting®Ú¾ÚEblasakimab²§¦ì©Ê¥Ö½§ª¢ªºÁ{§É«e, ¤@´Á , 2B TREK-AD Á{§É¸ÕÅçµ²ªG¡A°w¹ïÁ{§É¤T´Á»P¥Ó½ÐÃÄÃÒ(NDA)«eªº³W¹º¡A¥]§tÃĪ«¤Æ¾Ç»s³y»PºÞ¨î(CMC)¡B¤T´ÁÁ{§É¸ÕÅç(pivotal trial)³]p( ¾¯¶q ¥ÎÃÄÀW²v ¦¬®×¤H¼Æ ²Õ§O ¦¬®×±ø¥ó ¥Dn»P¦¸nÀø®Ä«ü¼Ð)¡AÁ{§É¸ÕÅç¦w¥þ©Ê»P¬ü°êFDA¶i¦æ¥R¤À°Q½×¡C¬ü°êFDA¦b·|ij¤¤¤]·|´£¨Ñªº«Øij
3§ë¸ê¤H·|¥ô»{¬°FDA®ÖãÃÄÃÒ¬O¬ÝÃĪ«Àø®Än¤ñ²{¦³ÃĪ«¦n, ³o¬O¤@ºØ°g«ä
4 ¬ü°êFDA¨Ì¾Ú 2 (¨Æ¥ý¬ù©w¦nªº³]p±ø¥ó¬O§_¹F¼Ð¨Ó®ÖãÃÄÃÒ)(¥Dn¬O¦w¥þ©Ê ¦³®Ä©Ê ÃĪ«¤Æ¾Ç»s³y»PºÞ¨î(CMC) ) 5 tralokinumab Àø®Ä¦³¤ñ Dubilumab ±j¶Ü? ¬°¤°»ò¬ü°êFDA ®Öã tralokinumab ÃÄÃÒ ( ¦]¬°¨Æ¥ý»P¬ü°êFDA¬ù©w¦nªº¤T´ÁÁ{§É¹êÅç³]p±ø¥ó¹F¼Ð) ( «D¥u¬ÝÃĪ«¶¡ªºÄvª§)
6²§¦ì©Ê¥Ö½§ª¢¯f±w¥þ²y2»õ¤H( ¬ü°ê4140¸U¤H ¼Ú·ù3070¸U¤H ¤¤°ê 3560¸U¤H ¤é¥»500¸U¤H) ¥Ø«e¥u¦³¦Ê¤À¤§8 ¯f±w¨Ï¥ÎDupilumab , ¨Ï¥ÎDupilumabªº¯f±w¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä,¬OÄY«¥¼³Qº¡¨¬ªº¯e¯f, ¹w´Á¬ü°êFDA¥¼¨Ó·|®Öã§ó¦h¥Íª«»s¾¯³æ®è§ÜÅéÃĪ«) , FDA §Æ±æ¦w¥þ¦³®ÄÃĪ«¶V¦h¶V¦n, ³Ì¦n°ª¶Q¤£¶Q ¥H«O»Ù¯f±wÅv§Q 7 AD¥«³õ¨ì2029¦~¹w¦ô240»õ¬ü¤¸, ¤£¥²¥þ®³ ,¥un®³¤U²Å¦X¥Íª«¼Ð°O»P¤£¾A¦X¨Ï¥Îdupilumabªº¯f±w, ¥«³õ´N°÷Åå¤H¤F ) ¥Ø«e¥u¦³dupilumab »PTralokinumab ¨âºØ¥Íª«»s¾¯³æ®è§ÜÅéÃĪ«,Tralokinumab¼Æ¾ÚÁö®t ((FDA 2021¦~12¤ë ®Öãtralokinumab ÃÄÃҥثe·Ç³Æ¶}½æ¤¤)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/14 ¤W¤È 10:49:18
²Ä 6442 ½g¦^À³
|
¨S¦³¤H·|ÃhºÃeblasakimab ¦³®³FDA ÃÄÃÒ¼ç¤O (¤£¥Î¦¸±Ú¸s¤ÀªR ) ²z©Ê¬Ý«Ý¤GB Á{§É §Q¥Î°²´Á¦n¦n¬Ý 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³Ì·s³ø§i¤¤
ªü´µÄõ»sÃĤ½¥q¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³Ì·s³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú TREK-AD ¬ã¨s«á´Á¤fÀY³ø§i´Á¶¡´£¨Ñªº¼Æ¾Úªí©ú¡Aeblasakimab§@¬°²Ä¤@ÓªvÀø¤¤««×²§¦ì©Ê¥Ö½§ª¢ªº¥Íª«»s¾¯¨ã¦³¼ç¤O¡A±q¶}©l®É¨C¤ë¤@¦¸µ¹ÃĪº®ÄªG¨ã¦³Ävª§©Ê •¨Ó¦Û¹ï±w¦³ÄY«¯e¯fªº±wªÌ¡]°ò½uEASI µû¤À¦Ü¤Ö21¡^¡]¦ûITT ±wªÌªº63%¡^ªº¨Æ«á¤ÀªRªº·s¼Æ¾ÚÅã¥Ü¡A¨C¤ëªA¥Î600 mg ¨Ì¥¬©Ô§Æº¿¡A«ùÄò16 ¶g¡A¾ÉPEASI µû¤À°§C74.5% ¡]»P¦w¼¢¾¯²Õ¬° 38.0%¡Ap<0.0001¡^¡AEASI-75 ¬° 53.6%¡]¦w¼¢¾¯²Õ¬° 12.9%¡Ap=0.0009¡^¡AÅã¥Ü¦w¼¢¾¯½Õ¾ãÀø®ÄÅãµÛÂX¤j ¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 10 ¤ë 13 ¤é¡]Àô²y³q°TªÀ¡^¡X ASLAN Pharmaceuticals Pte Ltd¡]NASDAQ¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡C«Å§G¦b²Ä 32¦b¦¨¤H¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢ (AD) ¤¤ªºeblasakimab¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·| (EADV) ¤j·| ©¡¡C Eric L. Simpson Âå¾Ç³Õ¤h¡B«X°Ç©£°·±d»P¬ì¾Ç¤j¾ÇÂå¾Ç¥Ö½§¬ì Frances J. Storrs ±Ð±Â©M TREK-AD ¬ã¨sªºº®u¬ã¨sû¤¶²Ð¤F¸Ó¬ã¨sªº¥Dnµ²ªG¡A¸Ó¬ã¨s¥ý«e©ó 7 ¤ë«Å¥¬¡C
1»P¦w¼¢¾¯¬Û¤ñ¡A Eblasakimab¦b²Ä16 ¶g®É¹F¨ì¤F¥Dn²×ÂI¡A§YÀã¯l±¿n©MÄY«©Ê«ü¼Æ(EASI) µû¤À¬Û¹ï©ó°ò½uªºÅܤƦʤÀ¤ñ¡A¦b¤TÓµ¹ÃIJդ¤¨ã¦³²ÎpÅãµÛ©Ê¡G¨C¥|©P¤@¦¸600mg ¾¯¶q¡]¨C¥|©P600mg¡^¡A³o¦b¼ÆȤW¬O³Ì¦nªº°õ¦æÁu¡A¨C¨â¶g¤@¦¸ 400mg ¾¯¶q¡]400mg Q2W¡^©M¨C¨â¶g¤@¦¸ 300mg ¾¯¶q¡]300mg Q2W¡^¡C
2¨Ï¥Î³o¨Ç¾¯¶qªºeblasakimabªvÀøªº±wªÌ¦bªvÀøªº³Ìªì´X¶g¤º¨³³t°_®Ä¡A¨ì²Ä¥|¶g®É EASI µû¤À¦³²Îp¾Ç¤WªºÅãµÛ§ïµ½¡C
3Eblasakimab¦b©Ò¦³¾¯¶q¤ô¥¤U³q±`@¨ü©Ê¨}¦n¡Aµ²½¤ª¢©Mª`®g³¡¦ì¤ÏÀ³ªºµo¥Í²v¸û§C¡CEADV ¤j·|¤W¤]µoªí¤F°ò©ó¹ïÄY« AD ±wªÌªº¨Æ«á¤ÀªRªº·s¼Æ¾Ú¡]°ò½u EASI µû¤À¦Ü¤Ö¬° 21¡A¦û·N¹ÏªvÀø (ITT) ¤H¸sªº 63%¡^¡C¦¹¨È²Õªº¤¤¦ì°ò½u EASI µû¤À¬° 31.1¡]¦b¬ü°êµn°Oªº±wªÌ¬° 31.0¡^¡A
4¦Ó ITT ±Ú¸sªº¤¤¦ì¼Æ¬° 24.0¡]¦b¬ü°êµn°Oªº±wªÌ¬° 19.2¡^¡C¨È²Õ¤ÀªRµ²ªGªí©ú¡A eblasakimabªvÀøªºÀø®Ä»P ITT ±Ú¸s¬Û·í¡A¦ý¦w¼¢¾¯¤ÏÀ³ÅãµÛ°§C¡C
5 §ÚÌ«Ü°ª¿³¦b EADV ¤j·|¤W®i¥Ü TREK-AD ¬ã¨sªº¥Dn¼Æ¾Ú©M·sªºªþ¥[¤ÀªR¡C§Ú̪º¬ã¨sµ²ªG¤ä«ù¤Feblasakimab§@¬°²§¦ì©Ê¥Ö½§ª¢ (AD) ªº·s«¬ªvÀø¤èªkªº¼ç¤O¡A±q¶}©l®É¨C¤ëµ¹ÃĤ@¦¸¡A¥B¤£¼vÅTÀø®Ä¡A
6 ASLAN »sÃĤ½¥qº®uÂåÀø©x Alex Kaoukhov ³Õ¤h»¡¡C¡u¹ï AD ±wªÌ¨È²Õªº¨Æ«á¤ÀªRµ²ªG±j½Õ¤F¤F¸Ñ AD Á{§É¸ÕÅ礤±wªÌ¸sÅéÅܤƪº«n©Ê¡C
7ÁöµM»PÁ`Åé¸ÕÅç¤H¸s¬Û¤ñ¡Aeblasakimab¦b±wªÌ«¯g¤¤ªºªí²{¦P¼Ë¥X¦â¡A¦ý±w¦³¸û»´¯e¯fªº±wªÌ¼Æ¶q¼W¦h¥i¥HÅãµÛ´£°ª¦w¼¢¾¯¤ÏÀ³¡C¡¨ ( 6, 7 »¡©ú¨È²Õ¤ÀªRì¦]) (¸û»´¯e¯fªº±wªÌ¼Æ¶q¼W¦h¥i¥HÅãµÛ´£°ª¦w¼¢¾¯¤ÏÀ³ ) (¤T´Á·|¦¬«¯g±wªÌ)
8 TREK-AD ¬ã¨sªº¿n·¥µ²ªG¬°eblasakimab§@¬°ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº·sÀøªkªº¼ç¤O´£¨Ñ¤F¥O¤H«HªAªº®×¨Ò¡A¥¦¥i¥H³z¹L´£¨Ñ¤è«K¡B¦³®Ä©M¦w¥þªºªvÀø¿ï¾Ü¨Ó´£°ª±wªÌªºÅ@²z¼Ð·Ç¡A¡v Eric»¡L. Simpson¡AÂå¾Ç³Õ¤h¡A«X°Ç©£°·±d»P¬ì¾Ç¤j¾ÇÂå¾Ç¥Ö½§¬ì Frances Jì¦]. Storrs ±Ð±Â¡ATREK-AD ¬ã¨sº®u¬ã¨sû¡C
²Ä 32©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|ºtÁ¿¸Ô±¡¡G¿ð¨ì¤fÀY³ø§i TREK-AD ªºµ²ªG¡G¤@¶µ°w¹ï¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢¦¨¦~±wªÌªº eblasakimab ÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó 2b ´Á¬ã¨s¡]ºKn ID 6703¡^ AD ¬O¤@ºØ±`¨£¡BºC©Ê¡B¦h¦]¤l¥Ö½§¯f¡A¨ä¥Dn§K¬Ì¯S¼x¬O»²§U T ²ÓM 2¡C²ÓM¿E¯À¥Õ²ÓM¤¶¯À (IL) 4 ©M IL-13 ³Q»{¬°¬O AD ªºÃöÁäÅX°Ê¦]¯À¡C¨âªÌ³£³z¹L¦@¨Éªº 2 «¬¨üÅé¡]¤@ºØ¥Ñ IL-4R£\ ©M IL-13R£\1 ²Õ¦¨ªº²§¤G»EÅé¡^µo¥X°T¸¹¡CEblasakimab¬O¤@ºØ¼ç¦bªº¤@¬y³æ®è§ÜÅé¡A°w¹ï 2 «¬¨üÅ骺 IL-13 ¨üÅé¨È°ò¡A³o¬OÅX°Ê¦hºØ¹L±Ó©Êµoª¢¯e¯fªºÃöÁä³~®|¡C
9 TREK-AD¡]¤@¶µeblasakimabªvÀø¤¤««× AD ¦¨¤H±wªÌªº 2b ´Á¬ã¨s¡^ªº¿n·¥¼Æ¾Úªí©ú¡Aeblasakimab¦³¼ç¤O±q¤@¶}©l´N´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¦Ó¤£¼vÅTÀø®Ä¡C
ITT ±Ú¸s¤¤ªº 289 ¦W±wªÌ³QÀH¾÷¤À°t¦Ü¨C¤ë¤@¦¸ 400mg¡]400mg Q4W¡^©Î 600mg¡]600mg Q4W¡^ªºeblasakimab ²Õ¡A©Î¨C¨â¶g¤@¦¸300mg¡]300mg Q2W¡^©Î400mg¡]400mg Q2W¡^ªº²Õ§O¡A©Î¦w¼¢¾¯Q2W ²Õ¡A«ùÄò16 ¶g¡A¦b¨â¦¸©Î¤T¦¸t²ü¾¯¶q«á¡C
10 ¹ï°ò½u EASI µû¤À¦Ü¤Ö¬° 21¡]ÄY«¯e¯f¡^ªº±wªÌ¶i¦æ¤F¨È¸s¨Æ«á¤ÀªR¡C ¦b ITT ±Ú¸s¤¤¡A»P¦w¼¢¾¯¬Û¤ñ¡A²Ä 16 ¶g®Éeblasakimab¾¯¶q600mg Q4W¡B400mg Q2W ©M300mg Q2W ªºEASI µû¤À§ïµ½ÅãµÛ¸û¤j¡]-73.0% [p=0.001]¡B-65.8% [p=0.029 ] ©M-69.8 % [P=0.005] vs -51.1%¡^¡C
11 ¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õªº¤ÀªR¤¤¡A»PITT ¤H¸s¬Û¤ñ¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G 600mg Q4W -74.5% /38.0%¡]p<0.0001¡^¡A 400mg Q2W -72.7%/38.0%¡]p<0.0001¡^¡A 300mg Q2W -69.8%/38.0%¡]p=0.0001¡^¡A
¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õ¤ÀªR¤¤¡A¹F¨ìEASI-75 ªº±wªÌ¦Ê¤À¤ñ¬°¡G¹êÅç²Õ/¦w¼¢¾¯²Õ 600mg Q4W 53.6%/12.9% (p=0.0009)¡A 400mg Q2W 49.7% / 12.9% (p=0.0014)¡A 300mg Q2W 52.1%/12.9% ( p=0.001) 400mg Q4W 36.1%/12.9% ¡]p=0.0328¡^ ¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌÀò±oÅçÃÒªº²§¦ì©Ê¥Ö½§ª¢¬ã¨sªÌ¾ãÅéµû¦ô(vIGA-AD) µû¤À¬°0/1 ªº±wªÌ¦Ê¤À¤ñ¦p¤U¡G¹êÅç²Õ /¦w¼¢¾¯²Õ 600mg Q4W 29.8% /6.8% (p=0.0172)¡A 400mg Q2W 37.6% /6.8%(p=0.0030) ¡A 300mg Q2W 27.1%/6.8%¡]p=0.0297¡^¡A 400mg Q4W ²Õ¬° 9.6%/6.8%
12¾ãÅé¦Ó¨¥¡A¥D°ÊªvÀø²Õªº°±ÃIJv¬Û·í¡A¦Ó¦w¼¢¾¯²Õªº°±ÃIJv¸û°ª¡CEblasakimab ªº@¨ü©Ê¨}¦n¡F»P¦w¼¢¾¯¬Û¤ñ¡A eblasakimabªºµ²½¤ª¢©Mª`®g³¡¦ì¤ÏÀ³µy°ª¡]¤À§O¬° 5.6% ©M 4.7%¡^¡A¦w¼¢¾¯§¡¬° 1.8%¡C
°£¤F³Ì·sªººt¥Ü¤§¥~¡AÁÙ¦bEADV ¤j·|¤W®i¥Ü¤FÃö©óeblasakimab©MFarudodstatªº¤T±i¹q¤l®ü³ø¡C±z¥i¥H¦bASLAN ºô¯¸ªº¥Xª©ª«³¡¤À½u¤W¬d¬Ý¹q¤l®ü³øªº°Æ¥»¡C
¥H¤W¤À¨É ¨Ì¾Úªü´µÄõ»sÃĤ½¥q¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³Ì·s³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/13 ¤U¤È 11:26:46
²Ä 6441 ½g¦^À³
|
¤G´ÁÁ{§É¦b±´¯Á ( ¾¯¶q µ¹ÃÄÀW²v ¥l¶Ò¼Ð·Ç ¦w¥þ©Ê ) ¨Æ«e¤ÀªR»P¨Æ«á¤ÀªR³£¦P¼Ë«n ( ¬°¤T´ÁÁ{§É°µ·Ç³Æ ) Eblasakimab¥uÆ[¹î16¶g §ó¨S¦³¨Ï¥ÎÃþ©T¾J, ¦b¨C²Õ¤H¼Æ¤£¦hªº±¡ªp¤U¦³³o¼Ë¼Æ¾ÚÀ³¸Óµ¹¤©¹ªÀy (¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç¤j·|·Ç¤©¤fÀY³ø§i´N¬O³Ì¤jªÖ©w)
ASLAN PHARMACEUTICALS ¦b²Ä32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç¤j·|±ß´Á¤fÀY³ø§i¤¤®i¥Ü¤FEblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº2B ´Á¬ã¨sªº·s¼Æ¾Ú- TREK-AD ¬ã¨sªº±ß´Á¤fÀY³ø§i´Á¶¡´£¨Ñªº¼Æ¾ÚÃÒ©ú¤Feblasakimab §@¬°²Ä¤@ӥͪ«»s¾¯ªº¼ç¤O¦b¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢¤¤¡A±q¶}©l®É¨C¤ë¤@¦¸µ¹ÃĪº®ÄªG¨ã¦³Ävª§©Ê- ¨Ó¦Û¹ï±w¦³ÄY«¯e¯fªº±wªÌ¡]°ò½uEASI µû¤À¦Ü¤Ö21¡^¡]¦ûITT±wªÌªº63%¡^ªº¨Æ«á¤ÀªRªº·s¼Æ¾Ú¡AÅã¥Ü¨C¤ëªA¥Î600 mg eblasakimab «ùÄò16 ¶g¡A¾ÉPEASI µû¤À°§C74.5%¡]¦w¼¢¾¯²Õ¬°38.0%¡Ap<0.0001¡^¡AEASI-75 °§C53.6%¡]¦w¼¢¾¯²Õ¬°12.9%¡Ap=0.0009¡^
«n¼Æ¾Ú¦p¤U ¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õªº¤ÀªR¤¤¡A»PITT ¤H¸s¬Û¤ñ¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G 600mg Q4W -74.5% /38.0%¡]p<0.0001¡^¡A 400mg Q2W -72.7%/38.0%¡]p<0.0001¡^¡A 300mg Q2W -69.8%/38.0%¡]p=0.0001¡^¡A
¦b¨È²Õ¤ÀªR¤¤¡A¹F¨ìEASI-75 ªº±wªÌ¦Ê¤À¤ñ¬°¡G¹êÅç²Õ/¦w¼¢¾¯²Õ 600mg Q4W 53.6%/12.9% (p=0.0009)¡A 400mg Q2W 49.7% / 12.9% (p=0.0014)¡A 300mg Q2W 52.1%/12.9% ( p=0.001) 400mg Q4W 36.1%/12.9% ¡]p=0.0328¡^
Àò±o¸gÅçÃÒªº²§¦ì©Ê¥Ö½§ª¢¬ã¨sªÌ¾ãÅéµû¦ô(vIGA-AD) µû¤À¬°0/1 ªº±wªÌ¦Ê¤À¤ñ¦p¤U¡G¹êÅç²Õ /¦w¼¢¾¯²Õ 600mg Q4W 29.8% /6.8% (p=0.0172)¡A 400mg Q2W 37.6% /6.8%(p=0.0030) ¡A 300mg Q2W 27.1%/6.8%¡]p=0.0297¡^¡A 400mg Q4W ²Õ¬° 9.6%/6.8%
¾ãÅé¦Ó¨¥¡A¥D°ÊªvÀø²Õªº°±ÃIJv¬Û·í¡A¦Ó¦w¼¢¾¯²Õªº°±ÃIJv¸û°ª¡C Eblasakimab ªº@¨ü©Ê¨}¦n¡F »P¦w¼¢¾¯¬Û¤ñ¡Aeblasakimab ªºµ²½¤ª¢©Mª`®g³¡¦ì¤ÏÀ³µy°ª¡]¤À§O¬° 5.6% ©M 4.7%¡^¡A¦w¼¢¾¯§¡¬° 1.8%¡C°£¤F³Ì·sªººt¥Ü¤§¥~¡AÁÙ¦b EADV ¤j·|¤W®i¥Ü¤F¤T±iÃö©ó eblasakimab ©M Farudodstat ªº¹q¤l®ü³ø¡C ¹q¤l®ü³øªº°Æ¥»¥i¦b ASLAN ºô¯¸ªº¥Xª©ª«³¡¤À½u¤W¬d¬Ý¡C(eblasakimabµ²½¤ª¢¤ñ²v¤ñDupilumab §C¬Û·í¦h)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦p¦³¿ù»~½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/10/13 ¤U¤È 10:34:54
²Ä 6440 ½g¦^À³
|
¶BÄF¶°¹Î¤½¥q
²{¦b¤½¥q»¡¤°»ò³£¨S¤H«H¤F
¦b¼Ú¬wµoªíªº¼Æ¾Ú¡A¸Ì±´N¦³¦Û¬Û¥Ù¬Þ¤£¦X²zªº¦a¤è¡A
®g½b«á¦Aµe¹v¡A
Ãø©Ç¥«³õ¤´¤£¶R³æ¡A
³o®a¤½¥q¤wµL¸Û«H¥i¨¥¡A
«Ó°¶¤jÂ_§À¨D¥Í¤~¬O¹ïªº¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/11 ¤U¤È 08:51:07
²Ä 6439 ½g¦^À³
|
¥Ø«e§e²{Eblasakimab»Pdupilumab Ävª§ºA¶Õ
1¬ü°êFDA 2023¦~10¤ë2¤é§_¨MLebrikizumabÃÄÃҥӽР(»s³y¤è±¥X°ÝÃD) Eblasakimab ¤Ö¤F¤@ÓÄvª§¹ï¤â, 2b ´Á¬ã¨sªº¶i¤@¨B¼Æ¾Ú¡A¥]¬A±wªÌ³ø§iªºµ²ªG©M¥Íª«¼Ð°O¼Æ¾Ú¡A¹wp±N©ó 2023 ¦~²Ä¥|©u«×´£¨Ñ (¥Íª«¼Ð°O¼Æ¾Ú±À´ú°µ¬°¤T´ÁÁ{§É¥l¶Ò¨ü¸Õ°Ñ¦Ò¼Ð·Ç, AD¥«³õªñ240»õ¬ü¤¸,¤£¥²¥þ®³ ,¥un®³¤U²Å¦X¥Íª«¼Ð°O»P¤£¾A¦X¨Ï¥Îdupilumabªº¯f±w, ¥«³õ´N°÷Åå¤H¤F ) ¥Ø«e§e²{Eblasakimab»Pdupilumab Ävª§ºA¶Õ Tralokinumab ¼Æ¾ÚÁö®t (FDA 2021¦~12¤ë ®Öãtralokinumab ÃÄÃÒ)
2 ¤GB Á{§É¬O¦b§ä³Ì¨Î¾¯¶q Eblasakimab§ä¨ì600mg4¶g¤@°w , dupilumab§ä¨ì300mg2¶g¤@°w , lebrikizumab §ä¨ì250mg2¶g¤@°w ·í¦~dupilumab ¤T´ÁÁ{§É¨Ï¥Î¾¯¶q¬°300mg ¤@¬P´Á¤@°w »P 300mg ¤G¬P´Á¤@°w («á¨ÓÃĪ«¤W¥« ¨Ï¥Î300mg¤G¬P´Á¤@°w) Eblasakimab¤Gb´ÁÁ{§ÉÃĪ«¦w¥þ©Ê¦n «Øij¤½¥q¤T´ÁÁ{§É¨Ï¥Î600mg¤G¬P´Á¤@°w»P¥|¬P´Á¤@°w ( ¨C¤ë¤@°w) ¥H¥Íª«¼Ð°O¼Æ°µ¬°¤T´ÁÁ{§É¥l¶Ò¨ü¸Õªº°Ñ¦Ò¼Ð·Ç, ÅýÀø®Ä¤j´T´£¤É °t¦X°ª¦w¥þ©Ê»PÀu¨}»s³y( ¤w©e°UThermo Fisher Scientific ¶}©l»s³y3´ÁÁ{§É¥ÎÃÄ »P¥¼¨Ó°Ó·~¤Æ¤§ÃĪ«»s³y)¥H¤À¹2029¦~¥þ²y240»õ¬ü¤¸AD ¥«³õ (Eblasakimab³W¹º¹L±Ó®ð³Ý ,ëC·ò¯lCSU »P COPD )
Àø®Ä«ü¼Ð ¤@ (4¶g1°w)
A IGA 0/1 Eblasakimab 2b 600mg (n=59) Q4W 31.2%/ 15.1% p=0.0502 ( 4¶g1°w) 2.01¿ (59¤HPȦ³¹F¼Ð) (80¤HPÈ·|§ó§C)
B EASI-75% eblasakimab 2b 600mg (n=59) Q4W 52.%/ 24.4% p value 0.0040 ( 4¶g1°w) 2.13¿
C EASI-90% Eblasakimab 2b 600mg (n=59) Q4W 27.6%/ 7.9% p value 0.0080( 4¶g1°w) 3.49¿
Àø®Ä«ü¼Ð ¤G (2¶g1°w) A IGA 0/1 eblasakimab 2b 400mg (n=56) Q2W 32.6 %/15.1% P value 0.0380 ( 2¶g1°w) eblasakimab 2b 300mg (n=58) Q2W 33.1%/15.1% P value 0.0327 ( 2¶g1°w) dupilumab 2b 300mg (n=64) /(n=61)Q2W 30 %/ 2 % P value 0.001 ( 2¶g1°w)
dupilumab phase 3 Solo1 300mg (n=224) /(n=224 )Q2W 37.4%/ 10 .2% P value 0.001 ( 2¶g1°w) dupilumab phase 3 Solo2 300mg (n=233) /(n=236 )Q2W 36%/ 8% P value 0.001 ( 2¶g1°w)
tralokinumab ECZTRA 1 15.8% /7.1 % P=0.002 (300mg 2¶g1°w16¶g) ( 601¤H/ 197¤H) tralokinumab ECZTRA 2 22.2 % /10.9 % P< 0.001 (300mg 2¶g1°w16¶g) ( 591¤H/ 201¤H) (FDA 2021¦~12¤ë ®Öãtralokinumab ÃÄÃÒ)
B EASI-75%
eblasakimab 2b 400mg Q2W (n=56) 43.6/24.4% P value 0.0360 ( 2¶g1°w) eblasakimab 2b 300mg (n=58) Q2W 51.2/24.4% P value 0.0050 ( 2¶g1°w)
dupilumab 2b 300mg (n=64) / (n=61 ) Q2W 53.1%/11.5% p value 0.001 ( 2¶g1°w)
dupilumab phase 3 solo1 300mg (n=224) /(n=224 )Q2W 50.3%/ 15.2 % P value 0.001 ( 2¶g1°w) dupilumab phase 3 solo2 300mg (n=233) /(n=236 )Q2W 44%/ 12% P value 0.001 ( 2¶g1°w)
tralokinumab ECZTRA1 25% /12.7% P < 0•001 (300mg 2¶g1°w16¶g) ( 601¤H/ 197¤H) tralokinumab ECZTRA2 33.2% / 11.4% P < 0•001 (300mg 2¶g1°w16¶g) ( 591¤H/ 201¤H) (FDA 2021¦~12¤ë ®Öãtralokinumab ÃÄÃÒ) C EASI-90% eblasakimab 2b 400mg (n=56) Q2W 25.3%/7.9% p value 0.0177 ( 2¶g1°w) eblasakimab 2b 300mg (n=58) Q2W 30.8%/7.9% p value 0.0028( 2¶g1°w) dupilumab 2b 300mg( n=64)/ n=61) 29.7 %/3.3 % p value 0.001 ( 2¶g1°w)
dupilumab phase 3 solo1 300mg (n=224) /(n=224 )Q2W 32.8%/ 7.4 % P value 0.001 ( 2¶g1°w) dupilumab phase 3 solo2 300mg (n=233) /(n=236 )Q2W 30%/ 7% P value 0.001 ( 2¶g1°w)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦p¦³¿ù»~½Ð§ó¥¿
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/10/7 ¤W¤È 07:49:45
²Ä 6438 ½g¦^À³
|
§Ú¬Q±ß¤w¸g¥Î1.4¤¸¥ª¥k½æ¥ú³oÄêªÑ ²{¦b¤ß±¡¶W¯ÅµÎ©Z¡A¥H«á¦A¤]¤£¥Î¬Ý³oÄêªF¦è ¤j®a¬Ã«¡A§Æ±æ³oÄêªF¦è¤£·|¦A¶^¯}1¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/10/6 ¤U¤È 10:12:20
²Ä 6437 ½g¦^À³
|
ªÑ»ùªº½T¥O¤H¥¢±æ, ¥¤ß¦Ó½×³o¥u¬O¤@Ó¤G´ÁÁ{§É, ¥Í§Þ¤½¥q¦b¤G´ÁÁ{§É¥u¦³±´¯Á»Pµû¦ô¡A¦³µo®i¼ç¤O¦AÄ~Äò©¹¤T´ÁÁ{§É¨«¡AFDA¥¼¨Ó¥u¬Ý¨âÓ¤T´ÁÁ{§É¼Æ¾Ú , §ë¸ê¤H¤ÏÀ³¹LÀY¤F, ²z©Ê¬Ý«Ý¤G´ÁÁ{§É , ¤Ó°õµÛ»P¤Ó§¹¬ü¥D¸q¤Ï¦Ó¤£¦n
²Ä¥|©u«n¨Æ¶µ¦p¤U
1¤U¬P´Á10¤ë11¤é¨ì13¤é¬ì¾Ç¤j·|¤W¶i¦æºt¥Ü ( 3Ó¤fÀY³ø§i 1Ó®ü³ø®i¥Ü °÷¥÷¶q¬ã¨s¤~·|㤩¤fÀY³ø³ø)
2 2b ´Á¬ã¨sªº¶i¤@¨B¼Æ¾Ú¡A¥]¬A±wªÌ³ø§iªºµ²ªG©M¥Íª«¼Ð°O¼Æ¾Ú¡A¹wp±N©ó 2023 ¦~²Ä¥|©u«×´£¨Ñ (¥Íª«¼Ð°O¼Æ¾Ú±À´ú°µ¬°¤T´ÁÁ{§É¥l¶Ò¨ü¸Õ°Ñ¦Ò¼Ð·Ç, AD¥«³õªñ240»õ¬ü¤¸,¤£¥²¥þ®³ ,¥un®³¤U²Å¦X¥Íª«¼Ð°O»P¤£¾A¦X¨Ï¥Îdupilumabªº¯f±w, ¥«³õ´N°÷Åå¤H¤F )
3 ¦w¥þ©Ê: ¾ãÅé¦Ó¨¥¡A¥D°ÊªvÀø²Õªº°±ÃIJv¬Û·í¡A¦Ó¦w¼¢¾¯²Õªº°±ÃIJv¸û°ª¡C ¨S¦³µo²{·sªº¦w¥þ°T®§¡A¥B¿n·¥ªvÀø²Õ©M¦w¼¢¾¯²Õ¤§¶¡ªº¤£¨}¨Æ¥ó (AE) ÀW²v¬Û·í¡C ©Ò¦³¿n·¥ªvÀø²Õ¤¤³Ì±`¨£ªºAE ¬O»ó«|ª¢¡]¦w¼¢¾¯²Õ¬°13.4%¡A¦w¼¢¾¯²Õ¬°8.8%¡^¡B²§¦ì©Ê¥Ö½§ª¢¡]¦w¼¢¾¯²Õ¬°8.6%¡A¦w¼¢¾¯²Õ¬°7.0%¡^¡BÀYµh¡]¦w¼¢¾¯²Õ¬°6.9%¡A¦w¼¢¾¯²Õ¬°7.0%¡^¤Î¤W©I§l¹D¹D·P¬V¡]¦w¼¢¾¯²Õ¬° 6.5%¡A¦w¼¢¾¯²Õ¬° 5.3%¡^¡C µ²½¤ª¢¡]¦w¼¢¾¯¬°5.2%¡A¦w¼¢¾¯¬°1.8%¡^¡Bª`®g³¡¦ì¤ÏÀ³¡]¦w¼¢¾¯¬°4.7%¡A¦w¼¢¾¯¬°1.8%¡^©M¯p¯l·P¬V¡]¦w¼¢¾¯¬°3.0%¡A¦w¼¢¾¯¬°3.5%¡^ªºµo¥Í²v¸û§C ( µ²½¤ª¢µo¥Í²v¬ù¥u¦³dupilumab ¥|¤À¤§¤@ )
3 »P¬ü°ê¹«~©MÃĪ«ºÞ²z§½Á|¦æ²Ä¤G¶¥¬qµ²§ô·|ij¡A¨Ã¹wp©ó 2024 ¦~±Ò°Ê eblasakimab ªº²Ä¤T¶¥¬qÁ{§É¶}µop¹º
4 TREK-DX¡]EblasaKimab ¦b Dupilumab ¤¤ªº¸ÕÅç¡^eblasakimab ¦b¦³dupilumab ªvÀø¸gÅ窺±wªÌ¤¤¶i¦æªº¬ã¨s¡A¹wp©ó2024 ¦~²Ä¤@©u¤½§G¸Ó¬ã¨sªº¥Dn¼Æ¾Ú
5Aslan 003¨r´³ ¤G´Á ¹wp©ó2024 ¦~²Ä¤@©u¤½§G¸Ó¬ã¨sªº¥Dn¼Æ¾Ú
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿ |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 101 ~ 200 «h¦^ÂÐ >> |